Transcriptional regulation of human neurotropic papovavirus, JCV by Kumar, Kotlo Umesh




.+. National Library010._
=~~Branch
~wa:=.SI-
K1A(N4
NOTICE
::~nationale
~oc~=~~
...~-~~l
AVIS
The quality of this microform Is
heavily dependent upon the
quality of the original thesis
submitted tor microfilming.
Every effort has been made to
ensure the highest quality of
reproduction possible.
If pages are missing, contact the
university which granted the
degree.
Some pages may have indistinct
print especially if the original
pages were typed with a poor
typewriter ribbon or if the
university sent us an inferior
photocopy.
Reproduction in full or in part of
this microform is governed by
the Canadian Copyright Act,
R.S.C. 1970, c. C·30, and
subsequent amendments.
Canada
La qualite de cette microfornie
depend grandeme"t de la quante
de 18 these soumise au
microfilmage. Nous avons tout
fait pour assurer une qualite
superleure de reproduction.
S'i1 manque des pages, veuillez
communiqui;r avec I'universite
qui a contara Ie grade.
La qualite d'impression de
certaines pages peut laisser a
desirer, surtout si les pages
originales ont ete
dactylographiees a I'aide d'un
ruban use ou 51 I'universite nous
a fait parvenir une photocople de
qualite Inferieure.
La reproduction, meme partlelle,
de cette mlcroforme est sQumise
it la Lol canadlenne sur Ie droit
d'auteur, SRC 1970, c. C·30, et
ses amendements subsequents.
TRANSCRIPTIONAL REGULATION OF HUMAN
NEUROTROP{C PAPOVAVIRUS, lCV
By
e KotJo Umesh Kumar, M.V.Sc.
A thesis submitted to the school of graduate
studies in partial fulfilment of the
requirements for the degrj>p. of
Doctor of Philosophy
Division of Basic Medical Sciences
Faculty of Medicine
Memorial University of Newfoundland
Aprll,1994
51. John's Newfoundland
1+1 NaliooalLibfary
"'''''''''''
:~nallonale
~ect~=S~~~S
=~
TIlE AUTHOR HAS GRANfED AN
IRREVOCABLE NON-EXCLUSIVE
LICENCE ALLOWING TIlE NATIONAL
LWRARY OF CANADA TO
REPRODUCE, LOAN, DISTRmUTE OR
SELL COPIES OF mSIHER TIIES!S BY
ANY MEANS AND IN ANY FORM OR
FORMAT, MAKING THIS THESIS
AVAILABLE TO INTERESTED
PERSONS.
THE AUTHOR RETAINS OWNERSHIP
OF THE COPYRIGHT IN HISIHER
TIIESIS. NEITIlER THE 1lIESIS NOR
SUBSTANTIAL EXTRACTS FROM IT
MAY BE PRINTED OR OTHERWISE
REPRODUCED WITHOUT HISIHER
PERMISSION.
L'AUTEUR A ACCORDE UNE LICENCE
IRREVOCABLE ET NON EXCLUSIVE
PERMETTANT A LA OffiLIOTHEQUE
NATIONALE DU CANADA DE
REPRODIJIRE, PRETER. D1STRmUER
au VENDRE DES COPlES DE SA
THESE DE QUELQUE MANIERE ET
SOUS QUELQUE FORME QUE CE SOIT
POUR METTRE DES EXEMPLAJRES DE
CETIE TIlESE A LA DISPOSITION DES
PERSQNNE lNTERESSEES.
L'AlITEUR CONSERVE LA PROPRIETE
DU DROIT D'AUTEUR QUI PROTEGE
SA nmSE. Nl LA THESE NI DES
EXTRAITS SUBSTANTIELS DE CELLE·
eI NE DOlVENT ETRE IMPRIMES au
AUTREMENT REPRODUITS SANS SON
AUTORISATION.
ISBN 0-315-96051-5
Canada
This lhesls is dedicated to
my pnrenls
8mt. K. Rukmlnl
nnd
Sri. K.V. RanganBlhom
ABSTRACT
The human papovavirus JC virus (JCV) replicates only
in glial cells and exhibits strict cell-specificity for
expression. JC virus (JCV) has been frequently found in the
plaques of brains of victims of the fatal demyelinating brain
disease, progressive multifocalleukoencephalopathy (PML). PML
is associated with immunodeficiency and has been identified
recently frequent complication of acquired
immunodeficiency syndrome (AIDS). The regub,tory region of JCV
is contained mainly within the two 98 base pairs (bp) tandem
repeats and is functional in both directions, with the early
and late promoter-enhancer (JCVE and JCVL ) controlling
expression of large and small tumour antigens and viral
structural proteins, respectively.
Previously, it was shown in our laboratory that the
regulatory region of JCV confers glial cell-specificity to JCV
and contains three potential nuclear factor 1 (NFl) lIlotifs
(Nakshatri~, 1990a). One motif tuwards the late side of
the genome has a 3 bp palindromic repeat and the other. two
located within the 98 bp repeats have 6 bp invertQd
palindromic sequences.
My initial objective was to evaluate the functional rolo
of NFl motifs in the restricted cell-specificity of JCV. This
was approached by site-directed mutagenesis of the nuclear
factor 1 (Nfl) motifs within the viral regulat"1ry region. The
NFl motifs, located within the 98 bp tandem repeats which
contain 6 bp perfect inverted palindromic sequences were
important for glial cell-specific expression of JC virus in
differentiated embryonal carcinoma cells .in....Y..i.Y.2. The Nfl slte
on the late side of the repeats was not important, an
observation confirmed by~ transcription studies. These
observations were correlated with .1n.-..Y..1.:tx2 DNase I
footprinting and mobility shift assays, which demonstrated
specific interactions of factors in glial cell nuclear
extracts with NFl sites.
To characterize the brain-specific factor(s) inducing the
expression of JCV, a eDNA encoding the factor binding to NFl
II/III located in the repeats was isolated by screening the
eDNA library prepared from retinrdc acid-differentiated PI9
embryonal carcinoma cells by Southwestern blotting. Co-
tranafection of eDNA with JCVt and JCVL reporter plasmids
resulted in the expression of JCV in nong11al cells such as
HeLa cella. These results suggested that NFl II/III plays a
key role in the glial cell type-specificity of JCV.
Mutations in all the three potential NFl binding sites
9reatly reduced the transcriptional activity of JCV early
promoter-enhancer in glial cells. However, a residual greater
than basal level of activity was still observed. Examination
of the JCV promoter-enhancer sequences revealed a cyclic AMP
response element (CRE) motif, TGAGCTCA, 4 bp from the NFl
ii
II/III binding site in the repeats. This increased thu
transcriptional activity of JCV£ after treatment with the cr,.,p
analogue dibutyryl cAMP and cyclic AMP inducer for-··, .in.
Mutations in CRE motifs abolished the induction of JCV
exprei!7'1ion by cAKP.~ binding studies showed the
interaction of an approximately 43 kDa protein with CRE
oligonucleotide. The results indicated an additive effect of
NFl II/III and CRE in the glial cell-specific expression of
JCV.
JCV large T-antigen functionally transactivates the
viral late promoter only in glial cells and the molecular
mechanism for transactivation has remained elusive. The NFl
sequer..ces of :::-.;1/ and the amino acids of JCV T-antigen reguired
for the transactivation have remained unclear. I performed
experiments to address these issues. Using site-directed
mutagenesis of NFl sites of JCVL, the integrity of nuclear
factor 1 (Nfl) binding motifs in the 98 bp repeats (NFl
II/III), but not the motif external to the repeats, was found
to be essential tor the induction of JCVL setivity by JCV T-
antigen, a result Which was confirmed by~
transcription assays. Mobility shift assays detected the
increased binding of NFl to the NFl II/III sequences in the
presence of T-antigen. This suggests that JCV T-antigen
facilitates the increased binding of NFl to NFl II/III site,
thereby activating the late promoter of JCV. A model
iii
describing the mechanism has been proposed.
The region(s) of T-antigen necessary for the
transactivation of JCVl was assessed with a series of
constructs containing mutated coding sequences whIch I
generated. The amino acids 196-437 region of JCV T-antigen was
required for most of the transactivation of JCVL and
transformation of primary baby rat kidney cells.
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CHAPTER 1
Intro4u.ction
Human JC virus (JCV) belongs to the family
papova·:~.ridae and subfamily polyomavirinae. The existence of
polyoma viruses was first described in 1965 (Zu Rhein and
Chou, 1965). The severe demyelinating brain disea'Se called
progressive multifocal leukoencephalopathy (PML) had been
described previously (Astrom~, 1958). A role of polyoma
viruses in the etiology of PML was suspected, since particles .
resembling the polyoma virus virions were detected by electron
microscopy in the brains of patients with PML (Zu Rhein and
Cheu, 19651 Silverman and 1\ubinstein, 1965). A polyoma virus
was isolated from the brain of a PML patient. This virus was
named JCV from the initials of the PML patient (Padgett &..2.1,
1971). Further, another polyoma virus, BK virus (BKV), was
isolated from the urine of a renal transplant patient (Gardner
.!i!..t.....il. 1971). It was thought initially that BKV and SV40, a
virus introduced into many of the recipients of early polio
vaccines due to contamination from monkey cells used in
vaccine preparation, were also associated with PML (Weiner II
Al, 1972; Gribble ll...Al., 1975; Holmberg~, 1977; Scherneck
~, 1981). Current evidence indicates that JCV is the only
or major viral caus'":! of PML (Eizuru llJ&l, 1993). Subsequent
to the isolation of JCV in 1911, evidence that JCV is
associated with Pl:tL was reported by several laboratories
(Gardner,1971; Taguchi.!i!..t....Al, 1982; Walker and Padgett, 1983).
1.1 BERO-EPIDEMIOLOGY OF JC VIRUS
Once the association of JCV with PML was established,
serological surveys were used to gain insight into the
incidence of the disease. Serological studies conducted in
Wisconsin showed that 65\ of individuals were positive for
anti-JCV antibodies by the age of 14 (Padgett and Walker,
1973). The high prevalence of antibodies against JCV was
further reported from different regions of the world.
Inapparent primary infection by JCV occurs in childhood
and approximately lot of children between the ages of 1 and 5
years demonstrate antibody to JCV. By 17 years of age, 65\ of
adults will havti! seroconversion and the adult popUlation in
some urban areas show as high as 92\ seroconversion (Walker
and Padgett, 1983). The virus is transported to the kidney and
probably persists there indefinitely (Arthur .!it....i\l, 1988 and
1989). In noncornpromised individuals attending urologic
clinics, JC viral DNA was detected in 29\ and the presence of
JCV DNA increased with age and peaked at 45t in the 60-89
ysars age group. Importantly, undar immunocompromising
c:onditions, such as renal and bone marrow transplantations,
pregnancy, elderly and cancer, the virus is reactivated and
can infect the brain (Hogan §!...t-.JU, 1980a, 1983; Gardner ~,
1984; Andrews~, 1988; Arthur~, 1988: Coleman rtM,
1980 , 19B3; Gibson~, 1981; Daniel.tt....Al, 1981; Kitamura
~. 1990). It has been demonstrated that 55 to 85\ of cases
of PHL have AIDS, again supporting the theory that
reactivation ot JCV is associated with immunosuppression
(Berger ~, 1987; Krupp ~, 1985). Recently,
overwhelming evidence has been found tor the association of
PML with the AIDS epidemic and PHL is a frequent complication
of AIDS (Quinlivan~. 1992).
Direct interaction of the AIDS virus (HIV type I) and
JCV proteins was also reported (Gendelman.t..t...Al, 1986; Tada .Q.t.
ll, 1990). PML is the cause of death of 4' AIDS patients in
North America (Markowitz.it...Al, 1993). Both pregnant women and
immunosuppressed patients who do not have PML shed JCV in
their urine, suggesting that loss ot i!llmunocompetence
predisposes individuals to the reactivation of a latent
infection (Coleman ll.Al, 1980; Gardner.e..t...Al, 1984). However,
the exact mechanism of primary infection by JCV has remained
unclear.
1.2. Mr,DE OP TUJfSHISBIOH OF ~"Tr:v
As JCV incidence is frequent in pregnant WOllen, studies
on the congenital transmission of the virus were attempted.
Sera from the umbilical cord of infants of normal mothers did
not reveal any JCV-specific IgM antibodies (Gibson ~.
1981) and fetal tissues also failed to show the presence of
virus (Andrews ~, 1983). serological studies confirmed
th"!.t humans are the natural reservoir of JCV and that the
virus is not transmitted by animal intermediates (Padgett §.t.
Al, 1977).
1.3. JC VIRUS GENOKE
1.3.1. GENERAL FEATURES
The genome of prototype strain, MAD1 contains a 5130 bp
covalently closed circular double-stranded DNA genome. The
genome of this virus encodes two non-structural proteins,
large T and small t a.ntigens, three structural proteins named
VP1, VP2, VP3 and an agnoprotein (Fig.1.1; Frisque ~,
1984). JeV exhibits close sequence homology to two other well
characterized primate papovaviruses, the simian virus (SV40),
and the human BK virus (BKV) (Osborn~, 1974; Frisque II
li, 1984). :lev and BKV share approximately 80% homology
between their early proteins and late viral capsid proteins.
Jev and SV40 share approximately 70% homology in these
regions. However, unlike BKV and SV40, JeV has a narrow tissue
tropism and JCV replicates efficiently exclusively in primary
human fetal glial cells rich in spongioblasts, the precursors
of oligodendrocytes (Aksamit and Proper. 1988; Wroblewska II
lit 1980). In transgenic mice expressing Jev T-antigen Jev
induces dysmyelination in central nervous system but not
peripheral nervous system (Small ~, 1986). sUbsequent to
the isolation of the JCV for the first time in 1971, nGW
isolates were reported. The first isolates of JC virus were
reported from the university of Wisconsin in Madison and the
isolates were designated as Mad1 (the prototype), Mad2, etc.
The prototype strain, Madl , contains two 98 bp repeats with
one TATA box in each as part of its regulatory region (Martin
~, 1985; Loeber and Dorries, 1988). Host of the isolates
of JCV were from the brain and few were from kidneys, urine of
PHL patients, renal and bone marrow transplant recipients or
from normal individuals. The genome of JCV isolated from the
urine of non-PML elderly individual who had no signs of
immunosuppression contained a 23 bp insertion which was not
found in prototype Madl strain. A 66 bp insertion was also
found in the genome between nt 80 and 98 of the tandem repeat.
The JCV genome with sequence rearrangements that includes 23
and 66 bp insertion is called the l1archetype" genome (Yogo g,t
ill, 1990).
1.3.2. REGULATORY REGION OP JCV:
The sequences corresponding to nucleotide positions
5112 to 270 form the non-coding region of JCV (Fig. 1.1). It
consists of promoter-enhancer elements essential for
transcription and also the core sequences important for viral
DNA replication. The regulatory region of JCV is functional in
both directions. In one direction, the early region encodes
large T and small t antigens. Second expression from the late
promoter-enhancer leads to the formation of structural
proteins of the virus. The sequences of replication origin of
SV40, BKV, and JCV are well conserved, whereas, the sequences
of promoter-enhancer elements diverge greatly. The regUlatory
rlegion of JCV contains two 98 bp tande. repeats (Pig. 1.1) and
the unique feature of this virus, compa.red with Bit: and SV40
viruses, is that the TATA box is duplicated in each of the 98
bp repeats. The requlatory reqion also contains seV(lral ili-
acting elellents bound by cellular transcription factors.
The activity of JCV requlatory re9ion unlike thoSQ of.
SV40 and BKV, is strictly r(lstricted to 91ial cells. "t Mo
been suggested that the JCV control region consisting of the
promoter-enhancer elements is responsible for the restricted
tissue specificity, because the greatest degree of divergence
is noticed in the regulatory region ot JCV compared to those
papovaviruses such as BKV and SV40 (Kenney ~, 1984;
Nakshatri ~, 1990a).
1.3.3. NOK-STRUCTURAl. PROTEINS:
1.3.3.1. LARGB '1'- AnIQBJh
The large T-antlgen of Jev has not been studied 1n as
.uch detail as the SV40 T-antigen. The large T-antlgen of SV40
exhibits several properties like specific and non-specific DNA
binding, alpha polymerase-primase binding, p53 and Rb binding-,
ATPase and hellcase. These features have been correlated wlth
SV40 transfonainq and oncogenic properties (Fanning, 1992).
Since JCV and SV40 large T-antigens bear significant
homologies, it was predicted that Jev T-antigen exhibits most
of the properties that SV40 T-antlgen does. consistently,
studies with JCV T-antigen showed that it has DNA (Lynch and
Frisque. 1991). p53 (Bollag~. 1989: Haggerty ~.1989).
and Rb (Dyson~, 1989; 1990) binding activities. It has
transformin~ (Friaque~, 1980) and transrequlating (Tlldll
&.-I.l. 1990) properties. In addition, it mediates DNA
replication of the JCV (Sock ~, 1991; Lynch and Frlsque
1991) .
1.3.3.2. SHALL t-AN'l'ZGEN:
The JCV early RNA transcript is differentially spliced to
produce small tumor (t) RNA (Fig.I.1). Tho large T and small
t-antigens have the same amino terminal region but differ in
their carboxyl terminal regions (Frisque ~, 1984). Like
large T-antigen. the small t-antigen of JCV is not studied in
detail. However. based on the sequence homology (82\), it is
presumed that JCV and SV40 small t-antigens behave
identically. SV40 small t-antigen was found to be necessary
for complete transformation of non-perwissive cells (Bouck n
li, 1978; Sleigh~. 1978). Small t-ant1gen also enhances
the transactivating function of large T-antigen (Bikel i.t......JJ..
1987) .
1.3.4. STRUCTURAL PROTEIlrI'S:
1.3 • 4.1. CAPSID PROTEINS:
Due to the diffiCUlty in propagating JC virus in cell
culture. limited work has been done on the structural
proteins. The largest open reading frame located near the
3'end of the late region encodes the 354 amino acid VPl capsid
protein, the major structural protein. It plays an important
role in the cell adsorption. The smallest open reading frallG
at the 5' end of the late region encodes a 71 amino acid
polypeptide, the agnoprotein. The exact function of this
protein is not clear but it is assumed that it binds DNA and
is involved in the viral maturation pathway. Between thQ S'
and 3' open reading frames of agnoprotoin and VPl proteins are
two open reading frames that encode VP2 and VPJ capsid
proteins ot 344 and 225 amino acids, respectively ( Frisque i.t
Al, 1984; Fig. 1.1).
1.4. HETEROGENEITY" OF JCV REGULATORY REGION
JCV DNA isolated from infected glial cells is variable
in size and considerably shorter than tne full length
infectious genot:le (Osborn ~, 1974; Howley i!..t.-U, 1976;
Martin~, 1979; Grinnel~, 1983). The mUltiplicity of
infection (moi) and the cell POPUlation influence the degree
of heterogeneity of JCV genome. For example, when passaged in
oligodendrocyte rich cultures of primary human fetal
glial (PHFG) celIe at 10101 moi, JCV DNA of unit length were
observed. However, when passaged in astrocyte rich cultures
with high moi, heterogeneous popUlations of JCV DNA were
recovered (Martin ~, 1983). This suggests that the
heterogeneity of the JCV genome depends on the .in...-..Y.1..t
propagation conditions, the source ot the DNA and the natural
genetic variation of the isolate.
l'i9. 1.1 Ciroular diagram of tb8 JCV g8nolll8.
The early and late regions are shown in the anticlockwise and
clockwise directions, respectively. The numbers indicate
nucleotide (nt) positions. The relative positions of the
origin of DNA replication and the 98 bp repeats in the
regulatory region of the JCV .)ro indicated on the top. The
open reading frames are shown as large open arrows of early
proteins. T-antigen (T) and t. The dashed lines indicate
intron sequences in large T-antigen coding: sequences. The four
open reading frames of latG structural proteins of the virus
are shown on the right side.
'This figure is made based on the Fig. 3 of Major~ (1992)
\'J
11
Initial studies were focused on the analysis of JCV DNA from
brains and kidneys of PML patients. The two types of DNA
varied in size and restriction patterns (Dorries 1984).
subsequently, a total of 13 DNA isolates from 6 different
patients were cloned from brain tissue or virus that had been
propagated in cell culture (Martin~, 1985). The results
suggested the presence of two types of JCV genome, type I and
type II. The regulatory region of type I isolates were
identical and contained the two 98 bp tandem repeats with
duplicated TATA box, one ~n each of the repeats, lacked the
consensus Spl binding site and thus resembled the prototype
MAOl strain. Type II genomes differed from one another but had
several features in common. Each of them had lost one TATA box
and diverged from the Madl sequence at nt 36. In addition,
type II genornes had a 23 bp insertion which includes Sp1
recognition site present in the archetype sequences. Several
iSOlates, namely Mad4, MadS-Br, Mad1l-Br and Herl-Br were
recovered during isolation studies. All of these genomes are
of type II except Madl and Mad4. Mad4 strain resembles Mad1
except for the absence of distal TATA box. The other variants
are all of type II, having 23 bp insertion with Sp1
recognition site. Madll-Br contains the 66 bp and 23 bp
insertions (Matsuda ~, 1987: Major ll.....al, 1987: Yogo §1
ll, 1990).
Interestingly, passage of the virus from the infected
brain tissue in PHFG cells resulted in a number of rearranged
regulatory regions. Some of these had lost the 23 bp sequence
found in type II regulatory regions, and thus resembled the
Mad4 isolate. In order to clearly understand the differences
in the regulatory regions of JCV genomes isolated from kidney
and brain of PML patients, sequencing of the Jcv DNA isolated
directly from kidney and brain tissue of a PML patient was
attempted. The brain isolate designated as GS/B was slightly
larger than the kidney isolate, GS/K. Comparison at coding
regions of the Madl and GS/B DNAs revealed a total of 96 nt
differences and only 4 amino acid changes were detected in the
large T-antigen coding region. Major sequence differences were
noticed in the regulatory regions of Madl, GS/S, and GS/K
genomes (Loeber and Dorries, 1988).
The regulatory regions of Madl and GS/S contained two
98 bp repeats and two repeats of 63 and 93 bp, respectively.
Seguences from 63 bp and 5' end of 93 bp repeat of GS/S were
highly homologous to the )' region of 98 bp repeat of MadL
The GS/S sequences resembled that of Madl strain to a certain
extent and also contained tandem repeats. The sequence of GS/K
strain differed from GS/S by not having large tandem repeats
and also by containing Spl factor blnuing site and 23 bp
insertion, which was highly suggestive of the presence of
archetype sequences. Based on these results, it was thought
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that the hypervariability of JCV regulatory sequences may be
a process of adaptation of JC vit"us from the kidney to the
brain prior to the onset of PML (Loeber and Dorries, 1988).
Subsequent attempts were made to isolate JCV directly
from non-PML patients to find out whether the kidney form of
JCV differs from that of isolates from PML patients.
Successful attempts in this direction have been reported ('logo
~, 1990). JCV DNA fror; the urine of 8 non-immunosuppressed
patients and two healthy individuals was analyzed in Japan.
The sequences of all the clones were related to each other and
differed only at 4 nt positions. The genomes resembled
archetype DNA with one TATA box and a 23 bp insertion relative
to the MAD-types. Interestingly, the sequences of these
isolates from Japan were similar to the GS\K strain isolated
in Germany several years earlier, except for the difference in
3 nt positions. These results suggested that the JCV DNA from
the urine of healthy and nonimmunocompromised individuals
predominantly contains archetype DNA. Hence, it was concluded
that the brain-specific forms are generat.ed from archetype
sequences by DNA rearrangements.
1.' LATENCY OF JCV
A longstanding puzde has been the cell type in which
JCV is latent. The brains from immu~"\osuppressed and
nonimmunosuppressed patients without PML contained no JCV
early and late proteins by immunocytochemistry and the JCV
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genome could not be detected by ..i.n.....lltl. hybridization (Hoqan
.t..t.-.Al. 1980b). Recently, PeR technology has been used to
demonstrate the presence of viral DNA 1n brain tissue from PML
patients (Arthur~, 1989; Telent! ~, 1990). However,
PeR ar.alysis did not detect JCV DNA in healthy brain tissue or
brain tissue with other neurological abnormalities (Henson I.t
SIl. 1991). Taken together, these observations suggest that
JCV remains latent outside the central nervous system (eNS)
and then gains access to the nervous system during
immunosuppression. JCV is shed in the urine of prelJnant women
and immunosuppressed renal transplant patients. This indicates
that the virus is latent in genitourinary tract (Coleman .lit
Al. 1980). In one stUdy it was found that 10\ of healthy
individuals have integrated JCV DNA in renal tissue (Chesters
~, 1983). Using dot blot hybridization, JCV genome was
detected in the kidney of five of seven PML patients (Grinnel
fi....Al, 1983).
Presence of archetype ONA is also demonstrated in
normal renal tissues (Tolllinaga ll.....A..l, 1992., White ~,
1992) . The phylogenetic analysis indicated that the archetypal
regUlatory sequences are conserved in the course of JCV
evolution (Iida ~" 1993). These observations furthor
supported the previous assumptions that the JCV is latent in
the kidney and during the immunosuppression, the regulatory
region undergoes rearrangements and subsequently infects the
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brain. Recent findings on archetype JCV DNA provided evidence
for the generation of a brain-specific form from the
archetype. The sequences corresponding to nt 177-204 and 192-
219 in archetype JCV contain high homology to v- (O)-J
recombination signals. A host cell DNA-cutting or recombining
activity might target the viral regulatory region leading to
its rearrangements. Such sites of breakage and rejoining are
present only at the sites mentioned above. The rearrangements
in the archetype JCV DNA sequences ultimately lead to the
generation of infectious brain-specific form (Ault and Stoner,
1993). Support for this comes from another r~cent study which
showed that the incidence of rearranged JCV regulatory regions
compared to archetypal sequences is higher in immunosuppressed
renal transplant recipients than in nc'·,iml1lunosuppressed
patients (Kitamura ~, 1994).
JCV Dt'JA sequences have also been detected in B-
lymphocytes of normal individuals and PML patients (Tornatore
§.L..lll, 1992). Using .in......eitY. hybridization, presence of JC
virus DNA was demonstrated in mononuclear CQ11s at 200-1000
copies per cell, indicating the replication of viral genome
(Houff ~, 1988). The B-Iymphocytes also possess
transcription factors that bind to the regulatory region of
JCV (Major ~, 1990). Taken together, these observations
suggested a model wherein the JCV can be present in the bone
marrow during latency and subsequently, the virus infected
,.
lymphocytes enter the perivascular space of the brain
resulting in Infection of the brain. It has been demonstrated
recently that the nuclei of peripheral blood leucocytes of
inununocompetent individuals harbour JC virus thus providing a
strong evidence for the persistence of JCV in leucocytes of
healthy individuals. In addition to kidney and eNs, the
leucocytes are also targeted by JCV and upon immunosuppression
the virus is reactivated and can infect the brain (Dorries II
li, 1994).
1.6. RESTRICTION OF JCV GROWTH '1'0 GLIAL CELLS :IN CELL CULTURE
The major difficulty in studying JCV is the
identification of a suitable cell culture system that allows
its growth. Human embryonic cells from the kidney, lung,
liver, amnion, and intestines were tested for expression of
JCV (Beckman ~, 1982; Beckman and Shah, 1983; Miyamura gt
Al, 1985). After several weeks in cUlture, only a few T-
antigen positive cells were detected in human embryonic kidney
(HEK) cells while the other cell systems were found negative.
Later an, monkey kidney cell lines such as, BSC-l, CV-l, and
Vera cells that supported the growth of SV4Q virus were tried
and were not found useful.
These observations raised the question of whether the
observed host cell restriction was at the level of virion
adsorption or penetration. 'fo address this question, several
JCV isolates were used to infect HER and human lung cells by
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transfecting their DNAs. In these studies, primary human fetal
glial (PHFG) cells were used as positive control. only DNA
from one JCV MAD type produced T-antigen and late capsid
proteins in all the cells tested. DNA of other types were
infectious only for glial cells. Therefore, it was concluded
that the restricted cell-specificity was not at the level of
virion adsorption or penetration but could be due to
intracellular factors that control the early gene expression
and replication (Frisque~, 1979).
consequently, primary human fetal glial (PHFG) cells
proved to be the best host for JCV growth. The propagation of
JCV was enhanced by elevating incubation temperature from 37°
C to 39° C (Grlnnel ~. 1982). cultures that are rich in
spongioblasts, the precur"'or of the oligodendrocytes supported
optimum growth of JCV (Padgett~. 1977). A large number of
virions were detected under the electron microscope in the
nuclei of spongioblasts and rarely in astrocytes, one of the
types of glial cells. However, efficient growth of JCV in
astrocytes was reported in another study (Major and Vacante,
1989). No major alterations in the genome, transcriptional
activity, virus titres, and lytic cycle were observed in
spongioblast rich cultures even after continuous passage.
Although the PHFG cells provided a better environment for JCV
growth, it is difficult to cUltivate these cells. Availability
of these cells is another limiting factor. In addition, these
,.
cells contain heterogeneous pOpulation of cells and Illost
studies showed that spongioblasts permit maximulll yields of
virus.
Attempts were then made to look for a permissive cell
system that does not have the disadvantages mentioned above.
Serial passages of JCV Madl strain in HEK cells resulted in an
adapted virus namely, JCV-HEK. This new adapted virus grew
efficiently in kidney cells because of deletions and
rearrangements in the regulatory region (Yoshiike~, 1982;
Mlyamura~ ,1985). Attempts to grow the virus in cells
from adult brain were also unl:luccessful (Wroblewska ~,
1980). To eliminate all the above mentioned disadvantages, a
human fetal glial cell line was developed by immortalization
of astrocyte cells with a replication defective SV40 DNA clone
that expresses high levels of large T-antigen (Major ~.
1985). This cell line was susceptible to JCV infection.
11lll'Ilortalization of oligodendrocyte precursor cells that divide
poorly in the culture was unsuccessful. PHFG cells were
transformed by origin defective JC virus to generate a cell
line called POJ that allowed maximum growth of JCV (Mandl ~
Al, 1987). Recently, productive infection of JCV was also
reported in Schwann cells, the c9ll typ9 responsible for
myelin production in the peripheral nervous system (ASSouline
and Major, 1991). Overall, the growth and expression of JCV is
essentially restricted to glial cells only.
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1.7 TRAIl'8CRIPTION
The restricted cell specificity of JCV is largely due
to its control region. The activity of JCV regulatory region
is limited to glial cells, unlike those of BIt and SV40
viruses. Hence further studies were attempted to find out the
promoter-enhancer elements and cellular transcription factors
that contribute to glial cell specificity of JCV. Before
explaining the transcriptional regulation of glial oel1-
specific expression of JCV, I would like to describe the
general transcription machinery and how cell-specific gene
expression is controlled at the level of transcription.
1.7 • 1 PROMOTER AND ENHANCER ELEMENTS
In eucaryotes, promoters transcribed by RNA polymerase
II consists of two elements: the TATA box which is usually
located 30 nt upstream of the transcription start site, and
the initiator elements which are at the start site. These
sequences are called the minimal or core promoter elements
(Smale and Baltimore, 1989). The TATA box is essential for
determining the transcription start site. In promoters lacking
TATA box, for example in case of terminal deoxynucleotidyl
transferase gene, the initiator element specifies the
transcription start site.
The second class of elements called "enhancers ll or
"upstream promoter elements (UPE) II are recognised by sequence-
specific DNA binding proteins tb:.t activate transcription from
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the promoter. The enhancers are of two types: inducible and
tissue speci~ic enhanc-ars. The enhancers which are responsive
to stimuli such as hormones, heat shock, metals, and growth
factors are called inducible enhancers. EXll1nples include
metallothionein, p-interferon, ,!C-..t££, and glucocorticoId
hOI1llone response element (Maniatis .i.t.....ll. 1987: Mitchell and
Tjian, 1989). The enhancers \IIhich are active in certain stages
of embryonic development and in specific tissues are called
tissuQ-specific Qnhancers. The examplos tor thio class include
B-cell specitic immunoglobulin enhancers, liver cell-specific
aminotransferase gena, and brain-specific myelin basic protoin
gene (Maniatis~, 1987).
1.7.2 TRAIlSCRIPTI\.}I PACTORS
1.7.2.1 GENERAL 'lRAlfSCRIPl'IOH PACTORS
The general transcription factors (GTFs) which are
important for basal transcription from the promoter are TPIID,
TFIIA, TFIIB, TFIIE, TPIIF, TPIIH, TfIII, and TFIIJ. Most are
multimeric complexes which include polypeptides with mUltiple
functional and structural domains (Swadogo and Sentenac, 1990;
Zawel and Reinberg, 1993).
TFIID is a multisubunit complex consisting of TATA box
binding protein (TBP) and the proteins associated with TBP
called TBP associated factors (TAFs) (Pugh and Tjian, 1990).
TBP, a 38 );:Oa protein, specifically recognises and binds the
TATA box and is important for transcription initiation (Hawley
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and Roeder, 1985; swadogo and Roeder, 1985). The carboy.yl
terminus of TBP is highlY conserved in a variety of species
and the amino terminus is highly divergent (Hoffman ~,
1990). The carboxyl terminal domain is essential for DNA
binding and species specificity (Cormack ~, 1991; Reddy
and Hahn, 1991). TrIID binds in the minor groove and induces
bending of DNA. This facilitates the interaction of TFIID with
other transcription factors and TAFs (Horikoshi~. 1992;
starr and Hawley, 1991). Recently, it has been shown that the
promoters transcribed by all three polyrnerases named
polymerase I, II, and III, including TATA-less promoters,
require binding of T8P (Hernandez, 1993; Zhau ll....Al, 1992).
The three dimensional TBP structure revealed the saddle shaped
DNJ\ binding domain. The concave surface of '".he saddle makes
the specific and non-specific contacts with DNA. The convex
surface is made available to the interaction with TAFs, GTFs
and gene specific regulators (Kim ~, 1993a; Kim ~,
1993b; Nikolov~, 1992).
TFIIA stabilizes the TFIID!DNA interactions. In vitro,
TFIIA stimulates basal transcription when native partially
purified TFIID is used but not when recombinant TBP is used.
This indicates that TFIIA is essential to remove a component
that negatively regUlates TFIID activity (Reinberg ~,
1987). TFIIA is a complex of 35, 19, and 12 kDa subunits
(Cortes ~, 1992; Coulombe n......su.. 1992a). A eDNA, hTFIIA/Cl':
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encodes both the p35 and pIS subunits of human TFIIA. It was
suggested that a protease specifically interacts with the
hTFIIA and cleaves 55kDa precursor protein into p35 and pIg
subunits (De Jonq and Roeder, 1993; Ma~, 1993; i'okomori
~, 1993a). It has been shown recently that TFIIA has no
role in basal transcription. Instead, it acts as a coactivator
in activating transcription by gene specific activators by
competing with negative regulators of TBP (Ma ~, 1993).
TFIIB interacts with DA complex through the sequences
of the carboxyl terminus. The TFIIB amphipathic alpha helical
amino terminus is proposed to interact with transcriptional
activators (Ra ll...Al., 1991).
TFIIE consists of two sUbunits, 57 kDa lIE Q and 34
kDa lIE p. Both sUbunits contain sequences homologous to
bacterial sigma factor (Ohkuma ~. 19911 Sumimoto ~.
1991). TFIIE stimulates the TFIIH-dependent kinase activity
that phosphorylates the carboxyl-terminal domain (CTD) of the
largest subunit of RNA polymerase II (LU ll..Al. 1992).
TFIIF consists of two sUbunits of 30 and 74 kDa. Henco
it is also called RAP30/74. TFIIF interacts with RNA
polymerase II and recruits polymerase to the promoter by
preventing interaction with non-specific sites. since TFIlF
exhibits ATP dependent DNA helicase activity, it may playa
role in the unwinding of the promoter DNA to form an open
complex: (Aso~, 1992; Greenblatt. 1991; Finkelstein!!.t....1!.l.
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1992).
TFIIH contains seven subunits with molecular Masses of
94, 75, 62, 46, 43, 38, and 35 kDa (Ohkuma and Roeder, 1994).
Hydrolysis of the p-y bond of ATP is eBsential for
transcription initiation and part of the energy is used for
unwindinq the DNA dOUble helix in the region of the initiation
site (Swlldogo and Roeder, 1984)_ TFIIH possesses DNA-dependent
ATPa~e and kinase activities. It phosphorylates CTD of RNA pol
II (Lu~. 1992). Recently, it has been demonstrated that
~ in the absence of TFIIE, TFIIH can not act: on CTD
because of the tight association of CTD with TBP and DNA
template. Addition of TFIIE enables TFIIH to enter the
preinitlation complex, thereby resulting in phosphorylation of
CTD of pol II, meltIng of DNA around start site. This finally
leads to transition from transcription initiation to
elongation (Ohkuma and Roeder, 1994). The cloning of one of
the subunits of TFIIH is an exciting development in
understanding the possible roles of GTFs. It has sequence
homology to ERCC-3 gene product, a helicase involved in human
DNA excision repair disorders such as xeroderma pigmentosullI
and Cockayne's syndrome (Schaeffer~, 1993; Sung n.....!!.l,
1993). TFIIJ is essential for transcription when highly
purified TFIID is used but not crude TFIIO.
The ordered assembly of these GTFs at the promoter
region specified by TATA box is a prerequisite for the
t.ranscript.ion init.iat.lon by polYlllerase II leading t.o basal
level of t.ranscript.ion (Flores ~, 1992). There are also
complex mixt.ures C!f poorly underst.ood polypept.ides int.eracting
at. the init.iator (lnr) elements (Zawel anel Iteinberg, 1993).
1.7.2.2 'f'JUUf8CRIPl'.IOM' AC'l'1:VA'l'ORB
Another clllss of t.ran!lcription tact.ors are called
activators. Activators and their DNA recognition sequences
torm a major focus of my studies. Activators interact with the
onhancer sequences, are modular and contain two domains: DNA
binding and activation domains. DNA binding domains includo
zinc finger, leucine zipper, homeodomain and helix-loop-helix
motifs. The activation domains are ot three kinds, acid rich,
proline rich, and qlutemine rich (Mit.chell and Tj ian, 1989).
Transcriptional activators stilllulate tho rate at t.ranscription
by contacting one or more of the general transcription tactors
asselllbled at the promot.er (ptashne and Gann, 1990).
1.7.2.2.1 XECH}UfrSM
AC'l'IVATORS.
In general,
'l'RAlfSCRIPTIOtfAL ACTIVA!l'IOM BY
eucaryotic gene expression requires
t.ranscriptional activat.ors binding to so.J..a-octinq elements
located either upstream or downstream of the \:l';anscription
start site (Mitchell and Tjian, 1989; Ptashne, 1988; StrUhl,
1989). The so.1.&-actinq elements are Spo.cific t.o each gen-a and
are recognised by Ubiquitous, development-st.age-s)lecitic, or
tissue-specific DNA binding proteins interacting with the
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basic transcriptional machinery via their transcriptional
activation or inhibition domains (Swadogo and Sentenac, 1990).
The interaction may depend on DNA looping or other chromatin
structures (Ptashne, 1988). The greater details of the
mechanism are discussed in the following subsections.
1.7.2.2.1. 1 INTEJU.cnON or ACTIVATORS WITH GENERAL
TRANSCRIPTION PACTVRS (GTre)
TFIIO is essential for the assembly of the pre
initiation complex (PIC) on all promoters tested ~.
Thus TFIID was thought to be a target for certain activators.
The mammalian transcription activator, activating
transcription factor (ATF), stimulated the rate of
transcription from adenovirus E4 promoter by interacting with
TFIID (Horikoshi ~, 19S8a). sUbsequently, TFIID was shown
to be a target for activators like Gal4 (Horikoshi ll....il.l.,
1988b) and upstream stimulatory factor (USF) that activates
adenovirus major late promoter (Swadogo and Roeder 1985). The
pseUdorabies virus immediate early protein (IE) stimulates
transcription~ by accelerating the recruitment of
TFIIO to TATA box (hbmayr ~, 1988). Adenovirus EIA
protein, a potent transactivator of transcription was shown to
interact with carboxyl terminal basic repeats of TFIID in
order to generate a rapid, efficient assembly of PIC {Lee ri
li. 1991).
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Generally. other viral transactivators like herpes
simplex VP16 (stringer ~, 1990) and papl110mavirlls E2
protein (Oostan! ~, 1991) enhance the rate of
transcription by interacting with TFIID and stabilizing the
complex at the promoter. Epstein-Barr virus zta protein, which
contains a transcription activation domain different from EIA,
interacts with carboxyl terminus of TFIIO and stabilizes the
association of TrIID with the promoter (Liebermann and Bark,
1991). The activator proteins such as p53 (Truant ~, 1993)
and PU.l (Hagemeier ~, 1993) have been shown to directly
interact with TBP. The tat protein of HIV transactivates
transcription in vivo and in vitro. Direct interaction of tat
with TFItD composed of TBP and associated factors (TAFs) was
observed. This suggested that tat may transduce regulatory
signals by interacting with TFIID (Kashanchi tt..JU., 1994).
The chimeric activator termed Ga14-VP16 consisting of
Gal4 DNA binding domain fused to acidic rich transactivation
domain of VP16 stimulatEs transcription by recruiting TFIIB to
the pre-initiation complex (Lin and Green, 1991). LSF cellular
factor accelerates the association of the TFIIB with TATA
bound TFIID and thereby stimulat.:es the rate of transcription
from SV40 major late promoter (Sundseth and Hansen, 1992).
These e)(amples demonstrate that activators accelerate the rate
of transcription by facilitating the recruitment of GTFs to
promoter.
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INTERACTION WITH TBP ASSOCIATED I'ACTORS
('l'''''.)!COACTIVIr.TORS
Initial studies with purified TBP exhibited only basal
but not activated levels of transcription of core promoters in
Y.it..J;:Q even in the presence of transcriptional activators like
Spl, USF, and NFL Instead, partially purified TFIID allowed
transcriptional activation by activators~ suggesting
that the proteins associated with TBP called TAFs are
important for activated tL'anscription. Some of the TArs can be
dissociated from TBP under conditions of high ionic strength
and some are tightly associated with TBP and require
denaturing agents like urea for removal from TBP. This
suggests that some TAFS are always associated with TBP and
some interact with TBP transientlY (Drapkin ~, 1993).
Subsequently TAFs were isolated from crude TFIID using
denaturing agents like urea. Addition of these TAFs to the
recombinant TBP stimulated the rate of transcription in the
prasence of activator proteins such as, Sp1 and CTF/NFl in
ili1::.2. (Tanese ~,1991.) • Thereby. it was suggested that the
activators int~ract with one or more of these TAFs directly
and regulate the activity of TBP by altering DNA-TBP
interactions. The components of TAFs that interact with
activators and form a bridge between TBP and activators to
l::timulate the rate of transcription from the core promoters
are also called co-activators.
At present 13 TAF. have been isolated that mediate
activator-dependent transcription by RNA polymerase J:J:. Two
complexes containing TBP were isolated from HeLa cells. One of
the complexes isolated from the 0.85 H KCI fraction contained
13 TAFs with molecular weights 230, 135, 115, 100, 95, 80, 55,
31, 30, 28, 20, 19, and 18 kDa and supported activated levels
of transcription by RNA pol IJ: in the present'!D of activator
proteins. The other complex isolated trom 0.3 M KCl traction
contained 4 TAFs or 190, 96, 87 and 60 kOa that substituted
for TFIIIB factor required for RNA pol II:". transcription
(Chiang ~, 1993). The pol I transcription factor SLI
contains three TAFs with molecular weights 110, 63, and 48 kUa
which are distinct from TAFs important for pol II and III
transcription (Comai ~, 1992). This suggests that there
are Pol I, II, and III specific TAFS mediating activator-
dependent trr.nscription.
Not all these TAFs have been cloned. The TAF 250
(Hieatake ~, 1993, Kokubo ~, 1993: Ruppert itt..Al,
1993) and Drosophila TAFs 110 (Roey~, 1993), 80 (Dynlacht
~, 1993), and 40 (Goodrich ~, 1993) have been cloned.
The human TAF 250 was identical to cell cycle regulator CCGl
and hence the suggestion was given that hTAF250/CCGl may be
involved in regulation of cell cycle progression (Hisatake.t.t.
U, 1993). It has been shown recently that the TAF1l 250 subunit
of the TFIIO rescues a temperature sensitive hamster cell line
2'
to overcollle a G, arrest. The nuclear extract from this cell
line failed to support the activated levels of trans~ription
by gene .;pecific regUlators, Spl and Ga14-VP16, without
affecting the basal level of expression. This is the first
report to demonstrate that a general transcription factor,
TAF-TBP complex, influonces the expression of genes
responsible for cell cycle progression (Wang and Tjian, 1994).
The Drosophila TAFnllO does not bind TBP directly but
interacts with dTAFII 250 and dTAFIIJOa which bind TBP directly.
TAFllO is thereby recruited to TBP (Kokubo ~, 1993;
Yokomori .i.t...A1" 1993b). In addition, dTAFIIIIO also interacts
with large subunit of TFIIA (Yokolllori fi....Al, 1993a).
The Drosophila TAF250 and 110 interact with Spl
activator and stimulate the rate of transcription (Ruppert ~
li, 1993; Hoey itU.1. 1993; weinzierl ~, 1993). Recently
it has been shown that the glutamine rich hydrophobic surface
ot Spl interacts with dTAFn 110 and activates transcription
(Gill ~, 1994). Another transcription factor CREB also
interacts with dTAFllllO, apparently through the regions
similar to that of Spl. This suggests that different classes
of ,';1ctivators utilize dTAFIl II0 as a coactivator and stimulate
the rate of transcription (Gill ~, 19941. However, in
another study it was shown that the acidic activator
containing an activation domain different from Spl and CREB
interacts directly with another component of TFIID, dTAF11 40,
30
to activate transcription (Goodrich ~, 1993). This
suggests that different classes of activators interact with
distinct components of TFIID such as TAF\l250, 110, and 40.
The discovery of coactivators revolutionised the field
of transcription, especially immunoglobulin gene
transcription. The lymphoid cell-specific oct"2 protein but
not ubiquitously expressed Oct-l protein was shown to be
important for B cell-mediated transcription in a number of
studies (Tanaka and Herr, 1990; Gerster ~, 1990). 19 H
promoter-specific, Oct-l factor specific, and B cell-specific
ceactivator that stimulated 19 H promoter effectively in the
presence of Oct-l but not Oct-2 questioned the role of
lymphoid cell-specific Oct-2 in immunoglobulin gene
transcription (Luo ~, 1992). Further, the disruption of
Oct-2 locus in B-cells had no effect on immunoglobulin gene
transcription (Feldhaus~, 1993), supporting the role of
a 8 cell-specific coactivator in immunoglobulin gene
transcription.
Dimerization of a liver specific transcription factor,
Hepatocyte Nuclear Factor-l (HNFl) is essential for thQ
transcription of liver-specific genes. A liver-specific
coactivator mediates the dhlerization of HNFl and thus plays
a key role in liver-specific transcription (Mendel !ll-cU..
1991). The evidence for the role of coactivators in the
transcription of eucaryotic genes, especially in tissue-
specific gene exprass!on, is well documented.
A mediator activity distinct from TAFs
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purified
frolll yeast cells and shown to be necessary for stimulation by
acidic activators such as VP16 and GCN4. The mediator
facilitates direct interaction between activators and
components of the basic transcription machinery (Kelleher n
Al., 1990; Flanagan~, 1991).
1.7.2.Z. 1. 3 STIMULATION OP BASAL TRANSCRIPTION BY RELUV:tNG
REPREBSION
Recently, histone-mediated repression of
transcription has received considerable attention. Order of
addition experiments revealed that nucleosomes prevent pre-
initiation complex formation by GTFs (Workman~, 1991).
Transcriptional activators like VP16 and Spi stimulated
transcription of histone Hl-mediated but not naked DNA
templates by 200-fold by stabilizing and accelerating the
recruitment of GTFs to the promoter (Croston ~, 1991;
Laybourn and Kadonaga, 1991; Laybourn and Kadonaga, 1992).
An activity called upstream factor stimulatory
activity (USA) distinct from co-activators was reported
(Meisterernst ~, 1991). USA contains two components,
negative cofactl. : 1 (Nel) and positive cofactor 1 (PCI). They
exhibit opposite effects on core promoter activity. Nel
inhiL.its promoter activity by interacting with TBP, thus
preventing interaction of TFIIA with TBP. On the other hand,
J2
PCI in combination with activators like Spl and USF reverse
the action of Nel by directly or indirectly facilitating the
entry of TFIIA into pre-initiation complex (Meisterernst §.t
Al. 1991). In addition. other factors such as negative
cofactor 2 (NC2) and TFIID binding factor 4 (08F4) and with
properties similar to Nel were isolated that reduce the core
promoter activity by forming a non-productive complex with
TFIID. The transcriptional activators reversed the inhibition
by facilitating the formation of a productive pre-initiation
complex (Meisterernst and Roeder, 1991).
A novel repressor activity namely Drl was isolated from
HeLa cell extracts that binds to TFIIO and prevents the
SUbsequent binding of TFIIA and B. However, activators liko
adenovirus EIA and SV40 large T-antigen disrupt this complex
and facilitate the entry of TFIIA and TFIID (Inostroza tl-al,
1992) .
1.7.3. FACTORS THAT INFLUENCE THE TRANSCRIPTIONAL ACTIVATION
BY GENE-SPECIPIC ACTIVATORS
1.7.3.1 DNA B:INDING SITE AND TRANSCRIPTIONAL RESPONSE
The individual ~-acting element in the regulatory
region of a gene can bind to one or many tl!fferent factors
which belong to the same or a different family. For example,
many homeodomain proteins and ligand-dependent nuclear
receptors bind to the same £1§.-acting element (Hoey and
Levine, 19881 Glass~ 1988; Beato, 1989). A site in hum.!!n
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osteocalcin gene is recognised by both~ and vitamin A
and D receptors. However, each exerts an opposite
transcriptional effect (Schulle ~,1990). Thus a single
ill-acting element can elicit different transcriptional
responses depending on the binding of the specific
transcriptional factor.
On the other hand, a single transcription factor can
bind to different DNA sequences. A good example for this is
the yeast HAPI zinc finger protein (Pfeifer ~, 1987).
Other examples are certain homeodomain proteins (Hoey and
Levine, 1985). Although different transcription factors bind
the same ill-element, the relative position, orientation, and
spacing of binding motifs can play an important role under
certain conditions. For example, the glucocorticoid and the
oestrogen receptors recognise related but distinct binding
motifs (Klock~, 1987). On the other hand, the receptors
for oestrogen, thyroid hormone, retinoic acid, and vitamin 0
bind virtually identical sequences. However, the relative
spacing and orientation determine the transcriptional response
which can be either activation or repression (Glass ~,
1988, Naar ll-Al, 1991; and Umesono ~, 1991).
1.7.3.2 INTRAPAKILY PROTEIN-PROTEIN INTERACTIONS
Some classes of trlllnscription flllctors bind DNA as
either homodimers or heterodimers. !I.Y.n and .f2.§. transcription
factors belonging to the leucino zipper family bind DNA as
"
heterodimers to a ill-acting site called AP-'. site and some of
them have different transcriptional activities (Nakabeppu II
li. 1988; Cohen ~, 1989). The glucocorticoid and oestrogen
receptors bind to their respective sites as homodimers (Kumar
and Chambon, 19881 Tsai ~, 1988). The retinoic acid
receptors bind DNA as heterodimeric complexes with other
nuolear factors called coregulators, one of them being tho
thyroid hormone receptor (Glass ~, 1989, 1990). These
coregulators affect DNA binding and transcriptional activity
of retinoic acid receptor. The muscle specific helix-loop-
helix protein, MyoD, dimerizes with ubiquitously expressed
proteins of the same family to activate transcription of
muscle-specific genes (Weintraub ~, 19911 Benezra .!!t....ltl,
1990) •
Heterodimer formation sometimes results in inhibition
of DNA binding and thereby represses transcriptional activity
of activators. Id, a member of helix-loop-helix family,
heterodimerizes w.l.th other members of the same family such as
Hyoo and E12/47 and inhibits the transcriptional activity of
these factors (Benezra .f!.t...-ll, 1990). I-POU, a protein
belonging to POU domain class specifically heterodimerlzes
with another POU domain protein, cfla, and prevents its DNA
binding and transactivating neural specific genes (Treacy tl
Al, 1991; Johnson and Hirsch, 1990).
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1.7.3.3 INTERFAMILY PROTEIN-PROTEIN INTERACTIONS
Recently, it has been shown that glucocorticoids
inhibit the transcriptional activity of~ on AP-l site.
Glucocort:icoid receptor prevents binding of~ complex to
DNA. Also, the~ complex prevents the glucocorticoid and
other nuclear receptors from binding to their respective
response elements (SchUle .!iLli, 1990; Jonat ~, 1990,
Oiamond ~, 1990). The VP16 transcription activator of
herpes simplex virus cannot bind DNA alone, but interacts with
the homeodomain protein Oct-l through its acidic rich
transcriptional activation domain to stimulate the rate of
transcription (Stern ~, 1989; Kristie and Sharp, 1990).
The pX protein of hepatitis B virus interacts with leucine
zipper proteins CRES and ATF2 and enables thel1l to bind to a
different set of DNA sequences (Maguire !!.t..Jllr 1991).
1.7.3.4 COVALENT MODIFICATION OF TRANSCRIPTION FACTORS AND
TRANSCRIPTIONAL ACTIVATION
certain transcription factors cequire posttranslational
modifications either to activate or inhibit transcription. The
phosphorylation of the threonine residue within the DNA
binding domain of Pit-l pituitary specific transcription
factor may differentially increase. or decrease. its binding
affinity for the ill-acting element present in prolactin and
growth hormone gene promoters (Kapiloff ~, 1991). The lIl.W
transcription factor is phosphorylated near its N-terminal DNA
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binding domain and protein kinase C activation leads to
dephosphorylation at this site. This increases DNA binding and
transactivation by the Jun!Fos complex (Boyle ~, 1991).
Similarly, phosphorylation of serine residue by c1>.MP dependent
protein kinase A is essential for transcriptional activation
of cAMP response element binding protein (Gonzalez and
Montminy, 1989; Sheng JlU1. 1990).
1.7.4 TRANSCRIPTIONAL REGULATION OF' CELL-SPECIFIC GENE
EXPRESSION
cell-specific gene expression is mainly regulated at
the level of transcription. The cis-acting elements and DNA
binding proteins involved in the expression of various genes
that are expressed in a call-specific manner are well
characterized, especially in the case of the liver (reviewed
in simone and Cortese, 19911 1992; Lai and Darnell, Jr, 1991),
muscle (reviewed in Olson, 1990; Tapscott and wein~ra\.lb, 1991;
and Li and Olson, 1992), pituitary (reviewed in Sharp and cao,
1990: Karin Ji!.Ul, 1990), erythroid (reviewed in Orkin, 1990)
and immune systems (reviewed in staudt and Lenardo, 1991).
1.7.4.1 MUSCLE-SPECIFrC GENE EXPRESSION
Muscle-specific expression is a well-stUdied system
serving as a model of tissue-specific gene expression. Musclc-
specific genes are mainly regUlated at the level of
transcription. Myoblast differentiation is accompanied by
transcriptional induction of muscle-specific genes. Earlier
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studies suggested. the existence of a master gene important for
setting the events that finally end up in the formation of
mature fibre. The eDNA for the master gene, MyoO was cloned
subsequently by subtraction hybridization using myoblasts and
fibroblasts. Transfection of HyoO cONI. into 10'1'1/2 fibroblasts
activated myogenesis (Davis.Bt...Jll, 1987). Subsequently. three
Iluscle specific transcription factors, myogen1n
(Edmondson and Olson, 1989), myt5 (Braun ~, 1989), and
lllyf6 (Miner and Old, 1990: Braun~, 1990) were isolated.
Like HycO, each of these factors can convert 10'1'1/2
fibroblasts to myoblasts.
HyoO alone can activate muscle specific gene expression
or set the events that lead to activation of muscle specific
genes. In cooperation with ubiquitously exprt:.lssed factors HyoO
can activate muscle cell-specific gene expression. The HyoD is
a muscle cell-specific factor that binds to a CANNTG sequence
called the "E-box site". The E-box binding site is present in
many muscle specific genes such as muscle creatine kinase
(HCK), troponin 1, alpha-cardiac actin and MLCl/3 genes. In
addition, the E-box binding sites are also present in the
regUlatory regions of other cell-specific genes, such as
illlllunogiobulin and insulin genes (Sen and Baltimore, 1986;
Walker~, 1990).
HyoD binds to DNA very weakly. However, in cooperation
with the widely expressed E2A gene products such as E12, E47,
3.
and TFE3 factors HycO acquires high affinity for binding DNA
and regulates transcription (Davis Jlt.....Al, 1990; Murre J!..t......a.l..
1989). Although the .eabers ot HycO and E2A gene products
binds to the SAme sequence, MycD can activate the
transcription of muscle cell-specific genes, whereas, E2A gene
products can not (Blackwell and Weintraub, 1990). It was
further shown that the basic region of HyoO plays a role in
the transcriptional activation of muscle cell-specific genes
(Davis ~, 1990).
Replacement of the basic region of HycO with that of E2A
gene products does not prevent the DNA binding activity of
MyoD but fails to activate muscle cen-specific transcri,?tion.
The mutations in the basic regIon of HycO that allows DNA
binding but I revent activation of mus;::le-specific genes was
also reported (Davis n.....Al, 1990). This observation provided
a clue that the activation dOllain of HyoD is cryptic and the
basic region somehow cOWDunicates with the activation domain
to stimulate transcription upon binding to E-box. Three
possible mechanisms were proposed. (1) The basic region may
interact with a co-activator that results in conununication of
the basic region with the activation domain. (2) Both HyoD and
myogen!n may undergo a conformational change, unmask.ing the
transcriptional activation domain. (3) Another mechanism may
involve interaction of muscle specific factors with other
transcription factors that bind to nearby sites 1n DNA leading
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to activation of muscle cell-specific genes. The examples for
this are the activation of Mel( enhancer that requires
cooperat.ive binding of MyoD and other Ubiquitous and muscle-
specUic transcription factors s\.:<;:,h as MEF2 (Weintraub~,
1991). Also, the activation of human alpha cardiac actin
pro.oter requires simultaneous binding of serum response
factor, BpI, and MycD (sartorelll~. 1990).
1.7 .... 2 BIlAZH-SPICII'IC aln SIPOSBION
JCV expression and replication is brain-specific. JCV
is oncogenic in animals and it is the only human virus known
to produce solid brain tumors in nonhuman primates (Frisque
and White, 1992). Therefore, it is also important to
understand brain-specific gene expression. The malll1llalian brain
is a complex organ containing a heterogeneous population of
cells. Hence it is very difficult to study its gene
expression. Analogous to the cell-specific gene expression of
liver, muscle and other organs, brain-specific genes are also
regulated mainly at the level of transcription (reviewed in
Takahashi, 1992; Mandel and McKinnon, 1993).
1.7.... :z. 1 OLI:AL CBLL-8FECI:FI:C a.NIl roXPRE881:01f
JCV has sim.ilarities to the control regions of myelin
basic protein (MBP), glial fibrillary acidic protein (GFAP),
proteolipid protein (PLP), and SlOOP genes which are expressed
mostly in glial cells as detailed in the following.
1.7.".2.1.1 GLIAL CBLL-8PBCII'IC BXJlRB88IOlf 01' OI'AP
Three regions (A,B, and D) in the regulatory region of
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GFAP were round important tor its glial cell-specificity. The
region A contains binding sites for transcription factors Spl
and nuclear factor 1 (NFl). Region B con~ains adjacent
activator protein 1 (API) and NFl binding sites. Region 0
consists of adjacent NFl and AP2 binding sites. Region B is
the most act.ive of the three regions and stimulates strong
glial cell-specific expression. Regions A, 8, and 0 activate
heterologous promoters such as that of SV40. in glial cells
but not in other ceU types. Region 0 functions primarily to
promote interactions that bring region B close to the promoter
CBesnard~, 1991).
1.1 .... 2.1.2 EXPRESSION OJ' 8100P I.N GLIAL CELLO
5100,8 protein is primarily present. in astrocytes and is
found in 30 to 100 fold higher levels than in other tissues
(Kato and Kimura, 1985). The binding sites for NP1, cAMP
response element binding protein (CREB) , and AP2 were found
important for the expression of 5100,8 in the glial cells
(Allore ~, 1990).
1.7.4 • 2 .1. 3 GLX~L CELL-8PBCIPXC EXPRE88XON OF PLP
proteolipid protein (PLP) 1s one of the components
essential for the formation of myelin that forms a ,<I, Jath
around axons. The regUlatory region of PLP contains NFl
binding sites and also both positive and negative ili-
regUlatory elements which dete:nnlne the glial cell-specificity
(Nave and Lemke, 1991). The .£iii-acting elements are highly
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homologous to those observed in MBP.
1.7 ••• 2: .1." MYELIN BASIC PRODIN GENE EIPRE88ION IN GLI~L
CELLS
MBP forms one of the important constituents of myelin.
MBP promoter consists of several regulatory sequences out of
which the proximal element MBI and one of the distal elements
are highly active in glial cells as compared to other cells
(Beach ~, 1990). The sequences around the NFl binding
sites in the proximal and distal regions were found to be
important for glial cell-specific expression of MSP promoter
(Myoma K..li. 1990). Another surprising finding is that the
TFIID from brain but not liver stimulated the transcription of
MBP in vitro, suggesting that different tis!lues contain
functionally different TFUD species (Tamura !!t..-Al, 1990a).
Hence the interaction of different proteins binding the MBP
regulatory region may influence the glial cell-specificity.
1.7.4.2.2 NEURON-SPECIfIC GENE EXPRESSION
The genes for neurofilament, proenkephalin. and
dopamine ,B-hydroxylase (DBHl genes are expressed only in the
neurons of the central nervous systell. The regulatnry regions
of neurofilament and proenkephalin contain adjacent NFL and
AP2 binding sites and cooperative interaction of these
proteins may playa role in neuronal cell-specific expression
(Comb .i.Lill. 1988; Nakahira ~. 1990).
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A role for a negative regulatory element in the neuron
specific expression of SCGIO, a neuron-specific growth
associated protein, and the type II sodium channel protein was
recently reported. Deletion of the ill-acting negative
regUlatory element or silencer region allows expression of
these genes in non-neuronal cells. Thus the silencer region
plays a major role in the cell-specific expression of these
neuronal genes (Morl ~, 1990: Maue ~, 1990). The
sequences of the silencer region of these two unrelated
neuronal genes is strikingly similar. In addition, the same:!
protein from various non-neuronal cells was shown to interact
with this silencer region (Morl~, 1992; Kraner §.Lll,
1992) •
Oopamine ,a-hydroxylase, the enzyme catalyzing the
conversion of dopamino to norepinephrine, is specifically
expressed in adrenergic and noradrenerqic neurons in the
central nervous system. By DNase I hypersensitive assay and
transient expression assays, a 4.3 Kb upstream sequence was
found to be essential for neuronal cell-specific expression of
DBH gene. By deletion and mutation analyses two regions in the
regUlatory region of OBH gene were identified that confer
cell-specificity. The first region, the cAMP response element
(eRE) is essential for positive regulation of DBH and confers
95% of cell specificity. The second region is a silencer
region that negatively regUlates its expression in non-
"
neuronal cells. Hence interplay between the eRE and
specitic silencer plays an iaportent role in the tissue-
specific expression of the DBH gene (Ishiquro~, 1993).
The tyrosine hydroxylase (TH) gene contair.s the consensus eRE
in the proximal region and the eRE plays an important role in
both the basal and cAMP inducible expression (Kim i..t.......Al.
1993). Thus these two genes for enzymes TH and DBR adopt
similar molecular strategies for their neuronal cell-specit'ic
expression by using same ~-acting element, eRE. As will be
discussed later (chapter 5), JCV also contains adjacent
Nuclear Factor 1 binding and CRE motifs (Amerniya ll..Al, 1992).
1.7.5 GLIAL CELL-SPECIFIC EXPRESRION OP JC VIRUS
1.7.5.1 TRANSCRIPTION INITIA1'ION OF JCV EARLY JUfD LATE GENES
The promoter-enhancer sequences of JCV were first
identified bl!lsed on the sequence comparison with BK and SV40
viruses. The peculiarity of J:'" is that it contains two TATA
boxes, one in ol!lch of the 98 bp repeats, in contrast to
presence of single TATA box in SV40 virus (Frisque ~,
1984; Fig. 1.1). The presence of two TATA boxes in JCV
promoter-enhlSncer was thought to control the early and late
transcription of the virus. The viral early gene transcription
was shown to initiate from nt 122-125 using TATA box located
in the repeat B (located far from the origin of replication
Fig. 1.1). as shown by 51 nuclease analysis (Kenney .i..t.......Al,
1986a). Using primer extension technique it was shown that the
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early transcription initiated from nt 5112 and 5082 and the
TATA box located in the repeat A (located near the origin of
replication Fig. 1.1) and that repeat B was not utilized
(l<ha111i J!t...Al, 1987).
Another study used primer extension technique to map
the early transcription start sites to nt 5112, 5119, and
5090, analogous with the above study (Vacante ~, 1989).
Early and late gene transcription was shown to utilize the
TATA boxes located in the repeat A and B, respectively (Tada
and Khalili, 1992). The discrepancies 1n the stUdy of
transcription start site have been resolved in a recent stUdy.
Using both primer extension and 51 nuclease analyses, the
transcription start sites for early and late genes were mapped
to positions 5115-5125 and 200-203, respectively (Daniel and
Frisque, 1993). Overall, these studies suggested usage of
different TATA boxes and start sites for early and late
transcription of JCV.
There are two other examples of the genes containing
dual TATA boxes. The CYC1 gene of the yeast saccharomyces
cerevlsiae contains two functional TATA elements at sites -178
and -123 upstream of start site. The sequence near the 5' end
is ATATATATAT, whereas the sequence near 3' the end is
'fATATAAAA. Further, it was suggested that the two TATA boxes
recognized different factors of the transcription apparatus
eLi and SheLllIan, 1991). The gene of Autographa californica
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nuclear polyhedrosis virus (AcMNPVl is controlled by tandem
promoters. Late transcripts initiate from conserved TAAG motif
utilizing proximal TATA box, while early transcripts initiate
from conserved CAGT motif usin; distal TATA element. Late
transcripts were not affected by alterations in the distal
TATA box. Similarly, early transcripts were not affected by
mutations in the proximal TATA box. The results suggested the
usage of different TATA boxes for early and late
transcription, respectively (Guarino and smith, 1992).
1.7.5.2 GLIAL CELL-SPECIPIC EXPRESSION OF JC VIRUS REGULATORY
REGION IN CELL CULTURE
The first report identifying the promoter-enhancer
signals of JCV was from Kenney~ (1984). They fused the
regulatory sequences of JCV to the reporter gene,
chloramphenicol acetyl transferase (CAT), in both
orientations. The activity of the reporter plasmids was
assayed in PHFG, HeLa, HEK, and CV-l cells by performing CAT
assay. Maximum activity was detected in PHFG cells. The
construct in which the JCV promoter-enhancer sequences were
cloned in the reverse orientation was about twice as active as
the one cloned in the sense orientation. The activity observed
in CV-l cells was negligible. In contrast, the CAT construct
with SV40 regulatory sequences was active in all the four cell
types tested. Deletion of a sin':fle copy of the 98 bp repeat
reduced the activity by 5-fold. Removal of all but the first
,.
46 bp of the first tandem repeat totally abolished the
activity. Deletion of one copy of the tandem repeat was more
detrimental to the promoter-enhancer activity in PHFG cells.
These results suggested that, unlike the other human polyoma
viruses such as BKV, JCV has restricted glial oe11-
specificity.
In another study the regulatory region of JCV was
replaced with that of either SV40 or BKV. The new hybrid
constructs were not viable in human fetal glial cells. In the
reverse hybrid constructs, the regulatory region of JCV
controlled synthesis of either SV40 or BKV T antigen in human
glial cells. T~,ese results suggested that SV40 and SKV T
antigens could interact with JCV regulatory region but JCV T
antigen, although shawn to bind SV40 DNA, could not substitute
for the homologous T p.cotein. It also indicated that JCV T
protein played a significant role in determining efficient
gene expression in a cell-type-specific manner (Chuke !ll-.Al,
1986) .
Regulatory regions of type r and type II JCV variants
isolated from PML patients were tested for their activity in
PHFG and HER cells. The activity of Mad1 strain was 15-fold
more in PHFG cells than in HEK cells. The activity of Mad8Br-
cat and the two Madll-cat constructs showed only minor
differences in their activity in PHFG cells. Mad7-cat and
Herl-cat constructs failed to show detectable activity in PIIFG
cells. The results with Herl-8r construct were surprising
since the sequences are closely related to those of MadS-Br.
The differences in the activity of different JCV strains in
FHFG cells were suspected to be due to diffarences in the
nulllber of prolloter-enhancer elements in these Iiotrains. The
suggestion that the presence ot a second TATA box in the
prototype MAOI JCV regulatory region may interfere with the
selection of the correct early IlIRNA start site was seriously
considered in this case (Mandl and Fr3 ..que, 1986). However, no
detectable difference was noticed in the activity of Madl and
Mad4 strains {the latter not having the second TATA box}.
Hence the possibility of interference of selection of start
site due to presence of a second TATA box was rulad out.
Further studies used additional cell types derived
from primate and rodent species to address the mechanism of
cell-specificity of JCV • A high level of expression was
observed i-.l glial cells but not in other cells. Quantitative
51 nuclease analysis showed higher levels of CAT transcripts,
suggesting the high transcriptional activity in glial cells.
In nonglial cell lines SUch as human cen-ical KaLa and monkey
kidney COS cells the CAT activity was negligible and it was
only 2-4 times more than the CAT construct lackinq promoter-
enhancer s~quences (Feigenbaum~, 1987). Tak~n together,
the results strongly -suggested that the expression of JCV is
limited to glial cells.
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A chilDerlc polyolla virus was constructed by inserting
SV40 21 bp triplicates and 72 bp repeats at the distal end of
the JCV regulatory region on the late side of 98 bp repeats
without int.3rruptinq the coding potential ot JCV T-antigen and
capsid proteins. Although the chimeric virus replicated
efficiently in human fetal glial cells, coll-induced delatione
were found in the regulatory region. DNA sequence analysis
revealed a 294 bp deletion from the original construct that
retained one of the complete 98 bp repeats ot JCV and one and
one-third of the SV40 72 bp repeats. The other JCV 98 bp
repeat and SV40 21 bp triplicates were consistently deleted.
The virus produced JCV T-antigen without any changes in the
amino acid sequence. The chimeric virus demonstrated widor
species and cell-type host-range, producing infectious virus
in human fetal brain and embryonic kidney as well as in rhesus
lDonkey fetal and adult glial cells. However, the species host
range was not extended beyond primate cells. These data
suggested that the JCV regUlatory sequences: restrict tho host
range and the SV40 sequences were needed for the extended
cell-type range. These sequences are responsible for the host
range phenotype and the glial cell tropism (Vacante ~,
1969) •
To further confirm the glial cell-specific expression
of JCV, the promoter-enhancer sequences of the kidney-adapted
variant of JCV, JCV-HEK-A were tested for activity. The
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activity of CAT constructs containing the regulatory sequences
of Madl and JC-HEK-A was tested in human kidney REK a1.J human
neuroblastoma cell line, GOTO. Madl expressed only in GOTO
cells, whereas, JC-HEK-A construct expressed in both the cell
types. The results suggested that the regulatory region of JC-
HEK-A might have undergone rearrangements and that the new DNA
sequence inserts were able to interact with the factors
present in HEK cells (SinoHara §.t....Al, 1989).
Two-phase partition assay for chloramphenicol acetyl
transferase (CAT) was done to compare the activities of the
JCV Madl, BKV, and SV40 enhancer sequences in African green
lIlonkey kidney (CV-I) and owl lI\o"key kidney (OMK) cells • The
activity of Madl was 2.0 and 1.2\ and BKV was 45 and S" in CV-
1 and OMK cells, respectively. This confirmed the restricted
cell specificity of JCV (Martin, 1990). Recent studies
compared the activities of Mad1, MadS-Br, and Madll-Br
promoter-enhancer signals in human cervical HeLa cells,
primary hamster fetal glial cell line FOJ, and monkey kidney
cell line SVG. In these cells, pHadl exhibited only low
activity, confirning the earlier Observations of glial cell
restricted expression of JC virus. MadS-Br construct was
active in all the three cell types. Madll-Br construct was
inactive in He1a cells, but 3.5- and lQ-fold more active in
POJ and SVG cells, respectively. The results suggested that
the heterogeneity of the regulatory sequences of JCV may alter
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the cell specificity of JCV promoter-enhancer under
conditions (Martin and Ll, 1991).
1.7.5.2. 1 .S'U88IOII or JCV III Plt ZIIBRYClIIAL CARCllfOMa. CELLS
previously, our laboratory used PI9 embryonal
carcinoma cells as a model system to study the glial c811-
specitic expression of JC virus. ElI'Ibryonal carcinoma (ECl
cells have been widely used as a model system for studying:
early lIIurinQ devQlopment. EC cells are the malignant stem
cells of teratocarcinoma and reselllUle the pluripotent cells
from the inner cell mass of early mouse preimpli!lontation
embryos (Martin, 1980). A number of differentiated cell types,
with characteristics of cells of the three germ layers can be
obtained by different treatments (Martin, 1980). When
implanted into mouse embryos, EC cells can contribute to the
development of normal embryos. This suggests that the
mechanisms of differentiation of EC cells are similar to those
of normal embryonic cells (McBurney~, 1988).
Addition of retinoic :acid (RA) at 10.6 M to monolayer
cultures of PIg EC cell line induces differentiation to a
heterogeneous popUlation consisting of endoderm- and mesoderm-
like cells. These cells are fibroblast-like and few neurons
are also found (Jones-Villeneuve~,1983). When induced to
differentiate with 300nM RA, PIg EC cells develop into cells
resembling those of embryonic brain tissue. Addition of RA at
300 nM to aggregating Pl9 ceUG induces heterogeneous
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population of neuronal cells consisting- of neurons, astroglia,
microglia and fibroblast-like cells (McBurney, 1993). Neurons
and glial cells in RA-treated PI9 cells are always found
together with the neurons usually lying on top of the glial
cell monolayer. The fibroblast-like cells are seldom covered
with neurone (Jones-Villeneuve ~, 1983f Rudnicki lind
McBurney, 1987). There is no evidence that the neuronal cells
induced by RA are mature brain glial cells. However, these.
cells are It mixture of glioblasts, astrl"cytes and microglia in
various stages of differentiation. PI9 EC cells can be
differentiated into skeletal and cardiac muscle cells when
treated with 1t dimethyl sulfoxide (DMSO).
Previous studies frol'D. our laboratory suggested that
the expression of regulatory region of JCV was seen only in
RA·treated but not in DMSo-treated or undifferentiated Pl9
cells. (Nakshatri K..Al, 1990a). The Pl9 cells are a good
system to demonstrate the Jlode of tissue-specific regulation
of JCV expression. These cells can be differentiated into
different cell types from an identical genotype. Hence, I used
P19 cells in my studies. Earlier studies suggested that JCV is
expressed efficiently in glial cells (Major J.t....A1., 1992). The
neural cells induced after treating P19 cells consist of a
heterogeneous population inCluding glial cells. This is the
disadvantage of the P19 cell system. However, previous studies
from our laboratory reported efficient expression of JCY
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regulatory region in RA-treated PI9 cells. I also used nuclear
and whole cell extracts prepared from RA-treated PI9 (;ells in
several in vitro studies presented in this thesis. Since RA-
treated PI9 cells contain a heterogeneous population of
neuronal cells, the exact cell type in which JCV is expressed
is uncertain. However, it is evident. from the edsting
literature that the expression of JCV is restricted to glial
cells.
1.7.5.3 CELLULAR TRANSCRIP'l'ION FACTORS 'l'HAT BIND '1'0 JCV
PROMOTER-EIOUUlCER dEQUENCEB
The studies mentioned above clearly indicated that the
expression of JCV is restricted to glial cells. Further, cell
culture stUdies, using different strains of JCV, indicated
that the glial cell specific expression of JCV is not due to
the cell-specific adsorption or penetration of the virus.
cell-specific expression was due to the intracellular factors
that bind to the sequences in the regulatory region of JCV
(Frisque §..t......Jll. 1979). Hence SUbsequent studies including
those in this thesis were focused on finding the sequences
that are bound by the transcription factors in the glial
cells.
using the oligonucleotides that span the 98 bp tandem
repeat of JCV and the nuclear extracts from human fetal brain
and HeLa cells, mobility shift and UV crosslinking assays were
performed to identify the sequences theot confer tissue tropism
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!lnd the cellular factors that bind these sequences (Khalili n
Al. 1988). complel:lenta.ry oligonucleotides having hOJ:lOlogy to
Nfl binding site that span nt 134-160 ot the 98 bp repeat of
JCV interacted with proteins of 45 and 85 kDa trom hUllan fetal
brain and HeLa cells, respectively. Oligonucleotide sequences
complementary to TATA box interacted with a protein of 78/80
kDa. The ollgonuclaotide having sequences homologous to the 5'
and J I ends of promoter-enhancer bound similar proteins of 82
and 78/80 kDa from both extracts. However, a protein ot 230
kOa frolll both extrar:ts interacted with several regUlatory
sequences of promoter-enhancer.
DNaseI footprinting experiments on JCV proDoter-
enhancer were conducted u!f'inq Ilouse brain nuclear extracts.
The protected sequences in the 98 bp repeats corresponding to
nt 35-58 and 133-156 were hOllologous to nuclear factor 1 (NFl)
binding sites. The second set of sequences that were protected
corresponding to nt 208-229 have a pseudo-NFl r:lOtit (TaJlura n
A1, 1988).
Mobility shift ASsays with JCV regulatory region
showed binding activity with the nuclear extracts froll "eLa,
PHFG, and human glioma cell line, A172. However, no binding
was detected with extracts from HER cells. Further, DNase!
footprinting was carried out on JCV regulatc,:,y region using
extracts from two glial-type cells and Hela cells. similar
sequences and NFl binding motifs were protected as observed
..
earlier by Tamura .8t.....lll (1988). con:petition experiments with
the NFl binding site oligonucleotide of adenovirus replication
origin confirmed that the protected sequences were NFl motifs
(AmC!"Iliya~, 1989).
DNaseI t'ootprintlng assay using extracts prepared from
undifferentiated (UO) , DMSO-differentiated and RA-
differentiated PI9 EC cells was attempted to detect the
proteins interacting with the sequences in JCV enhancer
(Nakshatri ~, 1990a). Protection of three regions, two in
the 98 bp repeats and one towards the late side of the repoat
was observed with extract frOlll RA-differentiated but not with
extracts from UD and OHSO-differentiated PIg cells. All thasa
sites contained sequences resellbling NFl binding motifs. The
sequences protected within the 98 bp repeats were named
regions II and III, respectively, whereas the region of
sequences protected outside the repeats was called region I.
In addition to NF1 binding site, region I also contained a
binding motif for E4TFl factor (Fig. 1.2). COl1petition
experiments with oligonucleotides corresponding to regions I
and II suggested that the same factor binds to all the thraa
NFl binding motifs, although they consist of different
sequences. A suggestion that the NFl I binding site located
outside the repeats may play a role in the cell-specit'ic
expression of JCV was offered based on competition experiments
(Nakshatri ~, 1990a).
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Another factor which binds to a sequence overlapping
the 1IFl motifs located in the repeats called Sacl motif was
also reported. It was suggested that the cooperativity of NFl
motif and SacI motif binding factors may be required for the
strong brain specificity of JCV (Tamura~, 1990b).
The 45 kDa protein from human fetal glial cells that
interacts with the sequences corresponding to nt 134-160 NFl
motif of JCV enhancer was purified and it complemented for the
activity of JCV enhancer in KeLa cells in~
transcription assays (Ahmed nJl, 1990). subsequently the
eDNA encoding the factor binding to NFl motif in the 98 bp
repeat was cloned. Expression of this eDNA increased the
transcription of the JCV late promoter-enhancer and to a
lesser degree the early promoter-enhancer (Kerr and Khalili,
1991) .
A glial cell transcription factor belonging to the
POU-domain family, Tst-l stimulated transcription of both
early and lata viral genes. Tst-l also stimulated viral DNA
replication and hence it was suggested that Tst-l is one of
the determining factors in the glial cell-specificity of JCV
(Wegner .i.Lll, 1993). Presence and role of a binding site
homoloqous to cyclic AMP response element (eRE) adjacent to
NFl II/III in JCV promoter-enhancer in the regulation of JCV
was sp~cull3ted in another study (Amemiya fi-Al., 1992). A
pentanucleotide repeat,~, present between the NFl
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II/III and TATA box interacts with an approximately 56 kDa
protein from glial and no0911al cells and down regulates the
JCV late promoter activity (Tada ~. 1991).
Overall, it is evident that JCV promoter-enhancer is
regulated by both positive and negative regulatory mechanisms.
The binding sites for the various transcription factors in the
JCV control region are diagrammatically represented in Fig.
1.2.
All the studies mentioned above used~ binding
assays to suggest that NFl may play a role in glial cell-
specific expression of JCV. Moreover, in the study reported by
Wegner~ (1993), cotransfection of a recornbiMnt plasmicl
expressing a brain-specific factor Tst 1 with the reporter
plasmid containing JC early regUlatory region activated JCV[
expression in glial cells. In my opinion, this study should
have shown the role of Tst 1 in glial cells as such. In
addition, studies on late gene expression of JCV, which is
important for the productive infection of the virus are
lacking. The regulatory region of JCV contains several ili-
acting elements (Fig. 1.2). At present there is no stUdy that
explains how the proteins binding to these elements function
in glial cell-restric.ted expression of JCV.
1.8 THEBIS RATIONALE MD ORGANIZATION
The purpose of my study is to understand the role of
factor(s) binding to the NFl motif and cyclic AMP response
Fig. 1.2. Diagrammatic representation of binding sites for
various transcription ractors in the regUlatory region or JCV.
The letters A and B and large boxes indicate the 98 bp
repeats. The numbers denote the nucleotide positions. Binding
sites for cellular transcription factors are indicated. The
early JCVE and late JCV. promoters are on the left and right,
respectively.
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element (eRE) located adjacent to the NFl sequence in the 98
bp repeats in 1n......YiY2 activity ot early gene expression ot JCV
and to correlate the~ activity with~ DNA-
protein interactions. It is also the objective of my study to
address the mechanism of regulation of JCV late gene
expression. In addition, I have attempted to determine how the
proteins binding to ili-acting elements located in the 98 bp
repeats function in regulating JCV gene expression.
The thesis is organized in five chapters. In chapter 2,
I will desc..rlbe materials and methods used for the work
presented in chapters 3, 4 and 5. In chapter 3, I will detail
the role of NFl binding motifs in glial cell-specific
expression of JCV and correlate the~ activity with .in
~ DNA-protein interactions. Additionally, the iso1a':ion
and preliminary characterization of a cDNA encoding a factor
binding to nuclear factor 1 (NFl) located within thQ 98 bp
repeats will be described.
The early gene product of JCV, T-antigen transactivates
the JCV late promoter leading to productive infection of JCV.
In chapter 4, I will datail tha role of NFl binding sitas in
the transactivation of Je..'lt and the delineation of amino acid
sequences of T antigen required for transformation and
transactivation of JCVL. A model for transactivation of JCVL
by T antigen will be presented.
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In chapter 5, I "'1111 detail the role of cyclic AMP
response element (eRE) in glial cell-specific expression of
JCV. The characterization of protein(s) binding to this
sequence is also presented.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materia.ls
The restriction endonucleases were purchased from New
England Biolabs and Bethesda Research Laboratories (Gibco-
BRL). T4 DNA ligase, calf intestinal phosphatase (eIP) and
reverse transcriptase were from BRL, BRL and Life Sciences,
respectively. The (14C] chloramphenicol and [32P1 dCTP were
obtained from leN and Amersham, respective.l:'. Acetyl coenzyme
A was from Sigma. Thin layer chromatography CTLe) plates and
X-ray films were purchased from Kodak.
synthetic oligonucleotides were purchased from
Regional DNA synthesis Laboratories, University of calgary.
The XbaI translation terlllination linker used in generating JCV
large T-antigen mutants described in Fig. 5.7 was commercially
obtained from New England Biolabs. The mutagenesis kit was
supplied by Bio-Rad. The plasmid psvocat was a kind gift from
Dr. B. Howard. The JC early promoter-enhancer reporter plasmid
pJCfcat was constructed as described (Nakshatri ~, 1990a).
The plasmid pBLcat2 was a generous gift of Dr B. Luckow.
The (Nick-column) Sephadex G-50 columns were obtained
from Pharmacia. Protease inhibitors like antipain, pepstatin,
aprotinin, and PMSF were purchased from Sigma. DNaseI, alpha-
albanitin, forskolin, dibutyryl c-:7clic AMP, and 5' bromo
deoxyuridine (BUdr) were from Sigma. The chemicals 5-bromo-4-
..
chloro-3-1ndolyl phosphate (SelP) and nitro blue tetrazolium
(NBT), and alkaline phosphatase-tagged anti-mouse IgG
secondary antibodies used in western blotting were purchased
from sigma chemicals and Bio-Rad, respectively. Poly dI.de was
purchased from Pharmacia. The nIck-translation kit was
supplied by Glbco-BRL. Circle nitrocellulose filters Wf:!'e
obtained from Mandel Scientific Company. The mRNA isolation
kit was from Pharmacia. The eDNA synthesis, and A packaging
kits were purchased from Gibeo-BRL.
Alpha-MEM medium and phosphate buffered saline (PBS)
were supplied by Flow Laboratories. Trypsin-EOTA, all-trans
retinolc acid were from sigma. Dimethyl !lulfoxide (DMSO) was
purchased from Baker. The mouse embryona .. f" ·rcinoma P19 cell
line was a kind gift from Dr. Hamada. Bockneck Laboratories
supplied fetal calf serum (Fes). The monoclonal antibodies
against SV40 T antigen, PAb loa and MHC class II antigen, I_1\K
were obtained from American Type Culture Collection (ATCC).
2.2 METHODS
2.2.1 Cell cuIture~ (Hfferentiation of embryonal carcinoma
cells, and transfection
The embryonal carcinoma cell line, P19, was cultured
in alpha-MEM medium with lOt heat-inactivated fetal calf serum
and cells were induced to differentiate as described (Rudnicki
and McBurney, 1987). Briefly, cells were trypsinised,
resuspended in media containing either 300 nM all-trans
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retinaic acid (RA) or 11 dimethyl sulfoxide (OM50) and then
cultured in bacterial culture plates for 48 h. Fresh media
containing RA or DHSO was added atter 48 h and cells were
incubated for another 48 h. After tour days of treatment the
cell aggregates were washed in phosphate buffered saline,
trypsinised and resuspended in media containing no RA or OM50
and plated in tissue culture plates. Eight hours after
plating, the cells were transtected with 10 119 ot indicated
test plasmids and 10 IJg of pUC19 DNA by calcium phosphate
precipitation (Graham and van der Eh, 1973). For the cAMP
induction experilllents described in chapter 5, the cells were
transfected with 5 Jl9 of indicated plasmids and 15 PlJ of pUC19
DNA unless and otherwise mentioned. T\,enty four hours after
transfection, the cells were incUbat.ed with mediufI in the
absence or presence ot" 100 J.lM forakol!n and 10 ~M dibutyryl
cAMP.
For the studies on transactivation of JCV late
promoter by T-antigen, the cells were transtected .... ith 1 Ilg of
indicated reporter plasmid with either 10 Ilg of CMV-JCV-TA T-
antigen expression plasmid or pUCl9 DNA. primary 5-day-old
Fischer baby rat kidney (BRl<) cells were used in the
transformation assays with JCV T-antigen as described (Pater
§LAl, 1988). Briefly, the cells were plated in the 60 mm
tissue culture dishes and the indicated wild type and mutant
T-antigen plasmids were co-transfected with EJ-ras oncogene.
..
After two days the .ediulD containing 2' fetal calf serum vas
added and the cells were subsequently .aintained in this
lIedium for three weeks. Then the trans!or1lled foci were stained
with crystal violet and counted.
2.2.2 Pl__ida aDd .Ite-directed .utaqan••i.
wild tyPe pJCLcat ie; tho samo allii pJ~ cat excopt that tho
regUlatory sequences of JCV are in reverse orientation (nt
5112 to 270) and as described earlier (Nakshatri ~.
1990a). site-dlrectc!d mutagenesis of JCV enhancer was
performed with a kit trom Gibeo-BRL, according to the
manufacturer's instructions. The JCV enhancer .fyy II to H.in.d
III fraqment trom 210 to 5112 served as the substrate for
1llutagenesis. Mutations in the Nuclear Factor 1 (NFl) binding
sites were generated using co.plell.entary strand-ho.olOC)ous
oligonucleotides for nt 235-206 for region I, 165-137 for the
two nt substitution mutations for ragion II and 152-1:29 fo.,
the remaining region II and III mutations, with appropriate
base substitutions. To introduce mutations into cyclic AMP
response element (CRE). a complementary strand-homologous
oligonucleotide for nt 142-169 with appropriate base
substitutions was used. The D1utatio:ls wore can finned by
dideoxy sequencing (Sanger~, 1977).
The mutated enhancer fragments (.Ii1ns1 n-.s..ID..il I) were
inserted into the u.J.ng III site of pSVOCAT such that the
chloramphenicol acetyltransferase (CAT) gene is expressed from
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the early JCV promoter (Naksbatri ~, 1990a). The
constructs were designated for the Nfl and eRE site(s) that
were mutated. The sequences mutated and the names of the
plasmids are shown in Figs 3.1 and 4.1 for Nfl mutations and
in Fig. 5.5 :tor CRE mutations.
The plasmids pRII and pmRII contain the single 98 bp
repeat having wild type and mutated NFl II sequences, cloned
into HJ.D.!1 III site of psvo cat. For pJCV-CREcat, the
AGCATGAGCTCATACC, JCVeRE oligonucleotide was cloned into~
I site of pBLcat2 expression vector. Insertion was confirmed
by DNA sequencing.
The CHV-JCV-TA plasmid for expressing JCV T-antigen
consists of JCV larg~. T-antigen coding sequences (nt 5013 to
2603) under the control of cytomegalovirus (CMV) promoter-
enhancer sequences as described previously (Nakshatri .!It....A.1..
1990a). The translation termination linker and deletion
mutations were derived from CMV-JCV-TA. Plasmids were numbered
for the sites of termination and the sizes of deletions.
Plasmids pK4984, PK4246. pK4129. pK4085. pKJJ59. pK301J, and
pK2896 were generated with tonainatior:: linkers having a
termination codon in all of the three reading frames. at t::l£<g
I. .asJ.II. ~I, ~I, ~I, ~I, and EY,yII sites,
respectively. Deletion mutations of the !!g!II-~I (pK 117),
.s..GI-MI CPR 726). and ~I CpR 1945) fraq1llents were
generated (Fig. 4.7).
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The plas.id. pCMVNFl contains the eDNA isolated trom
the eDNA library prepared from PIg RA cells after screening
with NFl binding site located in the 98 bp repeats of JCV. The
eDNA from the recombinant lKl phage was liberated by digesting
with NotI and SaIl restriction enzymes and cloned in NotI and
HindIII sites of pRC/CMV vector purchased from Invitrogen. The
insertion and orientation was confirmed by sequencing. The
plasmid pB~ cat contains the regulatory region of human BK
virus in early orientation as described previously (Pater and
Pater. 1988).
2.2.3 ChloraapheniClol acetyltransfarase (CA'1') assays.
Cells were harvested for CAT assays 48 hours after
transfection as described (Gorman~. 1982). Briefly, the
cells were washed with PBS, scraped into eppendorf tubes with
a rubber policeman, and pelleted. The pellet was resuspended
in 0.25 M Trig-Hel (pH 7.8) and sUbjected to three cycles of
liquid nitrogen freezing and thawing at 37° C. The cell debris
was pelleted and t~le supernatant was used in CAT assays.
Ten J.lI of the extract was incubated at 37° C for 1 hour
in a reaction mixture containing 14 1£1 of 1 M Tris-Hel (pH
7.8), 4 1J1 of 4 llIH Acetyl coA, 1 #1 or distilled water, and 1
J.ll of [t4C) chloramphenicol. After 1 hour of inCUbation, the
chloramphenicol was extracted by adding ethyl acetate and then
dried in a speed vacuum. The samples Here relluspended in 15 1J1
of ethyl acetate and spotted on TLC plates. Acetylated and
"
non-acetylated tOrJIS ot cblon••phenicol were separa~ed by
ascending TLC in chloroform:1Il.ethanol (95:5). Percentage
acetylation was deter-ined by liquid scintillation cOI:ntinq.
The Jl'-galactosidase control plas.id was frolll peRllO
(Pharmacial in which we replaced SV40 \lith Rous sarco.a virus
(RSV) prolllOter-enhancer sequences. This sarved as a control
for transfeet ion efficiency. " conversion on CAT assay figures
indicate the" CAT activity.
2.2.4 NUcl.ar extraot preparatioD and DNase I footprintiDq
The preparation of nuclear extract and DNase I
footprinting were done as described previously (Hennighausen
and Lubcn, 1987). Briefly, the cells trom 40 plates of
undifferentiated or RA-differentiated cells were used for
nuclear extract preparation. The cells were vashed with PBS
and then scraped with a rubber policeman and pelleted by
centrifugation at 1800 rpm at 4ll C for 10 minutes. The
pelleted cells were again washed in 10 volumes of PBS and then
resuspended in 5 volumes of 0.3 1'1 sucrose in buffer A (10 aM
HEPES-KOH, pH 7.9, 10 11M KCI, 1.S mH KgClz, 0.1 JDM EGTA, 0.5
mM dithiothreitol (D'I'T), 0.5 mM ot protease inhibitor
phenyllllethylsulfonyl fluoride (PMSF), and 2 ",g/ml each of
other protease inhibitors antipain, pepstatin A, and
aprotinin) . Cells were homogenised in a Dounce glass
homogenizer with a B pestle by applying .:0-12 strokes without
and 1-2 strokes with 0.3-0.41 of Nonidet P-40 (NP-40). The
nuclei were then pelleted by centrifugation at 2700 rpm at 4ll
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C and washed twice with buffer A containinq 0.3 M sucrose but
no NP-40.
The nuclei were resuspended with a dounce hoaogenizer by
applying 10 strokes in 2.5 pelleted nuclei volulles of butfer
B (400 mM HaCl, 10 111M HEPES-KOH pH 7.9, 1.5 ...... HgCll • 0.1 mM
ECTA, 0.5 mH OTT, 5\ glycerol and 0.5 11M PMSF). The
resuspsnded nuclei were gently stirred at 4° C for 30 minutes
and then centrifuged. for 1 h at 39, 000 rpm at 4° C. The
supernatant was dialysed for 4 h at 4° C against 50 VOlUlIlCS of
buffer C (20 mM HEPES-KOH pH 7.9, 75 mH NaCl, 0.1 mM EDTA, 0.5
11M O'rl', 20t glycerol and 0.5 lIM PMSF). After 4 hours of
dialysis, the lIaterial which was precipitated during- dialysis
was rellOved by centrifugation at 20,000 rpll at 4° C. The
supernatant vas aliquoted, !lash frozen in liquid nitrogen,
and stored at _700 C until further use. The protein
concsntration was estimated by the IMthod of Bradford (1976).
To generate probe for DNaseI protection assays, the H..iml
III to ~II fragment of JCV (nt 5112 to 270) was cloned in
.KIaI site of pUC19 vector. The SAlI to ~I fragaent
containing the insertion was used in the footprinting assay.
The .sAlI to .auI fraqments of Ilutated enhancers eluted from
the vector pTZ19 used in~ mutagenesis were also
included in the footprinting assay. The DNA fragments were
end-labelled by using reverse transcriptase in the presence of
alpha [uPl dCTP which fills the SAlI ends. The end-labelled
,.
DNA fragments were separated from the non-incorporated
nucleotides through 5ephadex G-SO columns.
Nuclear extracts in 15-20 J,ll volumes (containing 45-60
JL9 of protein) were incubated in 50 pI of binding buffer (50
ntH !.raCI, 0.1 mM EDTA, 20 roM HEPES-KOH pH 7.5, 0.5 mM OTT, 10%
glycerol) and one 119 of poly (dIode) for 15 minutes on ice.
The end labelled probe (40,000 cpm) was added and incubated at
20De for 10 minutes. Mgelz and caCIz were added to a final
concentration of 5 and 1 roM, respectively. Pancreatic
deoxyribonuclease (DNase) I at a concentration of 2 pg/pl in
a solution containing 150 mM NaCl and 50%: glycerol was diluted
with 25 rnM NaCI, 10 mM Hepes-ROH pH 7.5 and 0.5 mM OTT. The
reaction containing no protein (in lanes marked as free in the
figures) contained 2.0 and 1.0 n9 of DNase r. The probes
incubated with the proteins contained 240 ng of DNase I. After
30 seconds of digestion with DNase I, the reactions were
stopped by adding 100 pl of stop buffer (0.375%: 50S, 15 ntH
EOTA, 100 mM NaCl, 100 mM Tria-Hel pH 7,6, 50 j,tg/ml of
sonicated salmon sperm DNA, and 100 j,tg/ZTl1 pronase), The
samples were incubated at nO C for 15 mi,~~\tes ~nd 2 minutes
at 90° C followed by phenol-chlor;';fo>:il\-·isoamylalcohol
extraction and ethanol precipitation. Tbe reaction products
were analyzed on polyacrylamide-8M urea sequencing gels.
2.2.5 Whole cell extract preparation
Whole cell extract was prepared by the method described
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previously (Tasset i!t.......Al, 1990). Briefly, the ce11.J
washed with PBS and scraped with a rubber policeman and
pelloted by centrifugation at 1800 rpm at 4°C for 10 minutes.
The pelleted cells were washed again with 10 volumes of PBS
and suspended in 2 pelleted volumes o~ buffer containing 10 mM
Tris pH 7.6, 1 mM EDTA pH 8.0, 400 mM Kel, 1.5 mM MgC12• 20\
glycerol, 1 mM OTT, 10 ~g/ml of soya bean trypsin inhibitor
(SST!), 1 mM P1IJSF, and 2 Jl9/ml of each of protease inhibitors
antipain, pepstatin A, leupeptin, and aprotinin. This was
followed by three cycles of freezing in liquid nitrogen and
thawing on ice and centrifugation for 1 h at 39,000 rpm at
4°C. The supernatant was aliquoted, flash frozen in liquid
nitrogen, and stored at _70oC for further use. The protein
concentration was estimated by the method of Bradford (l976J.
The whole cell extracts expressing JCV T-antigen were prepared
from Pl9 RA cells transfected with 20 jJ.g of CMV-JCV-Tl\
plasmid.
2.2.6 Sequences of oligonucleotides used in~ binding
assays.
NFl I
NFl II/III
Mutant NFl II/ITI
5' -AAGGGGAAGTGGAAAGCAGCCAl\-3'
3 ' -TTCCCCTTCACCTTTCGTCGGTT-S'
5 '-GTCGACTGGCTGCCAGCCM-J'
J' - ACCGACG']TCGGTTGTCGAC-S'
5' -GGAGTACTGCCAGACCAG
3'- CATGACGGTCTGGTCCCT-S'
JCV CRE 5' -AGCATGAGCTCA-3'
3' - ACTCGAGTTCGT-5'
2.2.7 Mobility shift assays.
The end labelling of enhancer fragment of JCV and
oligonucleotides used in mobility shift assays was the same as
that used in DNase I footprinting mentioned in .2.2.4. Since
annealing of the complementary strand oligonucleotides
generates an overhang, the end labelling was done using
reverse transcriptase as described in 2.2.4.
The nu... lear and whole cell extracts were used in
mobility shift assays as indicated in figure legends. Mobility
shift assays were done as described previously (Chodosh £..t.....il.l,
1988). Briefly, the binding reactions in 15 loll volume were
done in buffer containing 12 mM HEPES-NaOH pH 7.9, 4 mM Tris-
HCI pH 7.9, 10% glycerol, 0.1 mM EDTA, 1 mM OTT, 5 Jlg of poly
(dI-dc) .poly (dLdC), 60 mM KCI, 15,000 cpm of end-labelled
probes and the indicated amounts of nuclear or whole cell
extracts. The reactions were inCUbated at 200 C for 30
minutes. The lanes labelled as free in the figures did not
contain protein. The reaction products were analyzed on 4"
non-denaturing polyacrylamide (acrylamida: bisacrylamide,
29:0.5) gels which were run at 4° C with circulation of buffer
at lOOv in 22 mM Tris-borate, 0.5 lIIM EDTA. Gels were dried and
subj ected to autoradiography.
2.2.8 uv crosslinking assays
uv crosslinking assays were done as described (Chodosh
~, 1986). Binding reactions in 35 /.41 volume were done as
described for mobility shift assays except that 100,000 cpm of
BudR incorporated, nick translated JCV CRE oligonucleotide, 10
Jjg of poly dIodC, and 60 IJg of whole cell extract were used.
After incubation for 30 min at 30°C, the reaction mixtures
were exposed to UV irradiation under the Fotodyne UV lamp for
30 min. The reactions were not treated with DNase I as the
size of the probe was less than 50 bp. The reactions were
stopped by adding 2X 50S-PAGE loading buffer (100 mM Tris-HCl
pH 6.8, ~OO roM OTT, 4% 50S, 20% glycerol, and 0.2% bromophenol
blue). The products were boiled for 4 minutes and then
subjected to electrophoresis on a lOt 50S-polyacrylamide gel
at a constant voltage of 100 volts.
2.2.9 southwestern blot analysis
Southwestern blotting was done according to the method
described previously (Vinson §t......al, 1988). Fifty IJg of protein
from forskolin (FSK) -treated and untreated whole cell extracts
prepared from RA-differentiated PIg cells was run by
electrophoresis on a 10% denaturing SDS-polyacrylamide gel and
transferred onto a nitrocellulose membrane by electrotransfer
in Tris-glycine buffer. The filters were blocked in binding
buffer containing 5% non-fat dry milk in 25 roM Hepes-NaOH pH
8.0, S mM HgCl2, 0.5 roM DTT, 2S roM NaCI at room temperature
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(RT) for 2 h. This was followed by incubation in the binding
buffer containing 106 cpm per ml of n1ck-translated Jcv eRE
probe at RT for 2 h. The membranes were then washed thrice 1n
binding buffer, 15 minutes each. SUbsequently, the membranes
were air dried and exposed to X-ray film for autoradiography.
2.2.10 RNA preparatioD aDd ribonuol.... IRN•••) protaction
RA-treated PIg cells transfected with and without 10 P9
of pJC! cat plasmid were harvested for RNA 48 h after
transfectioll (Chirgwin !.t......Al.. 1979). Total RNA at 10 Jl9 was
used in RNase protection experiments as described (Belaguli tl
Al. 1992). The RNA was hybridized with 100,000 cpm of cat and
6-galactosidase RNA probes at 56°C for 14 h followed by RNase
Tl (700 U of RNase Tl per mI) digestion. RNase resistant
hybrid RNAs were analyzed on 5' polyncrylamide-8M urea
sequencing gels. The quantitation of the signals was done by
laser densitometry. The cat and 6-galactosidase probes were
generated from the Hi..ns1III-E.Q.QBI DNA fragment (nt 5018-4768)
of pSV2 cat and ~I-AElI fragment (nt 3286-3063) of pRSV 6-
galactosidase DNA cloned in the vector, Bluescript KS+,
respectively.
2.2.11~ transoription assays
Nuclear and whole cell extracts were prepared from UD
and RA-differentiated PI9 cells as described in 2.2.4 and
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2.2.5, respectively.~ transcription was done
described earlier (Ahmed~, 1990). Transcription reactions
were prepared in 50 #11 volume containing 12 mM Hepes-NaOH pH
7.9, 12% glycerol, 60 mM KCI, 2 ntH MgClz • 1 mM each of ATP,
CTP. GTP and O. 5 tIlM of '2p UTP. 1 J.l9 of DNA template digested
with appropriate restriction enzyme and the indicated amounts
of protein. After incubation at 300 C for Ih, the samples were
extracted with phenol-chloroform-isoarnylalcohol and athanol
precipitated. The run-off transcripts were analyzed on a
denaturing 5% polyacrylamide-8M urea gel with the appropriate
size markers. The DNA templates were 1 P9 of .I:fQ.Q I and .fYJI II
digested JC early and late cat constructs to yield 550 and 160
nt run off transcripts, respectively. In cAl-!P induction
experiments described in chapter 5, I jig each of !!£2 I
digested pRII and pmRllcat DNA templates ware used to obtain
550 nt run off transcripts. pBLcatz and pJC-CREcat DNA were
digested with tfgQ I to yield 576 nt transcripts. The Hl?A 1
digested pRSV-6-galactosidase plasmid was used as an internal
control to normalize the recovery of transcripts.
2.2.12 Preparation ot eDNA library from RA-cUtterantiatec! P19
Obryon_l oaraino.a oell.
2.2.12.1 Isolation ot poly A+ RNA
Poly A+ RNA from P19 RA cells was prepared using the
mRNA isolation kit of Pharmacia according to the
manufacturer's instructions. Briefly. the cells were washed
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with sterile PBS and pelleted down by centrifuging at 1800 rpm
at 4° C. Lysis buffer (100 ml) was added to the pollet. The
pellet was resuspended and sheared by forcing the lysate in
and out of an 18 gauge needle until viscosity reached that of
the lysis buffer.
The lysate was then incubated for 2 hours at 4SoC with
intermittent agitation. The NaCl concentration of the lysate
(O.2M) was adjusted to O.SH and then added to oligo(dT)
cellulose equilibrated with binding buffer and incubated for
30-60 minutes at room temperature with intermittent agitation.
The resin was pelleted and washed with 5 bed volumes of
binding buffer until the buffer was clear. The washed resin
was poured into column and washed continuousI} until the AZ60
of eluate was less than 0.05. Then, the bound poly 1\+ mRNA was
eluted with 0.3-0.5 ml fractions of elution buffer. The
fractions 1-8 containing majority of the mRNA were pooled and
precipitated by adding 0.1 volume of 3M NaOAc and 2 volumes of
100%: ethanol at _200 C overnight. The mRNA was recovered by
centrifugation at 40 C. The amount of mRNA recovered was
quantitated by UV spectrophotometry and absorbence readings at
wave lengths of 260 and 280 nM were taken to estimate the
purity of the mRNA and confirmed the purity.
2.2.12.2 preparation of eDNA from mRNA
The eDNA was prepared from the mRNA isolated from
PIg RA-treated cells, using a kit from Gibco-BRL and according
76
to the manufacturer's instructions. Five 1J9 of mRNA was added
to 1 ",q of .H2tI. primer-adapter containing- 15 d'I' residues. The
mixture was heated to 70° C for 10 min, and quick-chilled on
ice. Then, the 5X first strand buffer (50 mM Tris-Hel pH 8.3,
75 trIM Kel, 3 mM KqClz• 10 mM OTT and 500 JlM each of dATP,
dCTP, dGTP, and dTTP) was added. This was followed by the
addition of 2 III (200 U/~l) of superscript RT in a reaction
volume of 20 III and incubation at 37° C. After 1 hour of
incubation, thQ mixture was placed on leo and the synthesis of
second strand was initiated. To the first strand mixture, 30
",I of 5X second strand buffer (25 mM Tris-Hel, pH 7.5, 100 10M
Kel, 5J1lM MgClz• 101llM (NH4}zS04, 0.15 roM ,a-NACo 250 mM each of
dATP, dCTP, dGTP and dTTP, 1.2 l:llM OTT) was added. E.Coli DNA
ligase (10 U), E.Coli DNA polymerase I (40 U) and E.coli RNase
H (2 U) were SUbsequently added in a total reaction volume of
150 ~l and incubated at 160 C for 2 hours. After 2 hours of
incubation, 10 U of T4 DNA polymerase was added and
incubation was continued at 1611 C for 5 min. The reaction was
stopped by adding 10 ~l of 0.5 M EDTA. The reaction products
were subjected to phenol-chloroform-isoamylalcohol extraction
followed by ethanol precipitation.
2.2.12.3 sl•• fJ:aotianatioD at eDNA and ligation of eDNA to
Agt22A veator
The eDNA was checked on denaturing alkaline
agarose gel before proceeding to the SUbsequent steps. ~
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linker was added at the 5' end of eDNA. Then, the eDNA was
digested with NotI and size-fractionated by column
chromatoqraphy. This removed the residual adapters and the
NotI fragments raleased by restriction digestion of pri.er-
adapter with NotI. The size-fractionated eDNA containing Sal!
and NotI termini was ligated to lCjt22A vector digested with
NotI and SaIl to ensure the preparation of a unidirectional
eDNA library.
2.2.12.4 Paokaging ot phage},. veotor-cONA and preparation oi
C10NA library
The ligated vector-cDNA was then packaged using BRL's A
packaging system. Briefly, the 5 1£1 of the ligated mixture was
added to the extract A supplied by BRL packaqlng ki t. Then. 15
III of extract B of the kit was added and mixed thoroughly but
gently and incubated at 20° C tor 2 h. Folloving the
incubation, 0.5 111.1 phage dilution buffer (50 11M Tris-Hel pH
7.5, 100 mK NaCl, 10 IlH MgC12, O.ou:ew/v) gelatin) was added
and mixed. Chlorofona (20 PI) was added next and mixed gently.
The phage mixture was mixed with the '{l090R- host bacteria in
phage dilution buffer and incubated at 370 C for 30 min. Three
111.1 of molten 0.7\ T-Tyn agar containing 10 111M MgC12 was then
added, mixed and poured onto 100 X 15 rnm 1.5\ T-Tyn agar
plates. After the top agar was set the plates were incubated
at 310 C overnight. The phage library consisted of 1.1 X 106
plaques.
,.
2.2.12.5 AapUfiaaUOD of aDD. library
The plates containing approxiaately 50,000 plaques each
were overlaid with 10 1Il1 of phage dilution buffer :and
incubated at 4D C overnight with gentle rocklng. The
bacteriophage suspension from. each plate was recovered and
pooled into sterile tubes. Chloroform was added to 5\ final
concentration and mixed and incubated for 15 min at room
temperature. The cell debris was removed by centr:\fugation for
5 min at 4000 X g. The supernatant was transferred to fresh
tubes and chloroform was added to 0.3\ and the aliquots were
stored in aliquots at 4° C for further use. After
amplification, the titra of the library was lOll pfu/lIll-
2.2.13 sor••Ding of cDNA library
The PI9 RA A got 2:i!A library was screened by Southwestern
blot analysis to isolate eDNA encoding the factor interacting
with Nfl II/III of JCV (Vinson ~, 1988). Briefly, th:'\
bacterial strain YI090R- was infected with recombinant phages
at 37° C for 30 1IIin. Then, 3 1111 of 0.7' top agar was plated
over the 1.5' T-Tyn agar plates 'Which were then incubated at
42° C for 4h. The IPrG-impregnated nitrocellulose membranes
were overlaid on the plates and incubated for 6 hours at 37°
c. The filters were then immersed in binding buffer (25 mM
NaCI, 5 mM KgClz, 25 mH HEPES, pH a.o, and 0.5 mH 0'1"1')
containing 68 guanidine hydrochlorido and were gently shaken
at 4° C for 15 min. The quanidine hydrochloride was
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sequentially diluted with an equal volume of binding buffer
and filters were immersed in this buffer for 5 min each. This
process of denaturation and renaturation was repeatt:od four
times,
The fil tars were then immersed twice in binding
buffer without guanidine hydrochloride twice for 15 min aach
time. Following this, the filters were submerged in binding
buffer with 5% nonfat dry milk powder for 2 hours. The filters
were further incubated in binding buffer containing 0.25%
nonfat rt.. }' milk powder and 106 cpm{ml of nick translated ten-
mer of NFl II/III oligonucleotide for 2 hours. Finally, the
filters were washed in binding buffer with 0.25% nonfat milk
powder three times for 10 min. The filters were dried and
SUbjected to autoradiography.
2.2.14 Western blot analysis
Western blotting was performed as described prev iously
(Harlow and Lane, 1988). Briefly, the lysates prepared from
Pl9 RA cells transfected with either wild type (WT) or mvtant
T-antigen expression plasmids were separated on 10% sos-
polyacrylamide gel and transferred onto nitrocellulose
membranes electrophoretically. The membrane was immersed in
Tris buffered saline (TBS; 100 rnM Tris HCl pH 7.5, and 0.9\
NaCl) containing 5\ nonfat dry milk overnight. The membrane
was washed five times for 20 minutes each wash with TBS
containing o. n Tween 20 (TTBS). This was followed by
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incubation 1n 'M'BS containing PAbl08 monoclonal antibody
against T-antigen for 2 hours. After 5 washes of 20 minutes
each in 'I'TBS, the membrane was incubated for 1 h with the
alkaline phosphatase-linked anti-mouse IgG secondary antibody
in TTBS. The membrane was washed five times with TTas and then
incubated with detection reagents, 0.5\ 5-bromo-4-chloro-3-
indolyl phosphate (BelP) and 0.5% nitroblue tetrazolium (NBT),
for colour development until the bands wer~ suitably dark. The
reaction was stopped by washing with stop solution (20 mM EDTA
in phosphate buffered saline) and the membrane was air dried.
2.2.15 Northern blot analysis
Northern blot analysis was done according to standard
molecular biology procedures (Satnbrook~, 1989).
.1
CDPTlR 3
BWIU JC yin. perfect palindroaic nucl.ar faCltor 1 (10'1)
binding .equence. iID.portant for glial oell-specifia ezpr•••ioD
in P19 dlfferentiatiD9 embryonal caroinclI. oella.
3.1 IftRODUCTION
AS discussed in the thesi~ introduction, .2.1.§.-acting
enhancer elements interact with cell-specific transcription
factors to regulate expression of specific cellular genes.
Unlike the other human polyoma virus SK, JC virus exhibits
strict cell-specificity and its growth and expression is
restricted to glial cells (Kenney !l.t......A.l, 1984; Small §.LAl,
1986). The restricted cell-specificity was attributed to the
transcriptional control region of JCV (Nakshatri ~,
1990a) •
Nucleotide sequence analysis of brain and kidney forms
of JCV from the same patient revealed variations in the
transcriptional control elellents (Loeber and Dorries, 1988).
Transcriptional control elements regUlate glial cell-specific
expression and the extremely restricted host range of JCV
(SlnoHara~. 1989; Kpnney.!i!..t....A.l., 1984). Hence mutations or
rearrangements in the JCV regulatory region may result in the
spread of the virus from kidney, where it remains latent, to
the brain, where it successfully grows.
Previous studies used .1.n...Y..1.t.I binding assays to suggest
that the NFl binding motifs may playa role in the g11al ce11-
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specificity of JCV (Khalili ~, 1988; Amemiya.§.tJ.l, 1989;
Taloura .!It....Al, 1988). No functional assays were done. In order
to conclusively determine the role of NFl sites in ~lial ce11-
sped.fie expression of JCV, I continued the preliminary
studies initiated in au:.:- laboratory (Nakshatri~ 1990a).
The main objectives of this chapter are:
1) TO examine the functional role of NFl binding sites in the
glial cell-specific expression of JCV by performing site
directed mutagenesis of NFl motifs in the JCV regulatory
region.
2) To correlate the~ activity of JCV promoter-enhancers
harbouring WT and mutant NFl sites with~ DNA-protein
interaction, employing DNaser footprinting assays.
3) To examine the interaction of factors with JCV promoter-
enhancer by mobility shift assays.
4) To isolate the eDNA encoding the factor(s) interacting with
the NFl II/III site.
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3.2 U8ULT8
3.2.1 Rol. of .peoit'la IIJ"I .equeac•• ill~ aotiYity of'
JeY eDbuoer
Previous studIes had shown that efficient activity of
JCV early requlatory region is restricted to cells of neural
origin (Kenney at aI, 1984; Nakshatri et aI, 1990a). using
nuclear extracts trom undifferentiated, DHSO, and RA-treated
PIg cells for DNase I footprinting, it walY shown that three
completely protected regions, all containing NFl binding
motifs, were produced specifically for RA-differentlated cell
extracts. competition with oligonucleotides that span these
protected regions suggested interaction of the same factor:
with all three sites (Nakshatri et aI, 1990a).
I exa_Ined the functional role of NYl motifs in RA-
treated PIg cell-specific expression of JCV. site-directed
mutagenesis of the JCV regulatory region was undertakan.
Several mutations were introduce1 into the three NFl binding
sites in the enhancer of JCV and the enhancer fragments
containing each mutation were inserted into the reporter
plasmid pSVOcat, a promoter-enhancer less vector (Fig. 3.1).
Plasmids were then tested for their functional activity in
undifferentiated (UO), DMSO (OM) - and RA-dlfferentiated (RA)
P19 cells. Mutation of NFl and E4TFl binding sites in DNase I
protected region I (Fig. 3.1) did not result in significant
alterations in CAT activity when tested in RA P19 cells
Fig. 3.1 wild type an.:! mutated NFl lIotit'S in JCVE sequences
in C1r.T plasmids and in DNaseI protected regions.
(Top) Diagram of sequences prer;ent in CAT plasmids. Arrows
indicate the boun~.arieg of sequences for the first seven
constructs listed below, and arrowheads indicate sequences for
the last t ....o constructs listed bela..... Early and late sides are
indicated. TATA bo)(es and NFl site motifs are indicated and
delineated by dark lines. Nucleotide positions are give, below
and above the lines. Boxes indicate the 98 bp repeats.
(Bottom) List of mutated plasmids and mut.ated sequences and
delineation of DNasel protected sElquences for the three NFl
sites. Mutated NFl nucleotides are indicated by lower case
letters. Wild-type NFl nucleotides are indicated in p3CVEcat
by capital letters and in other plasmids by dashes. Inverted
palindromic sequences are underlined for pJcEcat. DNasel-
protected sequences of Fig.3.4 are indicated by over:ines and
nucleotide numbers. The complete oligonucleotide sequence
protected for regions NFl II and NFl III is 5'-
AGGGATGGCTGC~GCATG-3'and that for region NFl I is 5'-
GGAAGl:!iQAAAGCAG~GGGAA-3'.
early 12 109110 207 late
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(F1g.3.2, I). However, constructs which contained mutated. GCCA
nucleotides of the right half side of the perfectly
palindromic NFl region II motif (Fig. 3.1) had 3.6 ( Fig. 3.2,
II) and J.l-fold (Fig. 3.2, I. II) lower cat activity in PIg RA
cells. surprisingly, these mutants had more than 2-fold higher
activity in PISI OM muscle cells (Fig. 3.2, DMSO). The
importance of co1Dbinations of the three JCV NFl sequences was
also examined with mutations in regions II plus III, I plus
III and all the three sites (Fig. 3.1). These mutants were
5.8- 4.3- and 7-fold, respectively, lower in cat activity in
PI9 RA-differentiated glial cells (Fig. 3.2, II.XII, I.III,
I.II-III). Once again these mutants displayed more activity in
PIg DM muscle cells compared to wild type (Fig. 3.2, DMSO).
The results suggested that the NFl binding sites located
within, but not outside, the g& bp repeats are important for
the efficient expression of JCV early regulatory region in Pl9
RA-differentlated cells.
Next, thf' possibility that a single perfectly
palindromic NFl binding motif located in the repeats would be
sufficient for glial cell-specific "xpression of JCV was
examined. Plasllidlil with a single repeat region which had
either a wild type or mutated NFl site were constructed
(Fig.3.1). wild type region II plasmid {Fig. 3.2, pRIIj
exhibited a substantial alllount of activity in PI9 RA cells.
This was similar to the activity seen for region I plus III
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mutant (Fig. 3.2, I.III). The cell specificity of theBe
pIas_ids was also si.lIar to that observed for intact enhancer
constructs. Mutation of the region II NFl site alone (FIg.
3.1, p-.RII) reduced the cat activity l.5-fold in PIg RA cells
(Fig. 3.2, pd.!I) co.pared with wild type re9ion II plasmid.
The results BUg'qeated. that the NFl site located in the 98 bp
repeats alone is 5ufticient for RA PIg cell-specificity of JCV
early regUlatory region. However, in PI9 DM muscle cells,
region II mutant (pmRII) showed 2. 4-fold more activity
compared to wild type pRII construct. Also, its activity was
1.9-fold more in PIg DMSO than in PIg RA cells (Fig. 3.2,
compare pRII and pmRII). ThUS, the results sugqested that the
lllutations in NFl site in 98 bp repeat resulted in slightly
increased activity in P19 OM muscle cella.
3.2.2 Roh of .,1 .aqueD.c•• in~ activity of JC'1
enhancer
The effect of NFl autatlons within the 98 bp repeats on
the expression of JCV early control region was examined by in
Y..1..t..l:2 transcription assays. Substantial activity was observed
for neural cell extracts (Fig. 3.3, left panel, lanes 3 and
5). Negligible activity was observed in undifferentiated cell
extracts (Fig. 3.3 left panel, lane 1). Template with
1lutations of the three NFl sites greatly reduced the levels of
transcript (Fig. 3.3, left panel, lanes 2 and 4). Trllll.plate
containing lIutations in reqion I NFl lllotif aupported wild type
Pig. 3.2. Btf.ct of autatioD of JCV NFl 8the on~
aotivity.
Results are for CAT assays in undifferentiated (UO),
dimethylsulfoxide (OMSO) - and retinoic acid (RA)-
differentiated Pl9 embryonal carcinoma cells. NFl site
mutations are indicated by the unique letters for the plasmids
of Fiq. 3.1. The cells were transfected, 8 hours after beinq
plated, with 10 IJg of test: plasmid and 10 1J9 of pUC19 DNA.
Values for CAT activity were calculated from assays with less
than 30\; conversion and were normalized with assays for Rous
sarcoma virus promoter-driven tJ-galactosidase plasmid. Results
are averages of three experiments. The error bars in the
figure represent standard deviations.
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rig. 3.3 Requir_ent of JrN Nl"1 .ite. for~ aoUvi ty.
~ transcription assay products were resolved in 5t
acrylamide gels containing :molecular weight markers. (Lett)
DNA templates were digested with J:i£QI. Lanes:l, pJCEcat and 75
/Jg of extracts from P19 UD cells: 2 and 4, pJCEcat I. II. III
and 60 and 75 j.l.g, . respectively, of extracts from RA-
differentiated cells: 3 and 5, pJCEcat and 60 and 75 I-£g,
respectively, of extracts from RA-differentiated P19 cells.
Tr, 550 nt transcript: IC, 286 bp end-labelled fragment
serving as internal control which was added before phenol
extractions. (Right) Extracts were 35 I-£g of RA-differentiated
glial cells and DNA templates were digasted with ~Ii. Lanes:
1, pJCEcat and incubation in the presence of 1 p.g ot alpha-
amanitin RNA poly:marase II inhibitor per mlj 2, pJCEcatj 3,
pJCEcatI. Tr, 162 nt transcript. Tha autoradioqraphs presented
in right and left pana1s are from diffarent experiments. The
resUlts were consistent for two experiments.
Tr
IC-
2 3 4 5
Tr
2 3
"II
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levels of~ transcription (Fig. 3.3, right panel).
Transcription was by RN" polymerase II since alpha-amanitin at
1 P9/ml concentration blocked all transcriptional activities
(Fig. 3.3, right panel). Thus, these result;; supported the in
Yi¥2 observations and further indicated that the NFl sites
within the two 98 bp repeats of JCV, but not the region I
site, are essential for efficient functional activity of JCV
enhancer in glial cells.
3.2.3 Bfteat of autationa in NFl binding sites on DNA-protein
interaotions
Since mutating one or both palindromic NFl sites within
the 98 bp repeats greatly reduced JC enhancer activity, I also
examined~ DNA-protein interactions in the context of
mutated NFl sites. For this purpose, DNaseI protection assays
were carried out. The region I mutation eliminated protoction,
but only for region I (Fig. 3.4, JCI). For the mutation of the
GCCA half side of NFl motif of region II, protection was
restrictod to the centrl',l nt of the region protected for wild
type probe and excluded the GCCA sequences (Fig. 3.1 and Fig.
3.4, JCII and 1.11). In addition, there was a similar effer't
on the DNasel protection of the non-mutated region III (see
the region III for lane RA of JCII). The double mutation
(JCI.II) displayed a simple additive effect (Fig 3.4, JCI.II).
Probes containing .utations in NFl binding motifs of both half
sides for regions T.I and III mutations were completely
Pig. 3.4 Effect of mutations on DNaseI footprinting of JCV
NP1 sites.
The protection from DNase I by extracts is visualized as
fainter regions. NFl sites mutated in the probes are indicated
at the bottom and correspond to those of Fig. 3. 1. For probes,
nt 5112 to 270 of JCV wild-type and mutated fragments (Fig.
3.1) were cloned into the pUC19 X!2.2I site, and ~I- .§..Jlli! I
fragments were end-labelled only on the bottom Sal I end with
[alpha-3Zp]dCTP. Lanes: AG, chemical cleavage of purines: F,
free DNA of assay with nuclear extract; un,
undi fferentiated cell extract; RA, retinoic acid-
differentiated cell extract. Protected regions I, II, and III
are bracketed and indicated. Protected sequences and binding
motifs for transcription factors are as delineated and
described in the legend to Fig. 3.1.
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unprotected in regions II and III (Fig. 3.4, JCII.III).
Mutations in both half sides ot all three NF1 binding sites
abolished protection in all three reqions (Fig. J.4,
JCI.:::I.III).
3.2.4 ••tar. of prot..in. iDteractiDq witb JfJ'1 _it••
To identify the cellular tactors trom PI9 cells that
interact with NFl binding sites of JCV regulatory region, DNA-
protein binding was further evaluated by mobility shift
assays. First JCV whole enhancer was usad as a probQ in
mobility shift assays. In addition to complexes observed tor
UD cell extracts, a low llobility DNA-protein complex was
detected only with extracts from PIg RA cells (Fig. 3.5,
arrow). The a.aunt of this complex increased with 2-fold
higher protein concentration for Pig RA cell extracts, while
the amounts of other complexes did not change for UO and RA
extracts (Fig. 3.5, CCllpare lanes UD and RA). The results
suggestt>d that II factor restricted to neural cells
specHically ini;eracts :.lth JCV enhancer and its affinity to
JCV enhancer is also higher.
Since the NFl II/III located in the repeats was
found to be important for iD....Y..1Y2 activity in RA PIg celllll,
DNA-protein binding was also examined by mobility shift assays
using an oligonucleotide for the region II NFl motH as a
probe. A diffuse DNA-protein band was detected with PIg RA
cell extracts but not with UO cell extracts {Fiq_ 3.6 UO and
rig. 3.5.~ bincUng of glial oell transcripticn
tactor(sl with JCV prolloter-enhancer in mobility shift assays.
Lanes: F, no nuclear extract: UO, undifferentiated cell
extract; RA, retinoic acid-differAntiated cell extract. Assays
were done using the intact JCV enhancer probe described in
Fig. 3.4 for wild type. Left and right panels, 2.5 and 5 }Jg,
respectively, of protein per assay. Arrow indicates the
specific low-mobility DNA-protein complex for RA lanes.
Arrowhead indicates free probe not bound to factor(s).
F UD RA F UD RA
Fig.3.6 In vitro binding of glial cell extract with NFl II/III
oligonucleotide using mobility sbift assays.
Assays were done using end-labelled double stranded NFl II/III
oligonucleotide sequence as a probe and 5 Jig of protein in
extracts. RI, RII, and mRII indicate competition with NFl I,
NFl II/III and mutant NFl II/III, respectively,
oligonucleotides in 200-fold excess amounts. The sequences of
wild type lUI oligonucleotide used as probe and the
OligonUCleotide competition were as follows: RI, 5'-
AAGGGGAAG~AAAGCAG~A-3';RIl, 5'-~C~-J';mRII,
5'-GTA~C~ACCAGCA-3'.The arrow indicates free probe and
the arrowhead specific low-mobility DNA-protein complex.
F UD RA
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RA). Moreover, competition with wild type but not mutant
NFlII/III. oligonucleotide abolished complex formation (Fig'.
J. 6, RII and JaRII) • Interestingly, competition with
oligonucleotide corresponding to the protected region I did
not abolish the complex formation (FIg. 3.6, RI). The results
suggested that factor(s) restricted to P19 glial (RA) cells
but not UD cells interact specifically with the NFl II/III
sequence of JCV enhancer. The results also provided a clue
that the protein factor(s) interacting with NFl I and NFl
II/III are different since NFl I sequence could not compete
with the factor interacting with NFl II/III.
3.2.5 Isolation and preliminary oharacterization of .. eDNA
&noodi1l.g' tbe factor bindiDg' to NJ'1 IZ/I:II binding motif ot JCV
3. Z. 5.1 Bore.nin;, ot the P19 RA library
The site-directed mutagenesis studies clearly suggested
that NFl II/III binding motif plays an important role in P19
RA cell-specific expression of JCV. In addition, the in...Y.i£J;:Q
binding assays indicated the interaction of PH RA cell-
specific transcription factor(s) with the NFl II/III
oligonucleotide. Hence, it was of interest to isolate a cDK~
that encodes for a protein able to bind the NFl II/III
sequence from retinoic acid-differentiated P19 cells .
Sequence-specific DNA binding proteins can be pur,i..fied
by DNA affinity chromatography (Chodosh~, 1986). However,
this requires large <mounts of starting material. Therefore,
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I decided to isolate the eDNA encoding for the factor
interacting with NFl II/III by screening an expression library
prepared troUl RA-dH'ferentiated PIg cells using Southwestern
blot analysis. This technique was t'lrst used to isolate a eDNA
encoding- for the i_unoglobulin enhancer binding protein
(SIngh ~, 1988). The technique involves direct screenim}
of an expression library with a specific DNA sequence as a
ligand.
Approdmately lXl06 plaques from PI9 RA ). gt 22A
expression library were screened by Southwestern blot analysts
as described in 2.2.13. primary screening resulted in
isolation of two positive clones (Fig. 3.7). To further
confirm specificity, one of the clones (1 Kl) was SUbjected to
further testing. The recombinant phage fro. this clone was
plated and replica filters were exposed to nick-translated
wild type NFl II/III, mutan'.;: NFl II/III. and non-specific NFl
I oligonucleotides. Wild type NFl II/III showed positive
plaques but not .utant or NFl I oligonucleotides (Fi9.J.8
compare A and C with Band D, respectively). The results
suggested that the isolated cDNA encodes a factor that binds
to NFl II/III in a sequence specific manner.
To determine whether the isolated cDNA encolles a
factor which is restricted to RA Pl9 cells, Northern blot
analysis of total RNA isolated from UD and RA-di!ferentiated
Pl9 cells was undertaken. The cDNA from l Kl recombinant phage
Fig. 3.7 Identification of A phage recombinant cDNA clone
whioh speoifioallY binds to NFl XX/IIX element.
The two positive clones were detected by oligonucleotide probe
in the southwestern blots. The positive eDNA clones detected
after primary screening are indicated by arrowheads.
\O~
Pig. 3.8 specHicity tor NFl II/III binding boy the positive
recombinant eDNA clone, ), Xl.
The recombinant l<lA phage was plated and replica filters were
screened in Southwestern blots as in Fig. 3.7 with wild type
NFl II/III oligonucleotide in panels A and C, mutant NFl
II/III oligonucleotide in panel B, and NFl I oligonucleotide
in panel D. Only quarter filters are shown for comparison.
A B
c D
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was used as a probe. A message of approximately 1.2 kilobase
pairs (kb) was detected for RNA from PIg RA cells and very low
level of message in UD cells (Fig. 3.9). The results indicated
that the factor isolated is restricted to P19 RA cells. Taken
together, the isolated eDNA encodes a PIg RA cell factor that
specifically interacts with the NFl II/III binding site
located in the 98 bp repeats which was shown important for
glial cell-specific expression of JCV.
3.2.5.2 Transoriptional activity of eDNA in nonglial cells
To examine the transcriptional activity of the eDNA and
to find out its ability to complement for the expression of
JCV regulatory region in non-neural cells, the eDNA was cloned
in eucaryotic expression vector pCMV. The recombinant plasmid,
pCMVNFl was cotran~.fected with JcvEcat and JCVlcat plasmids
into KeLa cells. In the absence of pCMVNFI, none of the CAT
reporter plasmids showed activity, confirming their glial
cell-specificity. However, cotransfection with pCMVNFl, pJCVE
and pJCVL CAT constructs showed 3.5- and 4.0-fold activity,
respectively, in KeLa cells (Fig. 3.10). The expression of
pCMV NFl had no effect on the expression of BK virus
regulatory region consisting of NFl sites. This suggests that
the isolated eDNA is functional and complements for the
activity at JCV control region in noog11al cells.
Fig. 3.9 Northern blo~ analysis of P19 total RNA, usinq Itl
eDNA as probe.
The RNA isolated from UD and RA-differentiated PI9 cells
were resolved on 1% formaldehyde-containing aqarose gels. A
northern transfer of this RNA was probed with the isolated
eDNA fragment from A Kl phage clone. RNA molecular weight
markers are indicated in kb on right side.
UD RA
- 2·37
- 1·35
- 0·24
\08
.i9. 3.10 Bqtr•••ion ot' Jev early, 1.~. and BO .arly
promot.r. in nong1ia1 c.11. in r ••pon•• ~o clone 1t1D1.
The lane" for JCV early, JCV late and BKV early promoters are
indicated. The assays were with and without eDNA, the pCMV
expression vector tor K1NFl. Ten JJg ot reporter plasmids were
cotranstected with 10 1/>9 at pCKY expression vectox' tor KINFI
into HeLa cells. Results are averages ot two different
experilaents.
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3.3 DI8COl810M
The purpose of the present study was to determine the
functional role of NFl binding motifs in the expression of the
JCV early promoter-enhancer. Site-directed mutagenesis of
these motifs led to the novel finding that the NFl motif
inside, but not outside, the 98 bp repea:s (Fig. 3.2, ILIII
and 1.11.111) is important for RA PIg cell-specific expression
of JCV. This observation provided the basis for further
stUdies such as isolation and prelimjnary characterization of
the factor interacting with NFl II/III described in this
chapter. The objectives of the study were a~hieved, largely
through site-directed mutagenesis and eDNA cloning.
Mutation of one of the perfectly palindromic NFl motifs
present in the 98 bp repeat resulted in a 3.5- to 4-fold
reduction and mutation of both motifs resulted in 7-fold
decrease in activity, specifically in RA Pl9 cells (Fig. 3.2).
However I the mutation of the NFl region I motif on the late
side of 98 bp repeats had no significant effect. The .in....Y.iY..2.
observations were further confirmed by~ transcription
assays (Fig. 3.3). These data provide direct experimental
evidence that the NFl factors interacting with these sequences
are important in RA Pl9 cell-specific expression of JCV.
Using cell extracts from retinoic acid-differentiated
Pl9 cells in DNaseI protection assays, it was shown previously
that in addition to the protection of three NFl binding sites
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in JCV enhancer, E4TFl, overlapping the NFl I was also
protected (Nalc8hatri ~. 1990a). The functional role for
this factor in glial cell-specificity remained unclear. In the
present study, the lIlutations introduced into the NFl I also
disrupted the binding site for the factor interacting with
this motif, as revealed by DNasel protection assays (Fig. 3.1
and Fig. 3.4, Jell. since the mutations in NFl I had no effect
on the expression of JCVE1 this suggests that the E4TFl motif
has no functional role in glial cell-specific expression of
JCV.
To examine the role of the individual NFl motifs in the
98 bp repeat, wild type (WT) and mutated single 98 bp repeats
were tested for comparison of t.heir functional activity in 00,
OM, and RA PIg cells (Fig. 3.2, RII and 1llRII). Three
observations could be: made. 1) For RA P19 cells there was 3.5-
fold lower activity as cOllpared to whole enhancer construct
tor pRII. This lower level of activity was similar to the
level seen when one of the two repeat region sites of the
whole enhancer construct was mutated. The blplication is that
region I NFl has no major role in glial cell-specificity and
region II activity is the same in I.III mutant and pRIX. 2)
The 3.5-fold decrease in activity after mutating the repeat
region NFl II site was similar to the results obtained with
Jllutated complete enhancer constructs. This demonstrated that
effects of such mutations were retained for a single site. 3)
113
There was a muscle cell-specific increase in activity when the
single NFl site was mutated. This observation is consistent
with the results for the different mutat~ons of repeat region
NFl sites within the context of whole enhancer.
In an earlier study (Tada ~, 1989), the
oligonucleotides encompassing NFl I, NFl II/III, And the
pyrimidine rich region and the TATA box of JCV regulatory
region were placed in front of the SV40 promoter in pAlocat.
The activity of these constructs was assessed in glial and
nongl1al cells. These constructs showed activity in glial
cells. However, chs constructs containing NFl I and TATA box
alone showed activity, even in nongl1al cells, although not to
the extent as that observed in glial cells.
Interestingly, the construct harbouring the NFl II/III
sequence failed to display any detectable activity in nongllal
cells while the vector, pAlO cat, by itself showed basal level
of activity. The authors interpreted the results as suggesting
that the NFl II/III sequences suppressed the SV40 promoter
activity and that these sequences are positive and negative
regulators of expression in glial and nongllal cells,
respectively (Tada ~, 1989). My observation that the NFl
II/III mutants exhibit higher activity in DMSO P19 cells give
credence to these suggestions. More importantly, while Tada Jlt
A.l (1989) analyzed the effect of NFl sequences using a
heterologous promoter, in my studies the functional role ot
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NFl ait.s In the glial and neng1!al expression of JCV was
assessed. in the context of the JCV pro.oter. SInce the
activity of JCV proaoter-enhancer in DHSO-ditferentlated P19
cells Is low, the increased activity of NPI autants in these
cells coapared to NT can be considered significant. Co.pared
to the regulatory regIons of BKV and SV40. the activity of JCV
promoter-enhancer In PIg RA-dlfterentlated cells is lower by
several-fold (Nakshtri ~, 19908). Hence the reduced
activity of NFl mutants in RA-differentlated PI9 cells,
although modest, is significant.
JC-HEK, a JC virus adapted to growth in human embryonic
kidney cells (HEK). displayed rearrangcl1l1ents in the control
regIon for early transcription. The control region of JC-HEK,
when placed in front of CAT gene in psvocat vector exhibited
activity similar to that of SV40. It also displayed 4 times
DOre activity than that of prototype MADI JC:V strain in HEX
cells (SinoHara .J.L.ll. 1989). This again suggests that the
rearrange.ents in the control re3ion might have resulted in
alterations in the potential NFL II/III sequences and thus
permitted the expression of JC:V early prolQoter-enhancer in
non91ial cells such as HEK cells. These rEsults are
qualitatively consistent with the results observed for~
activities of pRII and pllRII in DKSO-dlfterentlated P19 cells.
The results of experiments using CAT constructs with
a single 98 bp repeat confirmed t.hat, while the duplicated
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repeats with the two functional palindromic NFl sites have
more activity than constructs with a single NFl site, NFl site
of one repeat clin function independently for glial oel1-
specific expression. Furthermore, the tissue specificity of
the perfectly palifldromic NFl sites appear to be involved in
both the activation of JCV expression in glial cells as well
as the inhibition of expression in nongl1al cells. Previous
studies have shown that a protein of 56 kDa binds to the penta
nucleotide repeat sequence,~ adjacent to NFl II and
III and prevents the expression of JCV~ in nong1181 cells
(Sharma and Kumar, 1991). Therefore, it appears that the glial
cell-specific expression of JCV 16 tightly regulated by w-
acting elements that act positively in glial cells and
nogativoly in nong-lial cells. This is reminiscent of
regUlation of the neuron-specific expression of growth
associated protein, SCGIO, by W.-acting negative regulatory
element (Marl ~, 1990). pcssibly. the presence of two
perfect palindromic NFl sites in the repeats act indirectly to
overcome the effects of repressors interacting with
pentanucleotlde repeat sequences and allo\l transcription from
JCVE•
PI9 cells have proven to be a good system to
demonstrate this mode of tissue-specific regUlation of gene
Bxpression, as they can be differentiated into different cell
types froll an identical genotype. Hence, I could demonstrate
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the importance, specifically, of the NFl binding site present
in the 98 bp repeat in glial and nongHal cell-specific
expression of the JCV early promoter. Rowever, a heterogeneous
population of neuronal cells are induced by RA treatment of
PIg EC cells. Hence, this lIIay affect interpretation of my
data. For example, the JCV expression is regulated positively
In glial cells and negatively in nonql1al cells. In in.....Y1.t1:Q
transcription results the efficient activity of JCVE noticed
could be due to positive regulators from glial cells in a
mixed population of neural cells (Fig. 3.3). The negative
regulators frotn other neural cells might have an effect on JCV
expression. Depending upon relative concentrations and
affinities of gene-specific regl'lators, the expression
patterns could alter.
There has been a lot of discrepancy in studies
reporting the start sites for the early and late transcription
of JCV (Daniel and Frisque, 1993). In the present study the
importance of NFl binding site in glial cell-specific JCV
early transcription was confirmed i.n.....tit.x.Q by performing in
.Y..it.I:s! transcription assays (Fig. 3.3). The results suggested
that the transcription is initiated from position 5115-5125
utilizing the TATA box situated near the origin in repeat A
(Fig. 1.1). This result is consistent with the observations
reported recently by Daniel and Frisque (1993).
The effect of~ activity of NFl binding site
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mutations was correlated with alterations in the~
interactions with cell specific factors, as assayed by DNasel
footprint log (Fig. 3.4). Interestingly, the lllutation in the
NFl binding site in the central 98 bp repeat abolished
protection in the NFl binding site present in both repvats,
suggesting the c~perative interaction of the pt'oteins binding
to these sites (FiC]. 2.4 Jell). This was consistent \lith the
lesser effect on activity of mutating the second of the two
repeat region sites. This applies even when the second site is
the down stream site, which appears to have a greater effect
(Fig. 3.2, compare WT and II vursus LIII and I.II.III
effects, respectively).
Earlier studies had indicated that both NFl I and NFl
II/III oligonuclQotic!us competed ",ith all the three NFl sites
in DNaseI protection assays (Nakshatri .e..t-.Al, 1990a). Hence,
it was concluded that the proteins interacting with all t.he
three NFl sites of JCV may be the same and cooperative binding
of the factor interacting with NFl I and II ",as suggested. In
addition, a report by Amemiya~ (1989) suggested that the
proteins interacting with NFl I and II sites are the same.
However, in the present study, DNaseI protection assays with
NFl mutants clearly showed cooperative interaction of proteins
binding to NFl II and NFl III but not to NFl I and NFl II
(Fig. 3.4, compare JCI with JCI.II). Further, the results at
competition experiments in gel shift assays with NFl II/III
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oligonucleotide showed. that the factors interacting with NFl
:r and II are ditferent (Pig. 3.6). The difference in the
results of the present studies could be due to the more
sensitive techniques I used in asse881nq DNA-protein
interactions.
NFl binding sites have been found in sf!veral genes such
as BK virus control reqion (Nakshatrl At......4l. 1991). human
papillomavirusea (Nakshatri .!rt......Al, 1990bl. myelin basic
protein (MBP) gono of the central nervous system (Aoyoma n
Al. 1990), cytomegalovirus (Nowock.e..t.....A.l. 19851 Jeang .I..t-.ill.
19871, nanking regions of chIcken lysozyme gene (Borgllleyer Jlt.
.Al. 1984). hwaan 19M gene (HennIg-hausen .tlt......A1, 1985),~
gene (Siebenlist K...I.l. 1984) and sevaral C''''l:l.er genes of the
eNS (Ameralya &....Al. 1992). The NFl binding sItes located in
all these qenes indicated that the lllinillUlll nucleotide tnt)
sequence required for the bindinq at NFl is 15-16 nt with a
consensus sequence of 1'GG{N)6GCCAA. However, the first three
nt, TGG and the 6 nt spacer are sufficient for NFl bindinq but
an A or ~ nt followinq TGG increases the bindinq of NFl (de
Vries~, 1985; Leaqwater K..al, 1985). Mutation of GCCA in
the NFl binding site located in the promoter of the inutlediate
early gene of cytomegalovirus abolished the binding of the
protein (Hennighausen and Fleckenstein, 1986). However, in the
present study, mutations introduced into the half side ot the
NFl II palindrome (Fig. 3.4, JeII and JCI.II) abolished the
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binding for that region only and the other half side was still
protected. Mutations in the both half sites completely
abolished the binding of protein (Fig. 3.4 JC II. III,
I.II. III). Since this sequence is a perfect palindrome which
has pronounced two-fold rotational symmetry, possibly the
protein binds as a dimer. This is reminiscent ot the
repressor-activator-operator interactions commonly observed in
pro:k:aryotes (Ptashne. 1992). previously, NFl was shown to form
a dimeric complex with its binding site (Hennlghausen il.t...Al.
1985). The perfect palindromic sequence of JCV NFl II/III, but
not the imperfect NFl I sequence, may allow high affinity
binding by protein dlmers on DNA double strands.
Interestingly. while the sequence ~GCGGCG~ in
pBR322 and the sequenc'3~AA~ in a middle repetitive
element of mouse DNA contain consensus NFl binding motifs,
they were shown to be nonbinders (Hennighausen~. 1985).
The presence of a G-C within the central non consensus region
at the NFl site in pBR322 disrupted the binding of NFl
prl')tein. This suggests that the spacer sequence between the
consensus regions is also important. The NFl II/III sequence
of JCV. including the spacer sequence is a perfect palindrome,
while the NFl sequences located in several other genes ore
non-palindromic except for the sequence mSHN6)~' This
raises the possibility that the presence of the perfect
palindrome sequence in JCV may impart additional advantage in
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teras of binding atfinity. This ia conslatent with the
observation that a synthetic NFl oligonucleotides having the
perfect pallndro.ic~ sequence exhibited lO-fold
higher affinity than the NFl oligonucleotides that did not
have the pronounced 2-fold axis of symmetry, such as the NFl
.it.. of 19B g8ne (H8nnighausen and Fleckenstein, 1986).
NFl is It larqe !aldly of proteins and several forms are
generated by alternative splicing (santoro~, 1988). There
are tissue-specific NFl proteins that allow the £lxpression of
genes in a restricted manner and existence of epithelial 0811-
specitic NFl factore that interact with tho binding sites in
the HPV 16 genome has been recently reported (Apt ~,
1993). Interestingly, preliminary studies from our laboratory
have revealed the expression of both HPV 16 and 11, which
contain multiple NFl sites, in RA-differentiated P19 cells
(Kasinadhuni. 1994). Whether the same NFl protein is important
for the activity of both JCV and HPV remains to be
investigated. My construction of a eDNA library and the
isolation of a candidate eDNA frolll this library could readily
be used for this study. The RA- and DMSO-differentiated PIg
cells also allow expression of BK virus containing mUltiple
NFl sites. However, while the expression of JC virus 1s
restricted to RA-differentiated P19 glial cells, expression of
BKV is observed in nonglial cells (Nakshatri ~, 1991).
This .ay suggesl.. the presence of different cellular NFl
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proteins important for the expression of the two viruses. The
interaction of glIal cell-specific NFl is essential for the
restricted. glial cell specificity of JCV.
The isolation of cDlI'" from an expression library
prepared from RNA froll RA PI9 cells confirmed the presence of
a cell-specific factor and its possible involvement in
regulating the activity of JCV enhancer in RA PI9 cells.
Northern blot analysis rClVealed thQ RA PI9 cell-sp8Cific
expression of the eDNA (Fig. J.9). Moreover, the binding
specificity of this eDNA was revealed by its lack of
interaction with lQutant and non-specific oligonucleotides
(FIg. 3.8). The expression of this eDNA in HeLa cells enhanced
the activity of JCV early and late promoter-enhancers. In
addition, it has no effect on the expression of the early
promoter of another polyoma virus, BKV, which contains
multiple NFl bir"ding sites in its regUlatory region (Fig.
3.10). However, there is no evidence presented here that
transactivation in HeLa cells requires the integrity of any of
the NFlII\III sites. Co-transfection of pCMVNFl with mutated
prolloter constructs should provide furth'l!Ir information on
this. It is interesting to note that t:be eDNA is')lated
previously from brain cells encoded a factor bInding to the
NFl I"!:jIII site and activated the late but not early JC
promoter in nongl1al cells (Kerr and Khalili, 1991). The eDNA
which I isolated encodes a factor that stimulates the activity
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ot both JCV( and JCVL, suggesting that the NFl II/III binding
site ia bidirectional in function and that this site is
i1l1portant tor Qxpress!o:1 of both promoters as will be
discussed later (chapter 4).
Previous st.:udies had shown that a protein of 45 kDa
purified from calf brain supported the expression of JCVE in
BeLa cells In an iIL..YitJ;:Q transcription assay (Ahmed .et-Al..
1990). A eDNA was subsequently isolated by screening an
expression library prepared from human bruin cells using NFl
II/III binding sequence as probe. Surprisingly, this cOllA
encoded a 45 kDa protein which stimulated the late promoter
and to a very limit(!ld extent the early promoter (Kerr and
Khalili, 1991). These resUlts, although reported from the sallie
laboratory, are inconclusive. However, from the present study
it is clear that different factors are involved in the
activation of JCV early and late promoters. The following
observations prompt me to sU9qest that the eDNA isolated by llIe
is different frobl thilt isolated earlier (Kerr and Khalili.
1991). 1) My studies used a mouse cell line whereas the other
stUdy used hUJllan brain cells. 2) It is pc.'ssible that there Ilay
be mUltiple factors that regulate the early and late gene
expression or the same factor may affect both early and late
JCV gene expression. This is consistent with the observation
that the eDNA I isolated supported the expression of early and
late genes equally, while the eDNA isolated by Kerr and
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Khalil! (1991) activated only the late promoter. 3) Nfl is a
falli1y of proteins and hence different species of NFl might
exist which playa role in gene expression as reported earlier
(santoro §.LAl, 1988).
From the preliminary study presented here, it is not
clear whether the eDNA encodes NFl. However, the eDNA encodes
a factor that interacts with the un II/III Illotif of JCV in
~ and activates the JCV promoter-enhancer .i.n-Y..1.Y.2.
Clearly, further studies such as sequence analysis of eDNA and
~ binding studies with the isolated eDNA are needed to
characterize the nature of this factor. At prssent,
experiments on the detailed characterization of this factor
are being undertaken by another graduate student 1n
laboratory .
NFI/CTF is involvod in activating transcription and
also replication of adenovirus DNA (Jones ~I 1987). The
NFl II/III binding site of JCV is also essential for both
efficient transcription (the present study) and for
replication (Sock §.t...Al1 1991). Interestingly I the integrity
of the perfect palindromic NFl II/III binding site was also
found essential for the replication of JCV in vitro (Sock II
J.l., 1991).
The proteins from Heta and glial cells interact
differently with JCV enhancer I thereby affecting the i.n....YJ.yQ
activity (Amellliya i.t......Al. 1989). The proteins interacting with
12'
Nfl II site are different aaonq dltferent cell types. For
example, two prot.ina of 230 anc:l 85 kDa fro. ReLa and a
protein of 45 kDa froa glial cells specifically interact with
the NFl II/III WIOtit of JCV (}(hatH! .I..t.....Al. 1988). Moreover,
the 45 kDa brain cell-specific factor vas puri:fied and shown
to support transcription of JCV in HeLa cells (AhJted.J.1...l.l,
1990). Another cellular factor present in B-Iymphocytes also
interacts with JCV DNA (Major .t..t........J.. 1990). However, no
functional significance or studies on tho expression of JCIJ
enhancer in these cells are reported. One possibility is
that, while factors from different cell types can physically
interact with JC:V control region, only brain-specific factors
allow functional interaction. For muscle cell-specific gene
regulation, a nUllber of factors such as HyoD, myf-S and the
ubiquitously-expressed E2A gene products such as £12 and £47
bind the E-001l:. However, the .uscle cell-specific factors but
not the E2A products, are capable of activating transcription
ot muscle specific genes. Replace.ent ot the basic region or
HyoD with that ot E12 results in failure of activation or
transcript_' "n. This suggests that, although muscle-specific
and E2A tactors intera.ct with the sallle DNA sequence, the
functional consequences are different (Davis ~, 1990).
Regulation ot JCV expression might involve a similar
.echanisJI.
An alternative possibility tor JCV restricted cell
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expression is that a glial c611-specific coactivator allows
communication between NFl and the basal transcription factors.
The need for a coactivator has been suggested for several
cell-specific genes (Weintraub .n......a.l. 19l?11 Mendel ~,
1991; Luo &...Al. 1992).
The archetype JCV predo1ll1nantly recovered from kidneys
has a Spl binding site located between T1I.TA and NFl II/III
sequences. Also, NFl II/III sequences are not duplicated (Yoga
n...u. 1990). This straIn of JCV is transcriptionally inactive
in the brain and is never detected there. The rearrangements
in archetype sequences leads to the loss of the Spl factor
binding site, generating a brain specific form capable of
expression in glial cells (AUlt and Stoner, 1993). This
suggests that the interaction between factors binding to TATA
box and NFl II/III may be important for the glial cell-
specific expression. For the archetype JCV, the presence of a
Spl binding site between TATA and NFl II/III may interfere
with interaction between factors binding to NFl sites, thereby
rendering it incapable of expression in brain tissue. The
interaction of a factor binding to NFl II/III and TATA binding
protein (TBP) may be facilitated by a cOlloctivator. Such a
coactivator may be present only in glial cells. Therefore, the
binding activity detected in cell types other than glial cells
would not be suffioient for expression of JCV. Further studioB
are needed to examine this possibility.
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CHAPTER 4
Humah JC virus nuclear ractor 1 binding motH and larl;Je tUlllour
(T-) antigen dom_iDs required for transactivation of late
pro.oter.
4.1 Introduction
The regulatory region of JCV is contained mainly within
the two 98 bp tandem repeilts and is functional for both early
and late genes. The early and late promoter-enhancer (JCVE and
JCVl ) control the expression of large and small T-antigens and
viral structural proteins, respectively. Productive JCV
infection of glial cells requires the JCVl function that
occurs subsequent to T-antigen synthesis.
Transregulation of JCVL has been reported (Lashgari ~
y, 1989). As for JCVf , the activity of JCVL was also found to
be restricted to glial cells. A low level of JCVL activity was
detected in the glial cells. In the presence of JCV T-antigen
g- to 12-fold more activity was observed in glial cells.
Moreover, in nong11al cells JCV T-antigen activated the JCVt
to 4- to a-fold. 51 nuclease mapping, and nuclear run on
assays suggested that the effect of JCV T-antigen on lat~'
promoter was at the transcriptional leveL Hence, it was
concluded that the JCV T-antigen acts as a transactivator
(Lashgad ~, 1989).
The HIV tat protein and JCV T-antigcn activated the
JCVL • However, the effect of tat was several fold more than T-
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antigen. T-antigen transactivated the late promoter
significantly in both glial and oongl1al cells. However, the
tat protein of HIV activated JCV late promoter in glial cells
....hile in nongl1a1 cells very low levels of enhancement was
noticed (Tada~. 1990). Deletion analysis of JCVl was used
to localize the region(s) important for the transactivation of
JCVL by JCV T-antigen and HIV tat proteins. The results
suggested that the region between -110 to -172 nt upstream of
the start site is important for the transactivation of JCVl
and that the regions on JCVt that are responsive to T-antigen
and HIV tat protein are different. Hence, it was concluded
that the JCV large T-antigen and HIV tat transactivate the JCV
late promoter by different mechanisms (ChoWdhury~, 1990).
Another study used RA-differentiated P19 cells and
reported transactivation and repress:;'on of JCVL and JCVE'
respectively, by JCV T-antigen (Nakshatri ~, 1990a).
However, the mechanism of transactivation of JCVL by large T-
antigen remained elusive. specifically, the sequences of JCVL
and the amino acids of JCV T-antigen required for
transactivation of late transcription remained unclear.
Another function of T-antigen is its transformation
property. JC virus 1s oncogenic in various animals (Walkar n
Al, 1973; padgett~, 1977; Varakis!!.t....Al, 1978; London tl
Al, 1978). Perinatal injection of JC virus into the brains of
hamsters induced medulloblastomas (ZuRhein and Varakis, 1.979;
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ZuRhein, 1983). In humans, post mortem analysis of eNS tissues
of patients with PML revealed the presence of several glial
tumours (Sima ~. 1983). However, evidence that these
tumours were caused by JCV was not clear.
The Tokyo-1 strain of JC virus isolated from a PML
patient in Japan exhibited high neura-oncogenicity in hamsters
and 95% of the injected animals developed medulloblastomas
(Nagashima !tt.......sll, 1984). The medulloblastomas developed in
hamsters resembled human medulloblastomas histologically,
immunohistochemically and u1trastructurally. Tumours in both
species demonstrated highly malignant characteristics.
However, while all the tumours induced in animals expressed T-
antigen of JCV, this antigen is not detected in human brain
tumours. Importantly, JC virus is the only human virus known
to be able to cause solid tumours in non-human primates
(I"ondon ll...A.l, 1978; Reith~, 1980).
Although JCV readily induces tumours in experimental
animals, it transforms cells in culture in vitro inefficiently
(Frisque and white, 1992). Transformation efficiency of JCV T-
antigen is poor as compared to those of other DNA tumour
viruses such as, SV40 and SKV (Nakshatri~, 1988; Haggerty
K...sl.l., 1989; Fanr.. I.ng , 1992). Early studies indicated that JCV
transforms primary human fetal glial cells (PHFG) and human
vascu] ar endothelial cells (Fareed~. 1978; Walker and
padgett, 1978). Later it was shown that PHFG cells were
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transformed by origin-defective mutants of JCV to create the
POJ cell line (Mandl and Frisque, 1986). Primary hamster brain
cells were transformed by infection with Madl, Mad2, MadJ, and
Mad4 viruses and by trans feet ion with Madl DNA. The
transformants exhibited several features characteristic of the
transformed phenotype which include high saturation densities,
increased growth rates in high and low serum concentrations
and anchorage-independent growth. Saby hamster kidney cells
(BHK-21) and rat fibroblasts (Rat2) were transformed in
culture (8011ag ~, 1989; Haggerty~, 1989).
The JCV genome was detected in transformed cells
multiple copies in a tandem head-to-tail arrangement (Mandl
and Frisque, 1986; Mandl ~, 1987). Southern blot
hybridization indicated that JCV DNA integrates randomly into
the host chromosomes and free, unintegrated viral genomes have
not been observed (O'Neill ~, 1988). However, the large T-
antigen sequences important for transformation of cells
remained unclear.
The objectives of my study are as follows.
1) To examine the role of NFl binding motifs in the
transactivation of JCV~ by T-antigen.
2) To investigate the ability of these motifs to interact with
factors in the presence and absence of T-antigen.
3) To delineate the amino acid sequences of large-T antigen
required for transformation and transactivation of JCV~.
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•• 2.1 nl aottr_ requlr.« tor JCVL ~ru••cU.V.tl0D.
To examine the role of NFl binding sites in the
transactivation of Jf:VL by large T-antigen, site~directed
mutagenesis was performed (Fig. 4.1). Reporter plamDids
containing the various mutations were transfected into RA PI9
cells with or without T-antigen expression plasmid. A
substantial transactivation of pJCL cat (WT) was obtained by
cotransfecting with T-antigen expression plasmid (Fig. 4.2
WT). The mutated NFl I site (I) construct also showed
substantial transactivation by T-antigen (Fig.4.2, I). Next,
the role of NFl II/III was examined. Mutations in NFl II
greatly reduced transactivation in RA PI9 cells. Mutations in
NFl II plUS III and NFl I, II, plus III eliminated
transactivation (Fig. 4.2, II.III and I.II.III, respectively).
The results indicated the necessity of the NFl II/III binding
motifs located in the 96 bp repeats, but not NFl I, for
transactivation of JCVl by T-antigen in RA Pl9 cells. The
effect of NFl mutations on the transactivation of JCVl by T-
antigen was also tested in the DHSO-differentiated PI9 muscle
CQlls. The WT promoter and NFl I mutant (I) were repressed by
T-antigen Whereas, the NFl mutants II, II.III and 1.11.111
were not affected in the presence of T-antigen (Fig. 4.3). The
results suggested that the JCV T-antiqen activates JCVl in RA
PI9 cells and represses JCVl in nonglial cells.
Piq..... 1 Wild type anI! mutated NFl motifs in JCVL sequenoes
in CAT phslIlids.
Top: Diagram of JCVL sequences in the JCV fragments inserted
into psvocat. The early H..i.m!III and late ~II sides are
indicated. TATA boxes and NFl site motifs are indicated and
delineated by thick lines. The nt positions are indicated. The
boxes represent the 98 bp tandem repeats. Bottom: List of
mutated plasmids and mutated sequences for the three NFl
sites. Mutated NFl nt are indicated by lower case letters.
wild type NFl nt are indicated in pJcl cat by upper case
letters and in other plasmids by dashes. Inverted palindromic
sequences are underlined for pJclcat (WT).
early 12 109 110 207 lale
ITATA N£!...!!I ITATA ~I I~
5112 14 22 39 51 112 120 137 149 213 225 270
Plasmids NFl III NF111 NF11
pJClcat (WI) ~~ ~C~ m!lMAGCAG~
pJCleat I ------------- ------------- -a--------a_c
pJCleat II ------------- gta-----a-c -------------
pJClcat 11.111 g ta-------a - c gta-------a-c -------------
pJClcatl.ll.l1l g ta-------a - c gta -------a-c -a--------a-c
IN
'"
Fig. 01.2 8ffect of 1IJ'1 aut.tion. on JCVL tr.n.activation by
or-antigen in RA-tre.te4 Pl' cells.
Plasmids were wild type pJcvLcat (WT) and others with NFl site
mutations, as indicated by the unique letters for the
constructs described in Fig. 4.1. Transactivation is the
difference between CAT activity (\: conversion) in the absence
and presence of JCV T-antigen expression plasmid. CAT activity
was normalized with p-galactosidase. Results are averages of
three experiments. Percent CAT conversion in T-antigen
nonexpressing cells: WT, 5.9; I, 6.6; II, 6.21' 11.111, 4.2,
Io II. III, 8.4.
N ~ = - -
0
-I ~iil
:l
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Pig.".3 8rr.ot of HJ'1 aut.tioDIJ OIL JCVl traDlJraqulation by T-
antigan in Pl' .uacl. c.lla.
Plasmids are as explained tor Fig. 4.2. Other methods are the
same as in Fig. 4.2. In the figure ': conversion is shown
instead ot trnnsactivation described for Fig. 4.2 as
repression of late promoter in the presence of T-antigen was
noticed in contrast to activation in Pl9 RA cells.
... L _
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The role of NFl sites in late promoter function was
also examined by ..i..n......... transcription assays. In the
presence of P19 RA cell extract from cells which exprassed JCV
T-antigen, JCVL wild type (WT) and mutated NFl I promoters
were transcribed at S-fold and 5. a-fold greater rates,
respectively, compared l..-ith extract from non-T-antigen
expressing glial cells. Monoclonal antibodies against large T-
antigen reduced JCVL transactivation to 1.6-fold, confirming
tha involvement of T-antigen and indicating that T-antigen
acted .in.........Y.J. Mutations in the NFl II plus III sites
resulted in O.6-fold transactivation, a 1. 7-fold repression of
pJCVL (Fig. 4.4). The transcription was by RNA polymerase II,
because alpha-amanitin blocked all transcriptional activities.
Thus, the~ transcription assays confirmed the
requirement of NFl II and III, but not I, for transactivation
of JCVL by large T-antigen in PI9 RA cells.
4.2.2 Mediation ot JCV large or-antigen etteClt through NFl
n/nI
Mobility shift assays were used to examine whethel; the
induction of JCVL by T-antigen involved alterations in the
binding of the NFl sites of the 98 bp repeats. For normal PI9
RA cell extract, the 98 bp repeat probe with wild type NFl
II/III was bound in an upper complex and a doublet of lower
complexes. Extracts of T-antigen expressing Pl9 RA cells gave
a binding pattern in which tho:. upper complex was increased
Pig. 4.4 Effeot of T-anUgen and JeY NFl aites on JCVL in
~ t ....anscription.
Names of the plasmids are as described in Fig. 4.1 and 4.2.
Glial cell extracts had 75 IJg protQin. Labels: T, cells
transfected with T-antigen expression plasmid; Ab,
crossreacting SV40 monoclonal T-antigen antibody in assays; Q-
a, 1 IJg/ml alpha amanitin polymerase II inhibitor; RSV-,B-Gal,
p-galactosidase internal control RNA: JCVL• JCVl RNA;
Transactivation, fold transactivation by T-antigen. Pairs of
assays with extracts for cells expressing T-antigen and not
expressing T-antigen ..ere compared for fold transactivation
values. Results were consistent for two experiments, including
greater transactivation for 1.
\2,1
l?-')O+III'II
l? -':)0+10M
1.+"',11
1.+111-11
""11
1.+1 =In
QV+1.+1.M CD
,.:..
10M
l.+1.M In
n:l .... l:
C) > .!2
I u ...., n:l
c:Q >
I ..~ Un:l
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n:l
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7.Z-fold (Fig. 4.5, T). The increased binding for the upper
complex was due to the immediate function of the T-antigen,
because monoclonal antibodies for T-antigen blocked the
increase (Fig. 4.5, T~·Ab(S». Non-specific monoclonal
antibodies against MHC class II (I-AK) gene product failed to
block the increased binding of the upper complex (Fig. 4.5,
T+Ab (NS)) •
To further examine the effer:t of T-antigen on the
binding <lctivity, mobility shift assays were done with wild
type and mutated NFl II/III oligonucleotide probes. Only one
complex was observed with WT NFl II/III olgonucleotide probe
and T-antigen increased the amount of this complex by 6.2-
fold, similar to the increase for the upper complex with 98 bp
repeat probe (Fig. 4.6, WT, lane T). Monoclonal antibodjes
against T-antigen blocked the increase in the complex (Fig.
4.6, WT, lane T+Ab (5) ). The monoclonal antibody against !1HC
class II gene product had no effect (Fig. 4.6, WT, lane
T+Ab(N5)). IlJutated NFl II/III oligonucleotide was not bound,
confirming the specificity of binding to this motif (Fig. 4.6,
mu). These results confirmed that T-antigen facilitated the
binding and that the NFl II/III motif is involved in binding.
Overall, the results suggested that transactivation increased
the formation of a productive transcription complex at JCVL
due to an interaction(s) Io'ith the NFl II/III motif.
Fi;. 4.5. Effect of or-anti;en on binding of cellular factors
t.o JCV 98 bp repeat regulat.ory region.
Mobility shift assays used the ~I 98 bp repeat fragment of
Jev regulatory region and 8 .ug of protein. Labels: F', tree
probe with no protein; 8, binding for non-T-antigen expressing
glial cell extract; T, T-antigen expression plaslllid-
transfected cell extract; T+1I.b (5), T+ Illonoclonal T-antigcm
antibody in assays; T+Ab (NS), T+ nonspecific control Mile
monoclonal antibody. Fold change in binding ot upper complex
in the presence of T antigen, in comparison with lane B which
used extract with ~IO T-antigen, are T, 7.2-told; T+Ab (NS),
6.4-fold; and T+Ab (5), D.9-fold, as deterlllined by
densitometry.

Piq. 4.6. Effect of T-antiqen on NFl bindinq.
Mobility shift assays used wild type (WT) and mutated (mu) NFl
II/III oligonucleotide probes and 6 Ilg of protein.
Labels: F, hee probe with no protein; S, binding for non-T-
antigen expressing glial cell extract; T, T-antigen expression
plasmid-transfected cell extract; T+Ab (5), T+ monoclonal
antibody against T-antigenl T+Ab (NS), T+ nonspecific control
MHC monoclonal antibody. oensitometrically determined fold
increases relative to lane B for nonexpressing cell extract
and WT probe: T+Ab (8), 2.1; T, 6.2; T, 6.4; and T+Ab (NS),
5.6.
mu WT
~II ~I
Iii en Iii enz ~:c :c :c ...
c c c C
aD + + aD + +lo. ~ ~ ~ ~ lo. ~ ~ ~ ~
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4.2.3 T-antigen domains for JCVL transactivation anlS
transfortaation
The amino acid domaln(s) of JCV T-antigen necessary for
transactivating JCVL were also examined. Ten translation
termination linker and deletion mutations in the T-antigen
expression plasmid were generated (Fig. 4.7). See Fig. 1.1 for
a comparison of T-antigen with the wnole JCV genome. Wild type
and mutated expression plasmids were co-transfected with the
wild type reporter plasmid. Mutated constructs encoding the
first 10, 141, 180, and 195 amino acids (pK4984, p1<4246.
pK4129, and pK4085, respectively, Fig. 4.7) transact iva ted
poorly (Fig. 4.8). Constructs encoding the first 437,552, and
591 residues (pK3359, pK3013, and pK2B96, respectively, Fig.
4.7) showed nearly wild type activation levels (Fig. 4.8). The
internal deletions for amino acids 142-180 (pl<6117) and 196-
437 (pRD,726) reduced transactivation to a half and a third,
respectively, of wild type (Fig. 4.8). Taken together, thl';!
results suggested that amino acid residues 196-437 are
necessary for most of the wild type transactivating activity.
Transformation is an important function of 'r-antigen
and protein domains in general are often functional for
different or related biological functions. T-herefore, primary
BRK cells were assayed for transformation with the same T-
antigen domain mutants used for the transactivation studies.
The results of the transformation assays indicated that the
Fiq. 4.7. Diaqram of mutated T-antiqen sequences.
Expression plasmids are shown. Numbers in plasmid
correspond to sites of linker insertion and nUmber of nt
deleted. The pKA1945 deletion is out-of-frame. Labels: numbers
in diagram, JCV nt positions; ATG, ll>itiation codon; TAA,
termination codon; TAG and arrow heads, translation
termination linker insertion sites; solid lines, JCV T-antigen
ORr; dashed lines, intron sequences; black boxes, deleted
sequences.
ATG TAA
ptasmkls 5013 4n1 4426
CMV-JCV·TA , '- - -'
2003,
pK4984 --i....
"0
pK4246
__ ----l...
....
pK4129
__ --.i.
....
TAG
pK4085 - -
,
4Q85 TAG
pK3359 - --
,
"50 TAO
pK3013 - - ----L3013 TAG
pK2896 - -
,
....
pK..1117
-------4246 4129
pK.>T26 - - .... 3350
pK.1.1945 .... 3013
-
....
-,J
Fig. 4.8. 'I'ransaCltivation of JCVl by mutated 'I' antigen
expression plasmids.
WT indicates wild type CMV-JCV-TA. Other labels and estimate
of transactivation are as in Fiq. 4.2 and 4.7. CAT expression
values in T-antigennonexpressing cells: WT, 5.1; pK4984, 4.7;
pK4246, 5.2, pK4129, 5.7; pK4085, 5.0: pK3359 , 5.0; pK3013,
4.8; pK289V, 5.01 pKH17, 5.05; pKA726, 5.55; pKAl945, 4.9.
cr-
<:r
65432
pKd1945
PK6726
pKd117'
pK2896
pK3013
PK3359
pK4085
pK4129
pK4246pK4:. IIi i
o
Transactivation
Table 4.1 Transformation domains of jeV T antigen.
Plasmidsa Transfonnation of Numberofamino-
BRKcellsb acids in TantigenC
Exp.l Exp.2 Exp.3 Mean
CMV-]CV-TA 17 2S 21 ZZ 1-688
pK4984 0 0 0 0 1- 10
pK4246 10 6 8 8 1·141
pK4129 3 5 4 4 1-180
pK4085 2 4 3 3 1-195
pKJ359 16 19 10 15 1-437
pKJ013 16 21 11 16 1-552
pK2896 14 27 14 18 1-591
pKA1l7 9 16 1Z 1Z 1-141; 181- 688
pKd726 2 5 2 3 I - 195; 438 - 688
pKAI945 0 0 0 0 I - 19;(552 - 688)
a The indicated plasmids are as shown in Fig. 4.7
bBRK cells were plated in three 50 rom plates. After 24h, the cells were co- tJ::r!sfected with
5 J.lg/plate of the indicated plasmids and the same amount of E].Ha- ras-l-pML.
c The bracketed amino acids of pK.6.1945 are out-of-frame.
<1",
D
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transfonatlon dOlls1n was mostly in amino acid residues 196-
437 (Table 4.1). The requirement of domains was similar to
that for transactivation, considering the distinct nature of
the two assay systems.
4.2.4 •••terll J:)lot aDalrai. of 1f'l' and aut.llt 'l'-anti'lan
.xpr••don pl...id••
The difference in transactivation observed between wlld
type and Illutated T-antigen expression plasmids could have been
due to instability of the mutated proteins. Therefore, lysates
from Pl9 glial cells tran~fected with these plasmids for
expressing T-antigen were examined in Western blot assays for
T-antigen protein. For only the pK,41945 out-of-frame deletion
mutation encocUng the first 19 amino acids (Fig. 4.7) no JCV
T-antigen protein was observed (Fig. 4.9). T-antigen was
stably produced at comparable rates from the other 9 plasmids,
since the protein was present at comparable levels in the
glial cells (Fig. 4.9). The size of T-antigen for tho various
mutated constructs was similar to WT. This is most probably
due to the posttranscriptional modifications of T-antigen in
~. as also reported for BKV T-antigen (Nakshatri I..t.......ill.
1988). Taken together, the results indicate that the effect of
T-antigen mutations on transactivation and transformation are
due to functional T-antigen protein domains (Fig. 4.8; Table
4.1) •
Pig. ".9. Western blot analysis of T-antigen proteins
expressec:l trom mutatec:l plasmids.
JCV T-antigen is detect(" ~ as the band corresponding to the
arrow.The labelling is the same as described for Fig. 4.7.
Molecular weight markers (M) are indicated in kDa. Lower bands
may be degradation products of T-antigen.
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t.3 Di.cu••ioD
The st'-dies of this chapter examined the molecular
basis for induction of late Jc:Y gene expression in RA P19
cells by the transactivatinq early gene product, large T-
antigen. The involveJlent of the NFl motifs of the JCV late
rBg'lon was approached by site-directed mutagenesis of NFl
motifs. The results clearly showed that the integrity of the
two NFl sites within the 98 bp repeat, but not the third site
located towards the late side, was essential for the
transactivation of JCV late promoter-enhancer in glial cel:s
(Figs 4.2 and 4.4). Transactivation of JCVl by T-antigen
required direct T-antigen function during the assay I since
antibody to T-antigen abolished transactivation in vitro (Fig .
... <I). This indicated that the lIlechanism did not involve
alterations such as the level of In~ synthesis of NFl or
other transcription factors. The In Y.1..t..u:!: gel ..hirt assays
clearly suggested that T-antige:l mediates this effect by
radIi tating the increased binding of NFL Further,~
binding assays with oligonucleotide probes confirmed the
requirement of the specific NFl II/III motifs.
Transactivation of JCV late promoter by T-antigen in the
glial cells ....as Clearly sho....n ....ith 5-fold higher activity in
the presence of JCV T-antigen in~ tram' ~ription
assays. The NFl II and III were distinctly .LlDportant. These
reSUlts are in agreement ....ith the previous observations that
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JCV T-antigen mediates its transactivating effect through the
region between nt -110 to -172 (Chowdhury~, 1990). The
results from the present study clearly narrowed down this
region to Nfl II/III binding sites (nt -137 to -149 and -39 to
-51, respectively). The mutation of only NFl site II
eliminated most of the transacti".<:ttion. Therefore, the
duplicated NFl of the 98 bp repeat appp.ars to be important for
expression in glial cells. Nfl II/III ~s included in the 62 bp
region that was previously shown to be required for glial
cell-specific transactivation (Chowdhury .!ll.......Al, 1990) .
Moreover, the JCV genotypes identified in brain tissue
cons.lstently harboured duplications of the sequences that
specifically include 12-40 nt containing this Nfl site. In
addition, in the archetype JCV which is frequently prescnt in
the kidney, the corresponding NFl s1 te is never dupl icatcd
(Yoga ~, 1990). This suggests there are kidney-specific
NFl functions. NFl is a family of proteins, and distinct
factors have been shown previoUsly to regulate gene-spec;'fic
expression in other tissues such as liver (Jackson ~,
1993). Although the NFl motifs in the 98 bp repeats arc shown
here to be essential for the transact1vation of JCV late
promoter, my results do not rule out the requirement for other
sequences in the late promoter.
Earlier, several studies reported different start sites
for JCV late tran&cription and the results were ambiguous
15.
(Kenney!!.t.....A.l, 1986b; Khalil! K.Jll. 1987). The results ot in
~ transcription assays of the present study provided
precise and important information on the location of the start
site of JCV late transcription. Based on the size of the
transcript generated, the start site tor late transcription is
centred around nt 200-203, as suggested by primer extension
and 51 nuclease in the studies of Daniel and Frisque (1993).
The Nfl binding motifs (NFl II/III) in the JCV
regUlatory region are important for both early and late gene
expression of .TCV (}{err and Khalil!, 1991; results of the
chapter and chapter 3). TO examine the molecular mechanism, an
attempt was made to look. at alterations in the binding
activity of NFl in the presence of T-antigen. The results of
lIobility shift assays dellonstrated that T-antigen increased
the binding of NFl to the NFl motifs located in the repeats.
JCV is oncogenic in animals and it is the. only human
virus known to cause solid tumours in non-human primates
(London ~, 1978; Reith ~, 1980). Hence the JCV T-
antigen amino acid sequences important for transfornation were
investigated by constructing and studying a panel of T antigen
mutants. The present stUdy she wed that the transactivation and
transformation domains of JCV large T-antigen are similar,
considering the distinct nature of the two assay systems (Fig.
4.8; Table 4.1).
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Parental and chimeric DNAs of JCV. SKV, and SV40 have
been used to show that both the regulatory sequel'ces and the
large T-antigen amino terminus sequences are necessary for the
JCV restricted transformation behaviour. Characterization of
the cloned cell lines prepared from T-antigen transformants
revealed variations in the amount and stability of T-antigen.
Ability of T-antigen to form stable complexes with p53 was
also affected (Bol1a9 §.t....£l, 1989; Haggerty.!tt..ill. 1989). The
tumour supp.:essor, p53, is important for the control of cell
proliferation (Milner, 1991; Levine 1992). JCV T-antigcn was
also shown to interact with Rb and pIO? (Dyson ~, 1989,
1990). Rb and plO? are involved in control of cell cycle
progression and Rb blocks the cell cycle at a certain point in
Gl. JCV T-antigen interacts with all these proteins ilnd
possibly perturbs thE'; action of these proteins, thereby
resulting in the loss of control on cell proliferation. The
mutants pKA1l7 and pKA726 used in my study showed reduction in
their transformation potential (Fig. 4.7; 'I'able 4.1). The
mechanism of this reduction in transformation nlost probably
involves loss of T-antigen domain(s) important for binding to
one of these proteins involved in the control at' cell
proliferation.
The differences in transactivation and transformation
between WT and mutant JCV T-antigens could have been due to
variations in the stability and the levels of mutant T-
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antigen. However, results of western blot analysis revealed no
change in either stability or levels of T-antigen protein
(Pig. 4.9). The mutant T-antigen expression plasmid expressing'
the first 141 amino acids (pK4246) showed more transformation
efficiency than those expressing the tirst 180 (pK4129) and
195 (pK4085) aIIlno acids (Table 4.1). It is possible that the
T-antigen sequences located between nt 4246 and 4085 contain
an inhibitory domain. The interplay botween act,ivation domain
loc8ted within nt 4085-3359 for amino acids 196-437 and the
inhibitory domain within nt 4246-4085 may determine the
transformation potential of JCV T-antigen. This can be
supported by the observation that adenovirus Eta, an oncogenic
protein, contains sequences in the carboxyl (C-) terminus
responsible tor inhibiting its transtormation potential
(SUbramanian §.U.l, 1989). The suppressive e!!ect of the C-
terminal region ot Ela protein on ~-mediated transformation
was due to interference with the n,a.-directed transformation
pathway or abrogation ot Ela cooperation with 11l.fi (SUbramanian
~, 1989). Hence, tho possiblo interactions between
different rcqions of JCV T antigen, the cellular proteins such
as Rb, p107, p53 and ~ oncoqene lead to oncogen~.c
transformation in a complex process.
A similar cell system to that of my studies was used to
stUdy the BX virus large T-antigun domain important tor
transformation. The BKV T-antigen domain was mapped to amino
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acIds 265-417 (Nakshatri fd.......ll., 1988). My studies show that
JCV T-antigen amino acids 196-437 are important for
transformation (Fig. 4.7, Table 4.1). Therefore, the
transformation domain of T-antigens of JCV and BKV appear to
be within the same regions. This is not surprising since the
T-antigens of these viruses share a high percentage (85\J of
homology. The transformation domains of T-antigens of SV40 and
BK viruses are different and share only 54\ homology
(Nakshatri ~, 1988).
The domain of T-antigen required for transactivation
was mapped with a panel af T-antigen mutant constructs. Most
of the function was localized to the nd<.1~!l' t'1ird of T-antigen
and the amino terminus (Fig 4.7 and 4.8). The overall homology
among the genornes of JCV, BKV and SV40 is high (Frisque~,
1984). However, homology in the regulatory region is below
average and only JCV and SKV have NFl sites. The relativQ
expression level of JCV was 24-fold more than that for SVIIO
for glial cells compared with muscle cells, and 6-fold more
than that for BKV (Nakshatri ~, 1990, 1991). 'rhe
difference from BKV could be due to the unique productive
interaction of the different JCV NFl sites with a distinct
NFL Alternatively, the greater number of motifs, such as the
GC-rich sequences in BKV, might alter or cQllceal a similar NFl
specificity to glial cells. Consistent with the latter
possibility, interactions with SKV NFl sites were spoclfically
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weaker in muscle cell extracts than in glial cell extracts
(Nakshatri §..t......Al.. 1991)_
The TATA-less SV40 late promoter functions efficiently
through a coactivator interacting with Spl which recognizes
the SV40 GC-rich motH (Pugh and Tjian, 1990). The BK GC-rich
sequences may also function through a similar mechanism.
However. JCV has no GC-rlch sequences and has much lower
activity than SV40 and BKV, even in PIg glial cells (Nakshatri
n..Al. 1990a). Therefore, the brain-specific expression of JCV
appears to be relatlvel,y more dependent on the NFl II/III
sites.
In contrast to JCV, SV40 has no gl1.11 cell specificity.
Transactivation of the late promoter of SV40 has been
attributed to TEF-l (Coulombe .i..t........il. 1992b; Gruda .I..t...-.Al.
1993). SV40 T-antigen ....as sU9-;ested to transactivate the SV40
late promoter as a coactivator through its interaction with
TEF-l and TATA binding protein, TBP (for detailed explanation
refer to sUbsection 1.7.2.2.1.1 and 1.7.2.2.1.2). Although
SV40 differs frOID JCV by having TEF-l sequences and no NFl
site, the greater information available for SV40 warrants a
comparison with JCV. JCV and SV40 T-antlgens have 72\:
homology, compared to 83\: between JCV and BKV (Frisque §..LAl,
1984). The domain of SV40 T-antigen that binds TBP is within
amino acids 5-172, a region with apprOXimately 40\: of wild
type transactlvation activity (Gruda ~, 1993) I tho JCV
,.,
amino acids 1-141 had 12\ of wild type transactivation (Fig.
4.1 and 4.8). The domain of SV40 T-antigen that binds TEP-l
and TBP is within amino acids 5-383, and has the most of wild
type transactivation. Similarly, the JCV amino acids 1-437 had
equal activity to wild type and the deletion of amino acids
196-437 disrupted most of the transactivation.
The JCV amino acids 196-437 region is of further
interest, because it also corresponds to the SV40 TEF-l
binding domain and the nt 302-320 zinc fingor domain (Fanning,
1992). Whereas the DNA binding domain from nt 131-259 of SV40
probably bind~ TBP and has an dverage homology to JCV, the
zinc finger domain has a marginal 39% homology. The homology
between JCV and BKV is 78t for this region, possibly
reflecting a similar mechanism for both of these human
viruses. This is still significantly different from the 91%
homology for the DNA binding domains between JCV and BKV.
There is no quantitative data to suggest that T-antigen was
stably produced at comparable rates from the T-antigen
mutantl'i. Hence a cell line that constitutively produce JCV T-
antigen and the cells transformed by mutant T-antigen
expressing plasmids generated in the present stUdy can be used
to solve this problem.
The exact mechanism by which T-antigen activates the
JCVt is not clear. One possibility is that NFl protein may be
modified by JCV 't.-antigen leading to transactivation of JC'.Jt ,
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even though no obvious differences in the .ability of complex
1n the presence of T-antigen were drtected (Pig. 4.5 and 4.6).
However, the possibility of post-translational noditication of
NFl by T-antigen can not be ruled out.
Another possibility is that JCV Of-antigen llight be
acting as an intermediary Ilolecule ~etween NFl and one of the
basal transcription factors for late promoter activation,
analogous to adenovirus Ela (Scholer.t..t......Al, 1990; Lee ~,
1991) and SV40 T-antigen (Gruda .!!t-ill, 1993). However,
mcbility shift assays using the 98 bp repeat failed to reveal
any obvious difference in the lIobility of the complexes in the
fom of a supershift. However, the ternary complex containing
T-antigen could be unstable ar.d dissociate during the native
gel electrophoresis. There are several exa.ples for this. HTLV
tax protein increases the rate of transcription by
facilitating the binding of the factor ATF. Although the tax
protein interacts with ATF iD...x1t.m, no change in the nobility
of the cOlIplex containing ATP was observed, either in th~
presence of tax or with antibodies against tax protein
(Franklin J..t......A.l, i..993i Wagner and Green, 1993)· The authors
suggested ~hat with the gel conditions used, the complexes
might have dissociated. with respect to the glucocorticoid
receptor (GR), although it interacts with purified AP-1 .in
illI:2. no further retardation of the t2ILd.ml complex was
obll8rved in the pre.ence of ~ in liability shift assays. The
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lack of supershl ft was suggested to be due to dlsrupti,on of GR
during gel resolution (Konig .ct....Al., 1992). Instability of
ternary complexes in gel shift assays has been reported in
other cases such as interaction between oct-l and GR (Kutoh !ll
ill, 1992). SRF Serum response factor and Phoxl homeodomain
protein (Grueneberg.e:t...a.l. 1992) and NF-IL6 Nuclear Factor for
interleukin-6 expression and GR (Nishio ~, 1993). Henoe,
the possibility that T-antigen interacts directly with NFl <:'nd
the basal transcription factors can not be excluded, simply
based on the failure to detect supershifting in goal shift
assays (Fig. 4.5).
The JCV late promoter is down-regulated by LCP-l 56 kDa
repressor protein (see the following paragraph) which
interacts with a pentanuclsotide repeat sequence(~
which is indicated as NRE in Fig. 1.2). This sequence is
located adjacent to NFl binding sites in the repeats (Tada n
ill, 1991; Tada and Khalili, 1992). Another possible mechanism
for transactivation of late promoter by T-antigen might
involve changes in the balance of the interaction of this
repressor protein with NFl II/III and pentanucleotide repeat
sequence, leading to the increased binding to NFl II/III
observed in gel shift assays (Fig 4.6). Thif: might involve a
mechanism in which NFl and repressor compete for binding JCV
NFl site and NRE, l'ospectlvely. Therefore, the effect of T-
antigen might be to relieve this competition by pr.wenting the
,..
binding of the repressor to NRE.
A single-stranded DNA binding protein na.ed lytic control
element-binding protein 1 (LCP-l) binds the lytic control
element (LeE) (Tada and XhaUli. Hl2). previously identified
as a pentanucleotide repeat region located adjacent to the NFl
II/III (Tada.At......Al. 1991). Mutations in the LeE affected the
binding of LCP-l leading to l;oeduced early mRNA tranE:cription
and had no effect on late mRNA transcription. The
possibilities that there may be competition between early and
late mRNA start sites for transcription initiation and that
occupancy by origin of replication by large T-ant 1.9'eo hinders
the early transcription sIte were ruled out in a study by
Khal1li &...4l (1987). It was suggested that JCV T-antigen may
inactivate or sequester LeP-l fro. binding to LeE/
pentanucleotide repeat region (Tada and Khalili, 1992),
analogous to the blocking of binding ot AP2 factor to enhancer
region of SV40 by large T-antigen (Mitchell ~. 1987). For
JCVv the 56 kDa protein interacting with LCE/pentanucleotide
repeat region might repress the late promoter activity by
blocking the interaction ot NFl and TATA box binding factors,
which is essential lor transcription activa":ion. as confirmed
in SV40 system (Gruda &...Al. 1993).
Based on the results of my studies and those reported
by others, I propose a model wherein JCV T-antigen facilitates
the increased binding of NFl II/III by preventing the
pig. 4.1:00 1104.1 for po••ible ••ob&lli•• of tr&llllaotivatioD of
JCV lata pro.otar by larga 'l'-antig.n.
The JCV regulatory region with early and late sides is shown.
NRE (pentanucleotide repeat) and NFl denote the binding sites
for negative requlatory element and nuclear factor 1,
respsctively. The hatched box denotes the repressor protein
which binds NRE. The black box denotes the factor binding to
NPI motif. NRE is also called LeE.
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repressor binding to LeE. This would facilitate the
interaction of NFl with NFl II/III (Fig. 4.10). Thus, the
specific interaction of JCV NFl II/III motifs and brain-
specific NFl may be a doubly important factor in the
requirement for NFl-dependent function of the JCV early and
late promoter-enhancer in glial cells.
The early pro::noter of JCV is repressed by JCV large T-
antigen (Nakshatri §..t....Al, 1990a). Moreover, the integrity of
the pentanucleotide repeat region that interacts with the
repressor was shown to be important for efficient expression
of early but not late promoter-enhancer (Kumar !!..t........a., 1992:
Tl.da ~, 1991). My proposed model explains how this could
happen. The prevention of repressor binding by T-antigen .....ould
lead to activation of late and repression of early promoter of
JCV.
,..
CRAPO. 5
Rol. of eyelio aMI' r ••pon•• eI".Dt (CD) in JCV .lEPr•••ioD.
S.1 Introduction
The regulatory region of JCV consists of several
protein binding dOllialns (reviewed in Frisque and White, 1992:
Major~. 19921 and Fig. 1.21. site-directed mutagenesis of
JC:V control region suggested a role for nuclear factor 1
(NFl) binding sequences located in the 98 bp repeats in the
glial cell-specificity (chapters 3 I\nd 4 of this thesis).
Mutations in all three potential NFl binding sites greatly
reduced the transcriptional activity of JCV early promoter-
enhancer In glial cells. However, a residual activity, more
than the bas~:" level activity of the psvocat vector was still
observed, indicating the possible involve.snt of other factors
in expression ot JCV ( Fig. 3.2). Earlier studies (Amemiya At
Al, 1992; Ault and stoner, 1993) had identitied a cyclic AMP
response element (eRE) in the JCV regUlatory region.
Examination of the JCV promoter-enhancer sequences revealed
the presence ot eRE motif, TGAGCTCA 4 bp upstream of tho NFl
II and III binding sites, relative to the early region, in the
repeats.
Several eucaryotic cellular and viral genes contain
cAMP response element (CRE) in their noncoding region and the
genes are regUlated by cAMP (reviewed in Roesler ~, 1988:
Montminy.ilt.Al, 1990: Borrelli-itt...Al, 1992). Analysis of thesa
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!lequences identified TGACGTCA as the eRE consensus sequence.
A 43 kDa protein called cAMP response element binding protein
(CREB) binds this sequence as a dimer. Dimerization and the
transcriptional efficiency of CREB are regulated by its
phosphorylation by protein kinase A, PKA (Yamamoto rt-li,
1998j. PKA is located in the cytoplasm in an inactive form and
as d tetramOT ,1onsistinq of two catalytic subunits complexed
with two regulatory subunits. In the presence of elevated
intracellular cAMP levels, the catalytic subunits of PKl\ are
activated and translocated to the nucleus, where they
phosphorylate CREB on a serine residue. The phosphorylated
CREB is then able to bind the eRE sequence of the cAMP
responsive genes and activate their transcription (Borrelli §.t
Al, 1992). The presence of a CRE motif in the JCV
transcriptional control region prompted me to investigate the
role of this sequence. in the context of the NFl s1te. on the
expression of JCV early promoter-enhancer (JCVE) in glial
cells. Attempts were also made to characterize the protein (al
binding to the eRE motif by in.....Y.i.t..t binding studies.
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5.2.1 Role ot CRB in .iJL.nE espr•••ioQ of JCV
To exaaine the role of' CRE in JCV expression, the
plaslIlids pJC;C&t tor CAT exprassion froll JCVl and pRIIcat for
expression troll JCVI single 98 bp sequence (Fig. 3.1) ware
transfected into PIg glial cells. The cells were then treated
with and without 10 pM of dibutyryl cAMP, a cAMP analogue, for
24 hours. Transfected cells were also treated with 100 j.IM
forskol!n, an agent that elevates the intracellular cAMP
levels. Both plesmids expressed efficiently in PI9 glial cells
and treatlllent with cAMP induced CAT expression from pJCV£ cat
and pRIIcat by 2.0- and 2.7-fold, respectively. Forskolin
treatment increased expression of these plas.lIids by 2.1- and
2.6-fold, respectively (Fig. 5.1). No induction of pJCEcat and
pRIIEcat by cAMP was Observed in UD and DMSO-differentiated
Pig cells treated with cAMP and FSK (Fig. 5.;;! A and 5.2 8).
Thus, the results revealed the functional role of CRE in cell-
specific expression of JC:V in RA Pl9 cells.
5.2.2 Zffect of 1Q'1 aut_tioD8 OD induction by cAMP ot JCV
proaoter-enhalloer
I also wished to examine the effect of mutations in the
NFl binding sites, which are adjacent to the CRE in the 98 bp
repeats on the induc':ion by cAMP of JCV promoter-enhancer.
Thus, several combinations of NFl mutants were tested for
their expression in the presence or absence of either dibutyryl
Fig. 5.1 Induction by cAMP or CA'I' expression rrom JCVE and
the single JCV 98 bp sequence tor wild type and mutated NF1
sites in PA-differentiated P19 cells.
wild type (WT) and mutated CAT expression plasmids are
indicated as in Fig. 3.1. Labels: cAMP, cyclic AMP; FSK,
forskolin. values for JCV expression (t conversion) were
normalized with assays for enzyme activity of the RSV-
promoter-p-galactosidase plasmid. Results arc averages of
three experiments.
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cAMP or torskolin. The mutations in Nfl I introduced into
pJC"oJEcat behaved like wild type with 2.2-and 2.1-fold
increased CAT activity in cAHP- and F5K-treated cells,
respectively. However, mutations in NFL II and III (11.111),
in all three NFL binding sites (I.II.III) or in the single 98
bp repeat (mRII) resulted in 2.7-, 3.6-, and 4.2-told
activity, respectively, in cAMP-treated cells. The increase in
FSK-treated cells was 3.2-, 3.5-, and 4.a-fold respectively.
The increase in activity was more than that observed for WT,
I, and RII in cells treated with these agents (Fig. 5.1). In
cAMP- and FSK-treated UD and DMSO-differentiated PIg cells, no
induction of llIutated NFL CAT expression plasmids by cAMP was
noticed (Fig. 5.2 A and 5.2 B). The results suggest that
induction by cAMP of JCV£ is more pronounced in an NFl II and
III mlltation background in glial cells.
5.2.3 Role of eRE in !n....Y!.tl:2 expression of JCV
To further substantiate the .in.....Y..U.2 observations, in
~ transcription assays were done with RII and mRII CAT
expression constructs as described in Fig. 3.1. The RII showed
2.4-fold more activity in FSK-treated cells than in RA-treated
P19 cells. competition with 2S0-fold excess of either NFl
II/III or CRE oligonucleotides resulted in approximately 50\
reduction in activity (Fig. 5.3, RII). The results suggested
that the effects of NFl II/III and eRE binding sites on the
expression of JOVE are additive. The mutation in NFl II
Fig 5.2 A. Effeot of cAMP on CAT expression from JCVE and JCV
98 bp repeat tor "ild. type and mutated NFl Illite in
undifferentiated (UDI P19 cells.
wild type (WT) and mutated CAT expression plasmids are
indicated as in Fig. 5.1. Labels and methods are as describad
for Fig, 5.1. Results are averages of two experiments.
Fig. 5.2 B. Effect of cAMP on CAT expression from JCVE and JCV
98 bp repeat for wild type and mutated NFl site in OH80-
differentiat8l! P19 cells.
Plasmids are same as indicated in Fig. 5.1. Methods and labels
are as described for Fig. 5.1. Results are averages of two
experiments.
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Fiq. 5.3 ~ transcription assays with q1i81 oe11
extracts and et't'eot at' NFl II/III rolutations t'or cMP
induction.
RII and rnP~ ... are as described in rig. 3.1. The assays had GO
pg of protein. Labels are FSK, extract from forskolin-tre<:ltcd
PI9 glial cells; RA, extract from control P19 glial colIs;
NFl, specific competition by NF II/III oligonucleotide: CRE,
competition by Jr;V CRE oligonucleotide; a-a, 1 pg/ml alpha-
amanitin polymerase II inhibitor; Tr, CAT RNA from RIl and
rnRII CAT expression vectors; Rsv-6-gal, 6-galactosidasc
internal control RNA. Assays and calculations were as
described for Fig. 4.4.
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(2RII) abolished the activity of JCV early promoter in PI9
glial cells. In FSR-treated cells, a residual activity was
noticed. Competition with 250-fold excess of eRE but not NFl
II/III, oligonucleotide reduced its activity. (Fig_ 5.),
mRII). Taken together, the results of 1n.....Yi.t..J: transcription
SUppol-t the~ observations. The results also suggest
that the increased expression of JCV early promoter-enhancer
upon forskolin treatment is due to increased level of CAT
transcripts.
5.2.4 Meohanism of eMP regulation of JCVE
To examine if the increased expression of pJCV[cat was
at the level of transcrip.tion, RNase protection experiments
using RNA from FsIt-treated and untreated transfected cells
were undertaken (Fig. 5.4). Compared to untreated transfected
cells, the transfected RA-treated PIg cells treated with PSi<
had 2.9-fold CAT transcripts, measured
densitometrically. These results suggested that the increased
expression of pJcv[cat was due to increased levels of CAT
transcripts and that the effect of cAMP on the expression Clf
JCvEcat is most proba"'ly at the level of transcription. This
result also confirmed that the~ transcription was a
reflection of ..1n.....YJ.yQ function.
5.2.5 Iff.ot of autations in CRE OD eMlP induotion of JCV
proaot.r-.nbaJIc.r
To examine the functional role of CRE in JCV expression,
Fig. 5.4 Increased RNA expression frolll JOVE after induction by
cAMP.
Lanes are: P, probe markers for 6-gal (asterisk on the right)
and CAT RNA (arrowhead on the right); CAT+6-gal, RNA from
pRsV-cat- and pRSV-a-galactusidase-transfected PI9 glial cells
serving as positive control; E, RNA from COJ"ltrol PI9 glial
cells transfected with pJCEcati E-FSK, RNA from forskolin-
treated Pig glial cells transfected with pJCEcat; tRNA, E.coli
tRNA serving as negative control. CAT and a-gal RNA fragments
are indicated on the left and represent RNase Tl resistant
products. Molecular weight markers (M) in bp are indicated on
the right. Quqntitative estimate of the CAT transcripts in
FSK-treated and untreated cells determined
densitometrically and normalized for p-gal transcripts. E, 0.9
and E-FSK, 2.62.
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site-specific Ulutations in eRE were generated by site-directed
mutagenesis of JCV promoter-enhancer (Fig. 5.5). The enhancer
fragments containing IIlutations were inserted into pSVocat.
Plasmids were then tested for their functional activity in
dibutyryl cAHV-, FSK-treated and untreated PIg glial cells.
Wild type whole enhancer (pJCEcat) and single 98 bp repeat
CpRIIJCEcat) constructs expressed efficiently in untreated PIg
glial cells. Treatment with cAMP resulted in increased
expression from pJ'CEcat and pRIIJCEcat by 2.1- a ~t:'I 3. a-fold,
respectively (Fig. 5.6, WT and pRII). Forskolin treatment
increased expression of these plasmids by 2.3- and 3.2-fold,
respectively (Fig. 5.6, WT and pRIl). Mutations in eRE ot both
repeats or in a single 98 bp repeat revealed no change in the
promoter-enhancer activity in either the presence or absence
of cAMP or FSK (Fig. 5.5 and 5.6, I.U and mRI!). Moreover,
the activity of CRE mutants is the satlle as that of WT
constructs in untreated P19 g11al cells (Fig. 5.6). These
resu1ts suggest that the integrity of the CRE sequence is
essential for induction of JCV promoter-enhancer by cAMP.
S.2.6 Induction:by cAMP of expression of II. heterologous
promoter in gUa1 oel1. :by oAMP response element (CRE)
sequence~ of JCV
To further examine the functional significance of
the CRE motif, a doUble stranded oligonucleotide corresponding
to nt -154 to -161 of JCVf. was cloned (pJ'CCREcat) in the early
rig. 5.S wHO type and Illutated CRE Illotir. in JCV[ sequenoe. in
CAT plaslIlid••
eRE mutations war'" intxoduced by site-directed mutagenesis for
CAT exprQssion vectors. Top, diagr.all of sequences present in
CAT expression plasmids. ~arly and late sides are indicated.
TATA boxes and CRE motHs lire indicated and delineated by
thick lines. Nucleotide positions are given below and above
the lines. Boxes indicate the 98 bp repeats. Bottom, list of
mutated plasmids and sequences for CRE motifs. eRE II Dnd CRE
I indicate the CREs adjacent to NFl III and Nfl II,
respectively, in the 98 bp repeats. Mutated CRE nucleotides
are indicated by lower case letters and wild type eRE
nucleotides are indicated by capital letters.
rOy 12 '; 1091~ '~ 2mee I~ CAE 1M CAE I 18ta
511214 22 511 53 112 120154161 270
plasmid CAE II CAE I
IJoJCEcM (WT) TGAGCTCA TGAGCTCA
pmJCEcltl.11 TaAGCTCg T8AGCTCg
pRIIJC£cat(WT) TGAGCTCA
pmRlUCECII TaAGCTCg
00
UJ
Piq. 5.6 Effect of mutation of JCV CRE motifS on~
activity.
Results are for CAT assays in untreated control, cAHP- and
forskolin (FSK) -treated Pig glial cells. Mutations in eRE
motifs are indicated by the unique numbers and letters for the
names of plasmids of Fig. 5.5. The cells were transfected 8
hours after being plated with 5 $Ig of test CAT expression
plaslIlid and 15 IJ9 of pUC19 DNA. The other Illethods are as
described for Fig. 3.2 and 5.1.
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orientation in front of the thymidine kina'se (TK) promoter of
pBLcat2. The CAT activity of pJCCREcat and the parent vector,
pBLcat2, was compared in control untreated and cAMP- and
forskolin-treated P19 glial cells. The results are shown in
Fig. 5.7. The plasmid pJCCREcat was induced 6-fold in cells
treated with either cAMP or FSK. Induction was reduced to 2.6-
and 1. 5-fold when pUC19 plasmid containing a double stranded
JCV CRE oligonucleotide was cotransfected with pJCCREcat in 4-
and S-fold excess amounts, respectively (Fig. 5.7).
To further examine eRE induction, in .Y..!£.r.g
transcription assays were performed. No activity was observed
with pBLcat2 template when extract from FSK-treated PIg glial
cells was used (Fig. 5.8, pBLcat2, FSK). With pJCCREcat
template, no detectable activity was observed with extract
from untreated P19 glial cells (Fig. S.B, pJCCREcat, RA).
However, a substantial amount of transcriptional activity was
observed with this template and extract from FSK-treated P19
glial cells. This activity was abolished in the presence of
250-fold excess of CRE oligonucleotide (Fig. 5.8, pJCCREcat,
eRE). In the presence of 1 ~g/ml concentration of alpha-
amanitin the transcriptional activity of pJCCREcat was totally
abolished, suggesting that transcription was by RNA. polymerase
II. The results confirmed the presence of a functional CRE
sequence in JCV promoter-enhancer. These results also
suggested that the JCV CRE sequence enhances the
Fig. 5.7 Induction by oAMP of JCV CRE in the context of a
heterologous promoter in glial cells.
The vector, pBLcat2 and pJCCREcat are indicated. The 4X and ax
indicate competition with 4- and 8-fold JCV eRE
01 igonucleotide in plasmid pUC19. other labels and methods are
as described for Fig. 5.1.
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Fig. 5.8 Role or cAMP in activity or pBLcat2 and pJCCREoat as
assayed by in vitro transcription.
The DNA t.emplates used are indicated on top. Labels are: a-a,
1 /-I9/ml a.lpha-amanitin polymerase II inhibitor; Tr, CAT RNA
from pJCCREcat and pBLcat2 CAT expression vectors. RSV-p-gal,
p-galactosidase internal control RNA. FSR, extract from
forskolin-treated P19 RA cells. HA, extract from PIg RA cells.
eRE, competition in the presence of 250-fold excess of CRE
oligonucleotide.
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transcriptional activity of a heterologous promoter in glial
cells.
S.a.1 Interaction ot proteiDe troa forsJl:ol!D-tre.te4 .19
qlial oelh with J ...YOi CD ••quanc.
5.2.1.1 Ia-lik.Q iDteraot!ona detected iD 1I0bility ahift
The interaction of a protein with JCV eRE sequer.ce was
sU9'geeted by the in..:i..i.Y2 competition with eRE sequence in FSK-
treated cells (Fig. 5.7). To examine this possibility.
mobility shift experiments with double stranded
oligonucleotide corresponding to JCV eRE sequence was
undertak~·!l. The extract from PIg RA cells ....howed no binding
(:Fig. 5.9, RA, 5). However, with extract from PSK-treated PIg
glial cells, one complex was noticed (Fig. 5.9, FSX, B).
Addition of 500-fo1d excess specific competitor CRt:: sequence
abolished the complex (Fig. 5.9, S). Addition of SOO-fold
excess of a non-specific oligonucleotide (corresponding to NFl
binding sites) had no effect on complex fonatlon (Fig. 5.9,
NS). The results suggest that a protein from FSK-treated PIg
RA cells, but not untreated cells, specifically interacts with
JCV eRE sequence.
5.1.7.2 I4.atitioaUolI of proteia(llI) biading to JCV eRE
••quene. .c det.rained by 8outb".lJtern blot and UV
oro••linklnq ....y.
TO characterize the protein(sl binding to the eRE motif,
Fig. 5.9~ binding of JOV CRE o1iqonucleotide in
mobility shift assays.
Lanes are: F, free oligonucleotide probe in the absence of
extract; B, binding assay with and no competitor; RA, P19
glial cell extract; FSK, fcrskolin-treated cell extract; 5,
specific competition by homologous competitor. N5, non-
specific competition by JCV NFl II oligonucleotido; arrow,
free probe.
-RA FSK
8 18 B S NS I
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Southwestern blot and UV crosslinking assays were performed.
Southwestern blot analysis re-examines the interaction of
protein(s) with the oligonucleotide sequence. The Southwestern
blot results indicated that a protein of 43 kDa from
forskolin-treated P19 glial cells specifically interacts with
the eRE sequence (Fig. 5.10, FSK). No interaction of
protein(s) from untreated PIg glial cells was observed (Fig.
5.11, RA, B). In UV crosslinking experiments, two proteins of
approximately 150 and 43 kDa from FSK-treated cells were
eros-slinked with JCV eRE oligonucleotide (Fig. 5.11, FSK, B).
Addition of 500~fold excess of eRE oligonucleotide abOlished
the band corresponding to 43 kC'1l but not 150 kDa (Fig. 5.11,
FSK, S). Further, in the presence of SOO-fold excess of non-
specific oligonUcleotides corresponding to the NFl binding
site. NSl and NS2, the 43 kDa band was not sign.lficantly
affected (Fig. 5.11, FSK, NSI and NS2). Taken togethor, those
in~ assays suggested that a proteinCs) interacts with the
CRE. This protein appears to be an approximatelY 43 kDa
polypeptide frcm forskolin-treated P19 glial cells which
interacts with the JCV eRE oligonucleotide in a sequence-
specific manner in two independent~ assaylJ.
Fig_ 5.~O Sou!;hwestern blot analysis with JCV CRE
oliqonucleotide.
Lanes are as in Fig. 5.9. Numbers on the right indicate the
kDa molecular weights of protein markers. Arrow indicates the
43 kDa protein interacting with the CRE sequence.
RA RA FSK FSK
-200
- 97
- 68
- 43
Fig_ 5.11. UV crosslinking assays with JCV eRE sequence.
Labels are as described for Figs. 5.9 and 5.10. NSI and NS2,
competition with 500-fold excess of NFl II and NFl I
oligonucle:otides, respectively.
-FSK RA
I8 8 S NSl NS21 8 F
-200
- 97
- 68
- 113
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5.3 DISCUSSION
The results of this study clearly demonstrated the
presence of a functional eRE in the JCV transcriptional
contr!,}l region. The JCV eRE sequence (TGAGCTCA) is homologous
to the consensus eRE (TGACGTCA) except for CG to GC
transposition. However, the results of my study suggest
without any ambiguity the functional activity of a eRE in the
JCV regUlatory region. This was based on the observation that
the JCV early promoter-enhancer (JCVE) was inducible by
treatment with the cyclic AMP analogue, dibutyryl cAMP, and
the cAMP inducer, forsko!!n. In addition, mutations in the eRE
abolished induction of JCV expression by cAMP (Fig. 5.6). The
purpose of using forskol!n in this study is that forskolin
activates the adenylyl cyclase enzyme that converts ATP to
cAMP, thus increasing the intracellular cAMP levels. This is
folloW'ed by activation of PAA which phosphorylates CREB. If
there is a functional eRE in JCVE' the phosphorylated CREB
will bind the CRE and activate transcription. The results
cleat"ly showed the induction of JCV promoter-enhancer with
forskolin, suggesting the existence of a functional eRE in the
regulatory region of JCV. In addition, the Jcv eRE sequence
placed upstream of the TK promoter in pBLcat2 reporter plasmid
was inducible in transient cat assays and conferred glial
cell-specificity to a heterologous promoter (Fig. 5.7)
Increased~ transcription was also observed in the
aoo
presence of extracts trOll FSK-treated, but not untreated Pl9
RA cells (Fig. 5.8). This further confir1lS the existence of a
JCVE CRE sequence which functions as an enhancer element.
The JCV CRE is located 4 bp frc.'!Il the NFl binding sites
in the 98 bp repeats. Hence, the NFl .utants wer& t.e9ted for
their activity in cA!lP- and FSX-treated PIg cell'l. ;rh. ::esults
suggest that induction of JCVE is more on NFl mutant back
ground compared with WT (Fig. 5.1). No induction of JCVl by
cAMP was obsorvod in UD and DMSO-dltt'ercntiated Pig cells
(Fig. 5.2 A and 5.2 B). The results of in.....d..tJ;:Q transcription
with RII and mRII suggest that the etrect!: ot Nfl binding and
CRE motifs are additive. This study was also focused on the
characterization of JCV CRE by identifying and char&cterizing
the proteins interacting with CRE.
In previous stUdies, the understanding of regulation or
gene expression by cAMP was largely facilitated by cloning of
the cDNAs encodinq CRE-binding proteins (CREBs). The cONAs
were initially isolated from rat phaeochromocytoma (PCI2)
cells and human placental cell libraries (Hoefner ~,
1988; Gonzalez .I.t.....t.l, 1989). CREB was later shown not to be
restricted to these cell types but to be Ubiquitously
expressed. This suggests a housekeeping role for this factor
(Foulkes &..Al. 1991). The fact that CREB has a housekeeping
function was demonstrated by usinq transgenic mice (struthers
Jlt.....Al, 1991). The induction of JCVe by cAMP was observed in
2.'
RA-differentiated but not in UD and DHSO-differentiated Pl9
cells (F _~g. 5.1 and 5.211 and B). Since CREB is a ubiquitously
expressed factor, the involvement of this protein in glial
cell-specific expression of JCV is a puzzle. SpI, a ubiquitous
transcription factor, is developmentally regulated and in
mouse and in adult hUman brains its expression is restricted
to oligodendrocytes of the eNS and a limited number of other
cell types (Saffsr .I..t.....Al, 1991; Henson .t..t.....s.l, 1992). It is
possible that CREB is dovelopmentally regulated similarly Bnd
that different cells contain different forms of CREB.
CREB contains multiple properties that may allow
tissue-specific regulation. For example, the trl!lnscriptional
activation domain of CREB consists of several independent
regions. CREB belongs to the leucine-zipper family of
proteins (Landschulz ~, 1988). The leucine zipper allows
dimerization and fot1llation of the appropriate conformation of
the protein. This leads to the interaction of the basic region
of the protein with the cognate sequence on DNA. The CREB
leucine zipper is b1portant for not only homodimerization but
also heterodimorization between two different transcription
factors such as CREB and ATF. The heterodimers may have unique
cell-specific .functions.
The data of JCV in P19 RA colls suggests that the
binding of the protein interacting with JCV CRE lIay be
detectable only after phosphorylation of CREB by PKA. In fact,
2.2
CREB binding was shown to be modulated by phosphorylation
(Yamamoto ~. 1988). Since there are several isoforms of
PAA that are tissue specific, it is quite possible that the
PKA of PI9 RA cells may behave differently (Habener, 1990).
Moreover, the consensus phosphorylation sites of various
kinases such as protein kinase A (PKA), protein kinase C
(PKC), glycogen synthase kinase 3, and casein kinase (CK) I
and II present in CREB might be important in regulating its
activity. Also, various phosphorylation sites located in CREB
cooperate to elicit the regUlatory function of the protein
(Habener, 1990). In another report, no phosphorylation of CREB
was noticed when KeLa cell n'lclear extract was used in in
:tJJ;J;:Q studies, although the cells did contain PKA (Merino n
Al, 1989). This could have been due to lack of certaln call-
specific functions. support for this comes from another
interesting finding that PKA affects phosphorylation of CREB
variably depending on the cell type (Auwerx and Sassone Corsi I
1991) . Thus, the reports indicate that phosphCirylation of CREe
by PKA depends on the cell type and CREB activity is further
regulated by phosphorylation by kinases other than PM. There
also appears to be mUltiple CREe domains important for
hornodirnerization and heterodimerization which also affect DNA
binding and phosphorylation by additional cell-specific
functions.
2.3
.1.n....Y.JJa:Q binding studies have suggested interaction of
a 43 kOa CREB protein with eRE ( Montminy and Bilezikjian,
1987; Yamalloto .cLJll, 1988). There are several proteins
belonging to the CREe family and the cDNAs isolated from
different tissues suggest that the sizes of the proteins range
troll 39 to 120 tDa. In my study. the results of t1V
crosslinking assays revealed the interaction of tliO proteins
of 43 and lSI) kDa only in RA Pig cells treated with FSK (Fig.
5.11, FSK, B). In other reports CREB was shown to
heterodlll1erize with other proteins such as ATF, AP2 and c-jun
(BOrrelli &...Al. 1992). Hence, it is likely that the protein
recognizing the JCV eRE sequence binds as a heterodimer. CREB
may interact with a factor that is restricted to RA-
differentiated P19 cells. Such a factor may be a cell-specific
AP2, another protein which requires phosphorylation for
efficient DNA binding. The ISO kDa .'Orotein was not competed by
SOO-fold excess homologous eRE oligonucleotide competitor it
croBBlinking assays (Fig. 5.11, FSK. S). However, CREB was
specifically crosslinked with the CRE oligonucleotide.
Clarification and use of more sensitive teChniques are
required. The 43 kDa protein interacting with JCV CRE is the
same size as that binding to consensus CRE of the rat
somatostatin gene. Whether the protein binding to JCV CRE is
the same as the CREB that binds to the consensus eRE remains
to be investigated, considering that thera are multiple CREB
,..
polypeptides which are also sUbject to posttranslational
modifications.
Southwestern blot analysis with JCV CRE detected only
a protein of 43 kDa (Fig. 5.10, FSK). The two techniques are
different in their sensitivity and the sequence specificity
can better be analyzed with UV crosslinking assays than with
Southwestern blots. Moreover I in Southwestern blots the
proteins are SUbjected to renaturation and denaturation.
whereas, in uv crosslinking assays the proteins are in thoir
native form. Recently it has been shown that a CREB-binding
protein (CBP) of 265 kDa interacts with CREB and may function
as a coactivator for efficient transcriptional activity
induced by CREB (Chrivia fi....Al., 1993). The existence of such
a coactivator in PI9 RA cells which cooperates with JCV CRE
binding protein for its efficient transcriptional activity
remains to be tested.
Interestingly, the human cytochrome P450 C17 promoter
(Brentano ~, 1990) and JUN 0 promoter (Borrelli ~,
1992) contain the TGAGCTC sequence which is loot homologous to
that found in the JCV regulatory ~equence. The CREs of these
two genes are cAMP inducible and confer cAMP induction
potential to a heterologous promoter. Of note, in BK virus
belonging to the same family as JCV, a sequence highly
homologous to CRE is present 4 bp from the NFl sites in each
68 bp P block, an arrangement which is identir:al to JCV DNA
."
(Deyerle and SUbramani, 1988; Cassill ~, 1969). It has
been shown that the eRE of BKV is also cAMP inducible (Moans
~, 1990).
since JCV and BKV share many features, studies with BK
virus containing CREs in the transcriptional control region
are of interest. compared to the standard MT-l BKV strain
which has one copy of the eRE motif, the variant with a 34 bp
duplication containing the CRE site grew as efficiently as the
Gardne,: strain having three CRE sites. On the other hand,
another variant with a deletion in CRE grew poorly in human
embr~onal kidney (HEK) cells (sugimoto !ll...Al, 1989). It was
also shown that insertion mutations in the CRE motif abolished
the ability of BKV to transform rat cells (Watanabe and
Yoshiike, 1989). Taken together, these studies suggest a
functional role for CRE in BKV mUltiplication and
transformation. It will be of interest to isolate JC virus
variants which lack CRE sequences or contain more than two
copies of CRE. Such variants could be used to study the role
of the CRE motif in the mUltiplication and transformation
capabilities of JC virus.
Several genes that are expressed in a tissue-specific
manner have been shown to be responsive to elevated cAMP
levels. Examples are the phosphoenolpyruvate carboxykinase
gene (Chrapkiewicz ~, 1982; Cimbala ~, 1982), the
vasoactive intestinal peptide precursor gene (Hayakawa et aI,
2••
1984), and th_ liver tyrosine a.inotransferase gene (Hashimoto
.t.t.....Al. 1984). Several brain-specific genes possess nuclear
factor 1 binding sequences followed by activator pre' .eln
binding sites such as CRE, API, ATF, and AP2 (Ame.lye §J.....Al,
1992). Interestingly, the JCV regulatory region which is
strictly glial cell-specific also contains the NFl binding
site with adjacent eRE site. The questions that arise are:
"Why dOG. the 98 bp repeat of JCV contain several activator
protein binding motifs?" and "What is the significance of the
NFl site and eRE in brain-speciUc JCV expression?" The 10
ti.t1:2 transcription studies with RII and TllRII cat constructs
(Fig 5.3) preliminarily address these questions. competition
with either Nfl or CRE oligonucleotide reduced the. activity of
RII to approximately 501 in Fsx-treated Pl9 g11al cells. This
suggests that both NFl II/III binding and CRE sequences are
iaportant for the increased activity of JCV early prolloter-
enhancer. In addition, the effects of both of these dtes
could be additive. This is of interest and consistent with the
observation that CRE mutants exhibited similar levels of
activity to wild type constructs in untreated Pl9 glial cells
(Fig. 5.6). Since tho effects of NFl and CRE sites are
additive, the mechanism by wh,~.ch they activate transcription
from JCVE may be ditterent.
CREB has been shown to interact with several tisBue-
specific factors. For example, multiple copies of the AP2
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protein binding sites placed upstrel:lm of the eRE containing
genes conferred cAMP inducible transcription, while placing a
single copy of the AP2 site had no effect on transcription
(Chiu ~, 1987). Forskolin treatment did not increase the
binding activity of the AP2, while the transcriptional
activity was stimulated, analogous to CREB. The inability of
a single but not multiple AP2 sitp.s in activating
transcription of eRE containing genes may suggest that AP2
interacts with CREB. Interestingly. using the proenkephalin
promoter, it was shown that the AP2 site alone can not confer
transcriptional activity but acts synergistically with the eRE
to stimulate transcription (Comb ~, 1986). CREB was shown
to be expressed Ubiquitously whereas AP2 is restricted to
certain cell types. AP2 activity is absent in the human
hepatoma cell line Hep G2 and in undifferentiated human
teratocarcinoma cell line NT2. However, the AP2 activity is
induced upon differentiation ;"'r the NT2 cells with retinoic
acid (Williams !l.t........tl. 1988). In addition to AP2, CREB was
shown to interact with other tissue-specific factors. For
example, in case of alpha chorionic gonadotropin, CREB
interacts with a protein binding to placental tissue specific
element (TSE) adjacent to CRE sites in the promoter (Delegeane
~. 1987). All these stUdies indicate that CRE binding
protein interacts with factor(s) binding to adjacent sites,
resulting in efficient transcriptional activity. Howpver, in
,..
my study the results of in....Y.i..t..t transcription assays with RII
(Fig. 5.3) indicate that the effect of NFl II/III and adjacent
eRE sites on the expression of JCVE is additive and that the
interaction of these factors is unlikely. Most probably, each
of these factors stimulate JCVE expression by different
mechanisms. Support for this 5U9'9\lstion are results of
experiments with NFl and CRE mutants (Figs. 5.1, 5.3 and 5,6).
While the mutations in NFl II/III qnatly reduced the activity
in P19 glial cells, a substantial amount of i.n...:tJ,Y..Q activity
was retained for FSK- or cAMP-treated cells (Fig. 5.1).
Moreover, a substantial activity was retained when extract
from FSK-treated cells was used for in.....Y..1..tl:2 transcription
(Fig 5.3, JaRII). In addition, the eRE sequence placed upstream
of TK proRoter of pBLcat2 exhibited~ activity in the
presence of either FSK or cAMP (Fig. 5.7). AlGo, .in........Y..i
activity was observed in the presence of extracts from FSK-
treated but not untreated Pl9 RA cells in .in.........Y.i
transcription assays (Fig. 5.8). This confirms that CRE alon~
can enhance the basal activity of JCV early promoter in glial
cella. Overall, the CRE and NFl IIIIII sites clearly have a
combinatorial effect on the expression at' JCVE and the
presence of CRE adjacent to NFl II/III binding site in the JCV
regUlatory region further increases its expression in glial
cells. This is consistent with the recent speculation that the
glial cell-specific expression of JCV early promoter is
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regulated by the combinatorial action of transcription. factors
binding to their cognate sequences, in particular the factors
binding to eRE and Nfl sites of JCV enhancer (Henson, 1994).
Brain-specific expression of the JCVE may be tightly
regulated, based on the physiological status of the cell. The
CRES protein interacting with eRE motif under conditions with
elevated cAMP levels might bind adjacent to the NFl protein
binding to NFl II/III. This would result in the enhanced
expression of JCV early promoter-enhancer. Such a switching
mechanism may be regulated by phosphorylation of transcription
factors. These factors could tightly regulate JCVE expression
in the NFl site-dependent, glial cell-specific system . Such
a mechanism has been proposed for liver specific gene
expression (Roesler~, 1993).
Glial cell-specific expression of JCV appears to be
regulated by both inducible (CRES) and constitutively-produced
(NFl) transcription factors. In addition, a motif with
extensive homology to the NF-kB sequence of HIV-I is located
outside the regUlatory region of Jev. This transcriptional
element stimulated the expression of Jev late promoter in
glial cells and interacted with PMA inducible and noninducible
nuclear proteins from glial cells (Ranganathan and Khalili,
1993). The eRE and NF-kS binding proteins that interact with
eRE and NF-kB are coupled to different signal transduction
systems via PKA and PKC, respectively. The enhancer-binding
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factors that respond to various signal transduction systems
may have evolved to couple the transcription of cellular genes
to changes in the environment. These changes affect the
proliferative state of mammalian cells. Not surprisingly,
viruses use the same transcription factors to regulate the
expression of their genes, as their life cycles are dependent
on the proliferative status of their infected hosts. Thus
viruses can respond to different environmental cues by virtue
of possessing distinct inducible transcriptional elements in
their genome.
NF-kB is sequestered in the cytoplasm by the IkB
inhibitor and is released by phosphorylation of IkB by protein
kinases such as PKC (Baeuerle and Baltimore, 1988). cyclic AMP
may act as another second messenger leading to NF-kB
activation through the activation of PM (Shirakawa ~,
1989). This might result in the elevation of intracellular
cAMP levels, resulting in simultaneous activation of CREB and
NF-kB. These would in turn bind to thelr cognate sequences in
the Jcv genome, leading to increased tra"'lscription of JCV£ and
JCVL. Alternatively, since CREB and NF-kB arC! activated by
two different signal transduction pathways, transcription
factors that respond to more than one stimUlUS may cause a
more continuous transcriptional response than those that
respond to a single stimUlUs. This would give the virus a
greater advantage of having transcription elements for
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response to diverse signal transduction pathways. The
identification of the transcription factors that mediate such
diverse actions should further our understanding of gene
regUlation.
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PU'l'VRJt DIRBCTIOll.
Tissue-specific gene expression is mainly regulated at
the level of transcription. The transcription factors that
govern the rest.rlcted cell-specific expression of genes are
limited to such cells. In chapter 1, I described in detail the
transcriptional regulation of cell-specific gene expression.
The brain is a complex organ with a heterogeneous popUlation
of cells ancl certain cell types such as glial cells and
neurons, allow certaln genes to be expressed. Th.is restricted
cell-specific gene expression is malnly regulated positively
in the cells that are expressed. Expression is negatively
regulated in cells in which these genes are not normally
expressed.
The understanding of brain-specific gene expression is
difficult because of its COl'Qpl£lX nature. The human JCV polyoma
virus is a neurotropic virus and its expression is strictly
restricted to glial cells. The regUlatory region of JCV
contains 98 bp tandem repeats which play a key role in the
restricted cell-specific expression. The promoter-enhancer
region of JCV contains binding sites for several transcription
factors such as nuclear factor 1 (NFl) motifs, pentanucleotide
region, polypyrinlidine tract and cyclic AMP (cAMP) response
element (Fig. 1.2). Several studies used~ binding
assays and concluded that the NFL binding sites may play a
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role in the glial cell-specific expression of JCV. However I no
functional studies were done. My studies presented in chapter
3. clearly demonstrate the importance of NFl sites located
within the repeats in the glial cell-specific expression of
JCV. The importance of NFl binding sites in cell-specific
expression of JCV was assessed with JCV promoter-linked
reporter genes. In order to understand the effect of mutations
in NFl binding sites in JCV life cycle, it would be impo::-tant
to reconstrt.ct NFl mutants in JCV whole genome and test their
activity in primary human fetal glial (PHFG) cells.
understanding transcriptional regulation of neurotropic
JCV also facilitates the understanding of brain-specific gene
regulation. The eDNA encoding till;! factor binding to the NFl
site in the repeats supported the expres~ion of JCV in non-
glial cells, further confirming the importance of NFl II/III
in glial cell-specificity. My studies did not delineate t~le
DNA binding and transactivating domains of the NFL This can
be further studied in the future by functional analysis of
exonuclease III deletions of the NFl eDNA that I isolated.
These analyses of the eDNA would also help in understanding
the developmentally regulated expression of NFl proteir.s in
the brain that are important for tissue-specific gene
expression, such as the myelin basic protein (MBP) of eNS and
the NFl proteins that activate transcription of liver- and
adipocyte-specific gene expression. Whether the gene for the
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isolated eDNA 1s developmentally regulated will be important,
because many brain-specific genes contain the NFl motif
(Amemiya ~, 1992). This can be done by Northern blot
analysis and RNase protection assays for OM50- and RA-
differentiated PIg cells and for various mouse tissues.
JCV remains latent in kidneys (Frisqne and White, 1992)
and JCV is capable of replicating in 8-1Ylllphocytes (Major §.t.
li, 1990). JCV appears to undergo brain-specific types of
rearrangements in the lymphocytes, as an intermediate between
the kidney and brain. Hence, it will be interesting to study
the developmental regUlation of NFl in kidney cells and
lymphocytes. 'loth the MAD strains and archetype strains of JCV
can be compared in brain, lymphocytes and kidney tissues.
Replication of the archetype JCV is restricted to the
kidney. The hypothesis is that rearrangements in the
regulatory region of archetype JCV results in the generation
of the brain form of JCV (Ault and stoner, 1993). Another
hypothesis is that JCV remains latent in B lymphocytes and
these JCV-infected cells reach the brain, resulting in PML
(Dorries~, 1994). These two possibilities can be tested
by looking at the expression of archetype and prototype JCV
strains in kidney, B lymphocytes, and brain cells. The site of
rearrangements can be checked by Southern blots of DNA
isolated from these tissues. This should determine whether the
rearrangements in the archetype regulatory region occur in
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kidney, in B-lymphocytes, or in brain.
Recently the role of coactivators in the tissue-
specific gene expression has gained more attention. For
exalllple, the lYJll~hOid cell restricted oct-2, but not the
ubiquitously expres~,ed oct-I, was thought allow 8-oel1-
spec!tic gene expression (Gerster ~, 1990). However,
recent findings l.ave raised questions about these suggestions.
An 19H promoter-specific, octl factor-specific and 0-oel1-
specific coactivator, OCA-B, supports the exprassion of 198
promoter in :t.1..t..L:2 in the presence of oct-l but not oct-2
protein (Lue &....Al, 1992). A coactivator leads to activated
transcription by mediating dimerization of liver-specific
transcription factor, HNFI (Hendel~•.. 991). A coactivator
has also been suggested to help in the communication of basic
region of Myo 0 with its activation domain (Lin and Olson,
1991). Coactivators that support the activated levels of
transcription by gene specific regulators such as, Spl and
CTF/NFl have also been rclported (Pugh and Tjian, 1990).
OVer""!1, these observations suggest the role ot coactivators
in the transcriptional regulation of tissue-specific
transcription. Therefore, it is tempting to speculate the
requirement for coactivation by an NFl II/III specific and
gliaJ. cell-specific coactivator in the glial cell-specific
expression of JC virus. IAolation of such a coactivator would
also help in the identification of brain-specific coactivators
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that participate in activated transcription of brain-specific
genes. Affinity chromatography, a powerful tool to identify
protein-protein interactions, can blJ used to isolate the
coactivator as described (LuO~, 1992).
Interestingly, no transcription from the myelin basic
protein (HBP) gene was observed in the presence of TFIID
isolated from "aLa cells~. However, TFIID extracted
from brain cells supported the J.n....ill1:2 transcription of MBP
(TamUra~, 199081). Therefore, there may be tissue-specific
TFIIO factors which allow basal level gene expression. The
role of such a tissue-specific TFIID in glial cell-specific
expression of JCV is an attractive possibility. This can be
exallined by an affinity assay of extract from PI9 cells on an
affinity column for TATA sequence of JCV and through an NFl
affinity column.
JCV late promoter is down-regulated by a protein of 56
kDa that interacts with pentanucleotide repeat region located
adjacent to NFl II/III (Tada .i.t......Al.. 1991). However, JCV large
T-antigen transactivatCls the late promoter in glial cells. My
results in chapter 4 showed that JCV T-antigen facilitates
increased binding of NFl II/III and thereby activates the late
prolloter. The results described in chapter 4 lead me to
propose a model wherein the T-c:ntigen prevents the binding of
a repressor to pentanucleotide repeat region. This would then
facilitate the binding of NFl which is importllnt for
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expression of JCV late proDater-enhancer. The isolation of a
repressor protein or eDNA encoding this protein would allow
this model to be tested. The eDNA library which I made from
PI9 RA cells and the screening procedure which I used to
isolate eDNA encoding NFl should be of great help. The eDNAs
encoding NFl and repressor can be expressed in E.ccI! as
recombinant proteins and used~ for detertllininq their
interaction with T-antigen. The isolated ~iFl and repressor
cONAs will also be of great help in understanding proteins
interacting with one another. This can be achieved by
interaction cloning using the yeast two hybrid system (Fields
and Song, 1989). since coactivators form a bridge between
gene-specific activators and TBP, the yeast two hybrid system
can be used to clone the coactivator.
The adenovirus early gene product, Ela, has been shown
to be a potent transactivator (reviewed in Flint and Shenk,
1990). Ela also represses the expression of certain viral and
cellular genes (Timmers~, 1989). For example, Ela blocks
the differentiation of muscle cells by repressing the
transcriptional activating functions of muscle cell-specific
factors such as HyoO and Hyf-S (Braun!!:t.....al, 1992). I feel
that the JCV T-ant1gen also has a repressor property,
analogous to that of Ela. This is based on my observation that
JCV T-antigen transact1vates JCV late promoter 1n glial cells,
whereas, it repregses the Bame promoter in non91ial cells such
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8S P19 muscle cells (Fig. 4.2 and 4.3).
Transgenic mice expressing' JCV large T-antigen showed
regions of demyelination in brain and these regions axpressed
large T-antigen of JCV. 'f.:'herefore, my hypothesis is that T-
antigen down-regulates the myelin basic protein (HBP) gene
leading to demyelination of brain tissue that is observed in
PML. since MBP also contains Nfl binding sequences that are
important in its transcription, JCV T-antigen could repress
MBP expression indirectly by binding to the MBP promoter
through protein-protein interactions. This can be tested by
estimating MBP RNA levels by RNase protection assays using RNA
from HSp-expressing cells, with and without transfectlng T-
antigen expression plasmid. If the role of T-antigen in down
regulation of MBP is established, regions of the HBP promoter
through which T-'3ntigen exerts its repressing effect can be
mapped. Anoti!er possible mechanism for repression is that T-
antigen blocks the differentiation of oligodendrocytes which
synthsize myelin. This would be analogous to adenovirus Ela
blocking of muscle differentiation and can be similarly tested
(Braun~, 1992).
SV40 small t-antigen has been shown to be involved in
enhancing the transcription and transformation capacity of
l~rge T-antigen under limiting concentrations of large T-
antigen (Bike! ~, 1987). JCV small t-antigen bears high
homology to BKV and SV40 small t-antigens. Experiments can be
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desiqned to unravel the role of JCV small t-antiqen in the
transcription and transformation abilities of JCV.
In chapter 5, I described the identification and
characterization of CRE and its functional significance in
glial cell-specific expression of JCV. Studies with the BK eRE
have shown that eRE plays a role in transformation and
mUltiplication of the virus. I did not perform experiments to
deternlne the importance of JCV CRE in activities other than
transcriptional regulation of JCV. Hence, future experiments
can be analogously designed to determine whether eRE plays any
role in the transformation aHd mUltiplication of JCV. In
addition, it has been shown previously that NFl plays a role
in the replicatlon of JCV (Sock~. 1991). My studies have
shown that NFl and CRE binding proteins have an additive
effect on transcriptional activity of JCV in glial cells
(chapter 5) • The possibility that NFl and eRE binding proteins
function in an analogous manner in the repl ication of JCV
rellains to be investigated.
Finally, CRE binding proteins are a large family of
proteins ranging from 39 to 120 kDa. Since I did not observe
cAMP induction of JCV promoter-enhancer in undifferentiated
and DMSO-differentiated muscle P19 cells, the protein
interacting with JCV CRE probabl.y is a RA P19 cell-specific
factor. This factor can now be isolatBd and characterized by
acreening the eDNA library from RA-differentiated P19 cells
22.
that I have constructed with Southwestern blots with CRE
ollgonuc16otide.
The RA-dlfferentiated PI9 cells contaIn
heterogeneous population of neuronal cells. Since JCV
exprellsion is rQ'stricted to glial cells only, it is essential
to lIleasure the glial cell population in PI9 RA cells by using
glial cell-specific markers in double immunoflourescence or in
situ hybridization techniques. It is interesting to note that
RA inhibits nural induction in embryo. However, treatment with
300 nM RA of PIg Ee cells induce neural cells in culture. In
addition to RA, presence of other factors in whole embryo, but
not in RA-treated cells may account for this difference.
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